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ABSTRACT
Cerebral vasospasm, a grave sequel to subarachnoid hemorrhage (SAH), is
characterized by prolonged severe constriction of arteries in the base of the brain,
including the basilar artery. Spasmogens (serotonin, endothelin and vasopressin),
elevated in response to SAH, induce persistent depolarization of the myocytes in the
artery wall, leading to continuous influx of calcium (Ca2+) through voltage-sensitive Ca2+
channels (VSCC) resulting in hyperconstriction (spasm). The spasm of the arteries
restricts blood flow to the brain, inducing ischemic neurological deficits and
consequential high morbidity and mortality. The cellular pathogenesis of cerebral
vasospasm is poorly understood and the therapeutic options are limited.
Kv7 (KCNQ) potassium channels are reported to be critical determinants of
resting membrane voltage in several excitable cells including neurons and vascular
myocytes. Recent findings from our laboratory suggested that arginine8-vasopressin
exerts its vasoconstrictor effects on mesenteric arteries via suppression of Kv7 currents.
Hence, we hypothesized that suppression of Kv7 currents by spasmogens is a central
phenomenon in the pathogenesis of cerebral vasospasm and that Kv7 channel openers
would be effective therapeutic agents to treat the vasospasm.
Expression of Kv7 channels evaluated by reverse transcriptase polymerase chain
reaction revealed the presence of all five mammalian KCNQ channel subtypes (KCNQ15) in freshly isolated rat basilar artery myocytes. Kv currents recorded using the wholexviii

cell patch-clamp techniques were attributed to Kv7 channel activity based on their
voltage dependence of activation, lack of inactivation, enhancement by flupirtine,
retigabine (selective Kv7 channel activators), and inhibition by XE991 (a selective Kv7
channel blocker). XE991 depolarized the myocytes indicating that Kv7 channels are
principal determinants of resting membrane voltage. Spasmogens suppressed Kv7
currents and depolarized the myocytes. The effects of spasmogens were significantly
attenuated in the presence of retigabine. Celecoxib, a clinically used anti-inflammatory
drug, not only enhanced Kv7 currents but also inhibited voltage-sensitive Ca2+ currents.
Functional responses to Kv7 channel modulators were studied in intact basilar
artery segments using pressure myography. XE991 constricted basilar artery segments
indicating that Kv7 channels are important determinants of contractile status. In the
presence of XE991, spasmogens did not produce additive constrictor responses,
suggesting that suppression of Kv7 currents is the predominant mechanism for
spasmogen-induced membrane depolarization and constriction of basilar arteries. Kv7
channel activators dilated basilar artery segments pre-constricted with spasmogens, and
were more effective than nimodipine, an L-type Ca2+ channel blocker used as standard
care to relieve cerebral vasospasm in patients with SAH. Intraperitoneal administration of
Kv7 channel openers, retigabine or celecoxib, significantly attenuated basilar artery
spasm in rats with experimentally induced SAH. Both the Kv7 channel openers induced a
transient drop in mean arterial pressure (MAP) generally lasting 30-60 min after
administration, but mean 24h BP measured using radio-telemetry in normal rats was not
altered.

xix

In conclusion, Kv7 channels are expressed in basilar artery myocytes and function
to maintain resting membrane voltage in basilar artery myocytes and hence oppose the
constriction of the arteries. Suppression of Kv7 currents in myocytes is a mechanism by
which spasmogens induce basilar artery constriction. Targeting vascular Kv7 channels
using retigabine or celecoxib could provide a novel strategy to relieve basilar artery
spasm without inducing hypotension.

xx

CHAPTER 1
INTRODUCTION
Aneurysms are abnormal ballooning or outpouching of arteries at sites of
weakness in the blood vessel wall. Arteries in the base of the brain are common
predilection sites for aneurysms because of the vascular remodeling associated with
hemodynamic stress induced by blood flow and the anatomy of the arterial system in the
base of the brain. These intracranial aneurysms are very common, with a prevalence of up
to 6% in the adult population. Rarely, rupture of the aneurysms occurs, which forces
blood into the subarachnoid space resulting in hemorrhagic stroke. Aneurysmal
subarachnoid hemorrhage (SAH) affects 30,000 Americans yearly and accounts for about
5% of all strokes (Bederson et al. 2009). The most common complication of SAH is
cerebral vasospasm. As the name indicates, cerebral vasospasm is the intense constriction
of cerebral arteries, mainly the large conduit arteries (basilar artery and arteries of the
Circle of Willis) near the site of a ruptured aneurysm. Vasospasm is not usually detected
until at least 48 hours after rupture of an aneurysm, but may be pronounced after 3 days
of SAH and lasts up to 2 weeks after SAH. The consequent decrease in cerebral perfusion
frequently results in stroke and death or prolonged disability in the SAH patients. Though
considerable progress has been made in understanding the pathogenesis of cerebral
vasospasm, the cellular events that lead to the delayed vasospasm and subsequent
ischemic events remain poorly understood.
1
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This basic science project aims to study the involvement of vascular Kv7
potassium channels in the pathogenesis of basilar artery vasospasm and to test the utility
of selective Kv7 channel activators to treat cerebral vasospasm. The study utilizes
laboratory rats as a model system to examine the presence and function of the channel.
During the course of the project, we discovered that celecoxib, a clinically used drug, was
a Kv7 channel activator. The scope of my dissertation project was therefore expanded to
test celecoxib as a possible therapeutic agent to treat cerebral vasospasm. Finally, my
dissertation work also attempted to provide insights in to the mechanism by which
celecoxib modulates Kv7 channels.
Chapter 2 of the document provides a review of the literature as background
information for the proposed project. Chapter 3 states the hypotheses and research
objectives of the project; scientific rationale for the stated objectives is also provided.
Chapter 4 describes the methods used to test my hypotheses. Chapter 5 presents the
detailed results of the experiments that were performed. Chapter 6 discusses the results,
describes how the novelty of the findings fit with the existing broad range of literature,
and states the advancements made with this study. Chapter 7 states the salient
conclusions derived from the project. Chapter 8 documents potential future directions for
the project.

CHAPTER 2
REVIEW OF LITERATURE

Arterial constriction and cerebral blood flow
Anatomy of the cerebral vasculature
The human brain is supplied with blood almost exclusively via two paired
arteries- the left and right internal carotid and the left and right vertebral arteries. Threefourths of the total blood supply is provided by the internal carotid artery and one-fourth
by the vertebral artery (Scheel et al. 2000). The blood flowing through these four arteries
join in an equalizing manifold of arteries called the Circle of Willis (Kramer 1912). The
internal carotid artery is a branch of the common carotid artery that arises from the aortic
arch. Branches of the internal carotid artery supply most of the cerebrum and terminally
branch to the anterior and middle cerebral arteries, which form part of the Circle of
Willis. The vertebral arteries supply the hindbrain including the cerebellum and brain
stem, and portions of the cerebrum before coming together to form the basilar artery that
anestamoses into the Circle of Willis.

Cerebral blood flow
Blood flow to the brain is regulated by multifarious overlapping mechanisms,
which perhaps represent a natural adaptation to protect the brain from ischemia. Apart
3
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from several humoral factors, cerebral blood flow is regulated by specialized structural
and functional components that include myogenic arterial responses (cerebral blood
pressure autoregulation), flow-metabolism coupling and the neurovascular unit
comprised of endothelial cells, perivascular nerves and astrocytes (Peterson et al. 2011).
The mechanisms that underlie the ability of the cerebral vasculature to maintain a
constant blood flow despite variable mean arterial pressure (MAP), while rapidly
adjusting the flow to meet the metabolic requirements of the brain, remain poorly
understood.
All the aforementioned factors however modulate blood flow primarily by
constriction/dilation of the arteries through which the blood flows. Arterial constriction is
a function of the contractile state of the smooth muscle cells within the artery wall, which
is in turn governed by intricate actions of various ion channels and the signaling cascades
that affect the sensitivity of the contractile apparatus in the smooth muscle cells.

Regulation of arterial constriction
Vascular tone is primarily under the control of cytosolic free calcium ([Ca2+]c)
concentration in the vascular smooth muscle cells (VSMCs). A rise in [Ca2+]c causes
VSMC contraction by activating actin-myosin cross bridge formation. Activation of cell
surface receptors by vasoconstrictor agonists or mechanical force due to flow of blood
results in elevation of cytosolic calcium [Ca2+]c. Elevation of [Ca2+]c above resting levels
of around 100 nM leads to binding of free Ca2+ to an ubiquitous Ca2+ binding protein
called calmodulin and resulting in its activation (Akata 2007b). The [Ca2+]c concentration
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for half-activation of calmodulin is around 400 nM (Stull et al. 1998). The
conformational change of calmodulin induced by Ca2+ binding enables its binding to a
serine-threonine protein kinase called myosin light chain kinase (MLCK), resulting in
autophosphorylation and activation of the kinase. The active Ca2+-calmodulin-MLCK
complex catalyses the phosphorylation of serine-19 of the two 20-kDa light chains of
myosin, triggering cross-bridge cycling and contraction of the VSMCs. Relaxation is
induced by restoration of Ca2+ levels and dissociation of calmodulin from MLCK,
accompanied by reversal of the downstream events- dephosphorylation of myosin by
phosphatases and detachment of myosin from actin (Somlyo and Somlyo 2003). The
force of contraction: [Ca2+]c ratio or the myosin light chain phosphorylation: [Ca2+]c ratio
is not linear. This suggests secondary regulation of contractile responses by several other
factors that include RhoA/Rho kinase, protein kinase C and cyclic nucleotides (Somlyo
and Somlyo 2003; Akata 2007a; Hirano et al. 2004; Hirano et al. 2003; Rembold 1992;
Stull et al. 1991). These factors can modulate the sensitivity of the contractile apparatus,
but elevation of [Ca2+]c is the primary determinant of the contractile status of the artery.

Regulation of cytosolic calcium concentrations in VSMCs
An increase in [Ca2+]c in cerebral artery myocytes, or in VSMCs in general, is
brought about by either release of Ca2+ from the sarcoplasmic reticulum (the central
reservoir of Ca2+ within the cell), or by increased influx of Ca2+ from the extracellular
space.

6
2+

Ca release mechanisms
Ca2+ release from the sacroplasmic reticulum is mediated through several
channels, predominated by inositol 1,4,5-triphosphate receptor (IP3R) and ryanodine
receptors (RyR) (Berridge et al. 2000). Activation of Gq-coupled seven transmembrane
receptors leads to phospholipase C-mediated cleavage of the membrane-bound
phosphatidylinositol 4,5-biphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3), a soluble
second messenger, and diacylglycerol (DAG) (Berridge and Galione 1988). IP3 binds to
its receptors on the sarcoplasmic reticulum to release Ca2+ from the stores. The Ca2+
released through IP3 receptors induces a bimodal modulation of IP3R activity, with a low
concentration (<1 μM) stimulating further release and a higher concentration (>1-10 μM)
inhibiting it (Bootman and Lipp 1999). A continuous release of Ca2+ through IP3
receptors and reuptake into the sarcoplasmic reticulum, independent of Ca2+ entry, have
been reported to give rise to “Ca2+ waves” in some VSMCs (Foskett et al. 2007). These
Ca2+ waves that normally occur physiologically as discrete events within the cell however
may occasionally get synchronized to initiate vasomotion (Mufti et al. 2010; Peng et al.
2001). The Ca2+ waves have been reported to promote both depolarization, by activating
Ca2+-activated Cl- channels (ClCa channels), and hyperpolarization, by activating largeconductance Ca2+-activated K+ channels (BK channels) (Young et al. 2001), leading to
enhanced or reduced Ca2+ entry through voltage-sensitive Ca2+ channels (VSCC)
respectively. Activation of Gq-coupled receptors with uridine triphosphate (UTP) or
norepinephrine have been shown to induce Ca2+ waves in VSMCs (Jaggar and Nelson
2000; Ruehlmann et al. 2000). However, physiological concentrations of Gq-coupled
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vasoconstrictor agonists like vasopressin do not induce appreciable IP3-mediated Ca

2+

release, implying minimal contribution of these events to global elevation of Ca2+ (Byron
and Taylor 1995). Therefore, the physiological significance of these waves remains
uncertain (Hill-Eubanks et al. 2011).
Cytosolic Ca2+ itself is the principal activator of RyR receptors in the
sacroplasmic reticulum to release Ca2+ by a process called Ca2+-induced Ca2+ release
(CICR). While CICR is a predominant mechanism in cardiac myocytes, the amount of
Ca2+ required to induce CICR may be higher than what is achieved within smooth muscle
cells during peak excitability, limiting the contribution of the RyR-mediated Ca2+ release
to vascular contractility (Sanders 2001). Quantal local release of Ca2+ due to the opening
of four to six RyR receptors, referred to as “Ca2+ sparks”, activates closely juxtaposed
large-conductance Ca2+-activated K+ channels (BK channels) increasing their open
probability and producing hyperpolarization (Cheng and Lederer 2008; Jaggar et al.
2000). Ca2+ overload increases the spark frequency, probably acting as a feedback
mechanism to limit membrane depolarization and Ca2+ influx through VSCC (Jaggar et
al. 2000; Perez et al. 1999). Thus, RyR activation under physiological conditions seems
to induce VSMC relaxation, opposite of the effect of IP3 receptor activation, which is
most commonly associated with VSMC contraction.

Ca2+ entry mechanisms
Ca2+ entry into the cell across the plasma membrane principally occurs through
three different types of channels defined by their mechanism of activation as (i) receptor-

2+

2+
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operated Ca channels, (ii) store-operated Ca channels and (iii) voltage-sensitive Ca
channels.

(i) Receptor-operated Ca2+ entry: The transient receptor potential “canonical”
(TRPC) superfamily of non-selective cation channels are the predominant receptoroperated channels through which Ca2+ enters in to VSMCs (Dietrich et al. 2010). These
channels are not activated directly by receptor ligands, but through signal transduction
events activated by Gq-coupled receptor stimulation. The functional channels are
constituted by homo- or hetero- tetramers of the family members. Of the seven family
members (TRPC1-7), TRPC3/6/7 are well characterized as receptor-operated channels
(Maruyama et al. 2006). The channels formed by the TRPC3/6/7 subgroup are directly
activated by diacylglycerol, a signal transduction intermediate in the Gq-PLC-pathway
(Dietrich et al. 2005). These channels primarily conduct Na+ ions rather than Ca2+ ions.
Influx of cations through these channels has been proposed as an important mechanism of
membrane depolarization by vasoconstrictor agonists (Maruyama et al. 2006; Soboloff et
al. 2005; Onohara et al. 2006).
The ATP-gated P2X receptor is the only direct receptor-operated cation channel
that induces identifiable Ca2+ influx in VSMCs (Hill-Eubanks et al. 2011). These nonselective receptor-operated channels predominantly conduct Na+ ions, but also allow
substantial influx of Ca2+ in VSMCs upon binding of ATP (Lamont and Wier 2002).
(ii) Store-operated Ca2+ channels: Store-operated Ca2+ entry (SOCE) is the influx
of Ca2+ in response to depletion of intracellular stores. The Ca2+ release-activated Ca2+
influx through SOCE serves as a mechanism to replenish Ca2+ stores. The molecular
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identity of these channels in VSMCs remains controversial (Leung et al. 2008). TRPC
channels, particularly TRPC1, have been identified as store-operated Ca2+ channels,
accounting for at least part of the SOCE (Xu and Beech 2001; Sweeney et al. 2002;
Brueggemann et al. 2006). Recent evidence, however, points to STIM1 as the
transmembrane endoplasmic reticulum Ca2+ sensor that activates a cell surface channel of
the Orai family to mediate the SOCE (Varnai et al. 2009). A recent study also suggested
STIM1 and TRPC1 as components of SOCE (Takahashi et al. 2007). The role of SOCE
in the regulation of vascular contractile status is minor under physiological conditions.
SOCE however likely plays an important role in VSMC proliferation and remodeling
under certain pathological conditions (Leung et al. 2008).
(iii)Voltage-sensitive Ca2+ channels: Calcium entry through voltage-sensitive
Ca2+ channels (VSCC) is the primary contributor to global increase in [Ca2+]c in VSMCs.
These channels open in response to membrane depolarization induced by a variety of
humoral, chemical, or mechanical stimuli. The voltage-sensitive Ca2+ currents also
inactivate rapidly in response to membrane depolarization. The inactivation is both
voltage- and Ca2+-dependent. The activation and inactivation characteristics of VSCC are
such that in a range of membrane voltage (around -60 to -20 mV) in which activation
occurs, inactivation of the currents is incomplete. The remaining current is termed
window current (Sanders 2001; Fleischmann et al. 1994). Though the magnitude of the
sustained Ca2+ current within this “window” is small, the amount of Ca2+ influx driven by
the steep difference in the concentration gradient is significant relative to the cell volume
(Sanders 2001). Membrane depolarization of smooth muscles by about 15 mV from the
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resting voltage (about -50 to -40 mV) activates VSCC and stimulates Ca influx enough
2+

to elevate global [Ca2+]c to ~300-400 nM (Hill-Eubanks et al. 2011). VSCCs are
composed of a pore-forming α1 subunit and regulatory subunits β, α2δ and γ (Catterall
2000). The channels are classified based on the α1 subunits that encompass the pore,
selectivity filter and the voltage-sensor. They are referred to as Cav1.1, Cav1.2, Cav1.3,
Cav1.4 (L-type VSCC), Cav2.1 (P/Q-type VSCC), Cav2.2 (N-type VSCC), Cav2.3 (R-type
VSCC), Cav3.1, Cav3.2, Cav3.3

(T-type VSCC) (Lacinova 2005). T-type channels

activate at a more negative membrane voltage (around -60 mV, and hence are called low
voltage-activated channels), while other types of channels activate at more positive
voltages (around -40 mV, and hence are called high voltage-activated channels) (PerezReyes 2003). L-type and T-type Ca2+ channels are the most abundantly expressed
subtypes in VSMCs. L-type Ca2+ channels inactivate relatively slowly, whereas T-type
channels inactivate fast and have low unitary conductance, providing only a transient
Ca2+ conductance. Though it is widely believed that L-type channels are the predominant
Ca2+ channels in VSMCs, recent reports suggest that multiple types of Ca2+ channels are
expressed in VSMCs derived from basilar artery (Nikitina et al. 2010; Navarro-Gonzalez
et al. 2009).
The contribution of Ca2+ influx through each subtype of Ca2+ channel is difficult
to ascertain because of several limitations, including lack of specific antagonists for
certain subtypes, difficulty in knocking down a specific channel subtype without altering
the expression profile of other channels, difficulty in electrophysiological isolation of
currents through each subtype of Ca2+ channels (even though there are subtle differences

in their biophysical characteristics) and heterogeneity of expression of Ca

2+
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channel

subtypes between myocytes in the same artery.
Calcium influx is mediated by multiple types of VSCC, with L-type and T-type
being the predominant functional channels expressed in basilar artery myocytes (Nikitina
et al. 2010; Navarro-Gonzalez et al. 2009; Nikitina et al. 2007). Calcium channel
blockers selectively targeting L-type Ca2+ channels are used clinically to treat several
cardiovascular disorders including hypertension, cerebral vasospasm, and angina
(Kochegarov 2003).

Electrical properties of membrane and membrane potential
Ions are unequally distributed across the cell membrane, which acts as a charge
storage device or capacitator. The electrical field or potential created by the charge
separation across the membrane is given as V= Q/C, where V=voltage, Q=charge and C=
capacitance. Membrane potential (Vm; also called membrane voltage) is the potential on
the inside of the cell, equal to the difference between V inside the cell and V outside the
cell. The normal resting membrane potential of most excitable cells is between -70 mV
and -40 mV. Change in the membrane potential towards more negative voltages is termed
hyperpolarization and a change towards more positive voltages is called depolarization.
Changes to the membrane voltage are governed by the simple laws of physics. As
per Ohm’s law, voltage (V) = Current (I) * Resistance (R). The input resistance of
excitable cells (with particular reference to VSMCs) is high, in the order of 5-15 GΩ,
implying that even a small change in current will induce a significant change in voltage at
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resting levels. At resting levels, Vm is close to the reversal potential (a potential at which
the current reverses direction of flow) of potassium ions (K+) (EK = -85 mV), indicating
that under these conditions, the membrane voltage is predominantly controlled by K+
current. The Cl- current, non-selective cation currents and voltage-sensitive Ca2+ currents
make only minor contributions (Nelson et al. 1990). Hence, at near resting conditions,
modulation of very few K+ channels would induce a significant change in membrane
voltage.

Potassium channels
Potassium channel activity largely determines the resting membrane voltage, and
thereby controls the activity of VSCCs, which conduct Ca2+ into the cells to activate the
contractile apparatus. Despite their importance as determinants of arterial smooth muscle
contractility, K+ channels, which constitute the largest class of ion channels, have
surprisingly not emerged as clinically favored targets to modulate blood flow and blood
pressure.
Four types of K+ channels have been described in cerebral arteries; ATP-sensitive
(KATP), inwardly rectifying (KIR) K+ channels, large conductance Ca2+-activated (BKCa),
and voltage-dependent (delayed rectifier) K+ channels (Faraci and Sobey 1998; Wellman
2006).
(i) ATP-sensitive K+ channels: ATP-sensitive K+ (KATP) channels in smooth
muscle cells are formed by a 4:4 octomeric complex of pore forming Kir6.2 subunits, a
member of the inward rectifier K+ channel family, and SUR2B regulatory sulfonylurea
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receptors (Aguilar-Bryan et al. 1998). These channels are not voltage-dependent, but
couple electrical activity of the cell to its metabolic status by activating in response to a
decrease in [ATP]i (Quayle et al. 1997). In VSMCs, KATP channels open in response to
hypoxic conditions, limiting the contractile force to conserve ATP (Daut et al. 1990).
Vasodilators that activate protein kinase A (PKA) increase the open probability of KATP
channels and vasoconstrictors that activate protein kinase C (PKC) inhibit these channels
(Quayle et al. 1997; Zhang et al. 1994; Brayden 2002; Quayle et al. 1994). The channels
are also activated by synthetic compounds such as levcromakalin, pinacidil, nicorandil,
and diazoxide, and inhibited by sulphonylureas like glibenclamide (Quayle et al. 1997).
Pharmacological evidence supports a role of KATP channels in the regulation of cerebral
blood flow (Hong et al. 1994; Rosenblum 2003). These channels may be more abundant
in smaller cerebral arteries than in larger arteries like the basilar artery (Rosenblum
2003). KATP channels were implicated in vasoconstrictor responses when VSMCs were
dialyzed in 0.1 mM ATP (Bonev and Nelson 1996). Whether these channels are active
under physiological conditions in VSMCs, however remains controversial, as
physiological concentrations (1.5 – 3 mM) of [ATP]i reduce the open probability of the
channels (Nelson and Quayle 1995).
(ii) Inwardly rectifying KIR channels: Inwardly rectifying K+ (KIR) channels are
tetramers of two membrane-spanning pore-forming domains encoded by KIR2.1 in
cerebrovascular smooth muscle cells (Zaritsky et al. 2000). Under voltage-clamp
conditions, inwardly rectifying K+ channels predominantly conduct inward currents rather
than outward currents like other K+ channels (Nelson and Quayle 1995). The voltage at

+

which these channels open is dependent on extracellular K
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concentrations. The

sensitivity of KIR channels to extracellular K+ is observed experimentally by dilation of
the cerebral arteries in response to a modest elevation of extracellular K+ concentration
(Edwards et al. 1988). The rectification is due to block of the outward conductance by
binding of cytosolic positively charged polyvalent ions, such as Mg2+ and polyamines, to
the channel (Lopatin et al. 1994). Hence, membrane depolarization from resting
membrane voltages results in small outward K+ currents, whereas hyperpolarization
elicits large inward currents in VSMCs (Edwards et al. 1988). Enhanced neuronal activity
increases extracellular K+ concentrations activating KIR channels expressed in cerebral
artery myocytes, resulting in vasodilation and increased blood flow to meet the metabolic
requirements for the enhanced neuronal activity (Dunn and Nelson 2010). Apart from the
regulation of vascular tone to meet the metabolic needs of neurons, the physiological
significance of KIR channels still remains poorly understood. Unlike most other K+
channels in the cerebral vasculature, activity of KIR was not regulated by protein kinases
like, PKA, PKC, and PKG (Wellman 2006).
(iii) Voltage-dependent K+ channels: Voltage-dependent K+ channels are
tetramers of identical or closely related pore forming six transmembrane α subunits that
may be associated with 1 to 4 accessory β subunits (Cox 2005). Their versatile capacity
for heteromeric assembly along with the influence of accessory subunits results in
channels with diverse biophysical properties. However, most voltage-dependent K+
channels have similar pharmacological properties, making it difficult to determine which
channels are functional in a given cell. Genes encoding voltage-dependent K+ channel
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superfamily members constitute the largest of any ion channel family, with more than 70
genes identified in the human genome (Coetzee et al. 1999). The phylogenetic
superfamily includes 8 subfamilies of Kv (Kv1-Kv6 and Kv8-Kv9), KCNQ (Kv7), and
EAG (Kv10-12) subfamilies (Coetzee et al. 1999). The most commonly expressed Kv
channel subunits in VSMCs are Kv1.1, Kv1.2, Kv1.4-1.6, Kv2.1, Kv9.3 (Standen and
Quayle 1998). In dog basilar artery myocytes, messenger RNA (mRNA) for Kv1.2,
Kv1.5, Kv2.2, Kv3.1, Kv3.4 and Kv4.3 were identified with expression of Kv1.5 and
Kv2.2 being predominant (Aihara et al. 2004). Currents through these channels are
distinguished from other K+ channels by their sensitivity to the pharmacological channel
blocker 4-aminopyridine (4-AP) (Okabe et al. 1987). The open probability of these
channels is voltage-dependent with an increase in open probability (Po) increasing with
membrane depolarization. Kv channels undergo varying degrees of inactivation with
membrane depolarization depending upon the subunits involved. The voltage of halfmaximal channel activation (V0.5) for activation and inactivation of Kv currents in
VSMCs are -9 to -6 mV and -35 (-45 to -25) mV respectively (Nelson and Quayle 1995).
The Po increases steeply at voltages positive to -30 mV, indicating that a window current
should exist around the physiological range of membrane voltages (Nelson and Quayle
1995). The physiological role of the Kv channel varies with the vascular bed in which it
is expressed. In small cerebral artery myocytes with membrane voltage around -40 mV,
blockade of these channels leads to membrane depolarization and artery constriction
(Albarwani et al. 2003). The resting membrane voltage in myocytes derived from most
other vascular beds are more negative, ranging from -65 to -45 mV indicating that the Kv
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channels in these vascular beds function to limit the membrane depolarization following a
vasoconstrictor stimulus, with a relatively minor role under resting conditions. Kv
channels in dog basilar arteries have V0.5 for activation of -1.3 mV (Jahromi et al.
2008a), whereas the resting membrane voltage of basilar artery myocytes is around -35
mV in dog (Jahromi et al. 2008a), and between -46 and -60 mV in rats (Chrissobolis and
Sobey 2002; Weyer et al. 2006a). Hence, Kv channels are likely to provide negative
feedback following membrane depolarization and vasoconstriction by hyperpolarizing the
membrane.
(iv) Ca2+-activated K+ channels: Ca2+-activated K+ (KCa) channels, like Kv
channels, form as tetrameric assemblies of six transmembrane pore forming α-subunits
(encoded by slo or SK genes) and regulatory β-subunits. Large-conductance KCa αsubunits encoded by slo genes are expressed in VSMCs (Coetzee et al. 1999). Channels
formed by these subunits exhibit large single-channel K+ conductances (~250 pS in
symmetrical K+), and hence are called “big KCa (BK) channels” or “maxi” channels
(Nelson and Quayle 1995). The open probability of BK channels increases in response to
membrane depolarization and/or increased [Ca2+]c. Hence, opening of BK channels
serves as a negative feedback mechanism to limit the membrane depolarization and
elevation of [Ca2+]c that leads to vasoconstriction. The membrane hyperpolarization
induced by BK channel opening also serves to limit the myogenic responses observed in
resistance arteries and arterioles (Hill et al. 2010). A high [Ca2+]c, in the order of 1-10
µM, is required to activate BK channels at a membrane voltage of -50 mV (Hille 2001).
Such high Ca2+ concentrations could be achieved in the subcellular environment of the
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sparks) from the sarcoplasmic

reticulum through the opening of ryanodine receptors (Perez et al. 1999; Collier et al.
2000; Wellman et al. 2002). To the extent that Ca2+ sparks occur under resting conditions,
BK channels could potentially play a role in resting K+ conductance (Wellman and
Nelson 2003). BK channels are well studied as targets mediating the vasodilator actions
of endothelin-derived relaxing factors like nitric oxide (NO) and epoxyeicosatrienoic
acids (Dimitropoulou et al. 2007; Jiang et al. 1998; Kitazono et al. 1997). The channel
activity is increased by elevated [Ca2+]c, but also modulated by several different
intracellular signaling intermediates activated following binding of vasoconstrictors to Gprotein-coupled receptors (GPCRs) (Hou et al. 2009).

Pathophysiology and treatment of cerebral vasospasm
Subarachnoid hemorrhage
An estimated 1-5% of adults have weakened cerebrovascular blood vessel walls
causing localized ballooning of arteries called cerebral aneurysm (King 1997). Most of
the aneurysms are asymptomatic, but their rupture results in a devastating condition
called subarachnoid hemorrhage (SAH). The extravasation of blood into the
subarachnoid space is usually presented as a medical emergency with severe headache
being the most common complaint, though sometimes accompanied by nausea or loss of
consciousness. SAH affects as many as 30,000 people each year in North America alone
and accounts for about 5% of all strokes (King 1997; Graf and Nibbelink 1974).
Prognosis is disproportionately unfavorable for patients with SAH compared to ischemic
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stroke (Laskowitz and Kolls 2010). SAH is typically diagnosed by non-contrast cranial
computed tomography scan with the probability of detection of blood in the subarachnoid
space proportional to the clinical grade and swiftness of performing the scan after SAH
(Bederson et al. 2009; Vale et al. 1997). Cerebral vasospasm often occurs within a few
days after SAH and is typically diagnosed by angiographic narrowing of the basilar artery
or altered basilar artery blood flow as measured by transcranial Doppler ultrasonography
(Zubkov and Rabinstein 2009).
Cerebral vasospasm is the leading cause of morbidity and mortality after SAH and
affects 30-70% of patients with SAH (Heros et al. 1983; Kassell et al. 1985). The
condition is characterized by sustained constriction of the large arteries in the base of
brain – including the arteries that form the circle of Willis and the basilar artery. Though
vasospasm implies reduction in diameter of the artery, in SAH, it involves a complex
vasculopathy, impaired autoregulatory function, and focal reduction of cerebral perfusion
to a point of causing ischemia (Keyrouz and Diringer 2007). Under normal conditions,
the affected arteries account for 10- 39% of resistance to blood flow to the brain (Heistad
and Konotos 1983). The involvement of smaller diameter cerebral arteries in cerebral
vasospasm is not clear because of the limitation of angiographic imaging. The onset of
vasospasm is delayed, and usually starts 3-5 days after hemorrhage, and is sustained until
it reaches a maximum between 5-14 days. The spasm resolves gradually within 2-4
weeks. Consequent to the narrowing of the arteries, poor blood perfusion distal to the
affected artery causes ischemia and neurological deficits that may either resolve or result
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in cerebral infarction and permanent disability or death (Keyrouz and Diringer 2007;
Sehba et al. 2011).

Etiology for development of cerebral vasospasm
The etiology of vasospasm after SAH is not clear but appears to be multifactorial
(Macdonald et al. 2007). The role of Ca2+ in cerebral vasospasm has been debated mainly
because there is no known mechanism that causes a sustained increase in [Ca2+]c over a
period of several days (Hansen-Schwartz et al. 2008; Hansen et al. 2007; Tani 2002).
There is evidence however that vasospasm in cerebral arteries is largely Ca2+ dependent
and that Ca2+ influx is the major mechanism of elevated [Ca2+]c (Wellman 2006; Tani
2002; Zuccarello et al. 1996a).
An impairment of cerebral auto-regulation has been observed in a number of
experimental (Hauerberg et al. 1993; Hauerberg et al. 1995; Kamiya et al. 1983;
Rasmussen et al. 1992; Takeuchi et al. 1991) and clinical studies (Lang et al. 2001;
Soehle et al. 2004; Voldby et al. 1985) following SAH. The cause(s) for the impairment
of the auto-regulation are difficult to ascertain but likely include a multitude of factors
such as vasospasm itself, acidosis, and hypoxia after SAH (Voldby et al. 1985; Handa et
al. 1992). Increased resistance due to vasospasm induced by altered neuronal and
humoral influence and direct vasoconstictor action of the blood components results in
reduced perfusion. Loss of auto-regulation after SAH may damage the cerebral
microcirculation and increase cerebral edema.
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Spasmogens involved in vasospasm
(i) Endothelin: Endothelin (ET) is a collection of endothelium derived
vasoconstrictor peptides that exists as isoforms ET-1, ET-2, and ET-3. Endothelin
induces its biological effects through its interaction with ETA and ETB receptors. ET-1 is
the most potent of the isoforms and induces dose-dependent long-lasting constriction by
binding to the ETA receptors in the smooth muscle cells (Zimmermann and Seifert 1998).
ET constricts rat basilar artery with the Emax that is 122% of that produced by K+, ET has
a pEC50 of 8.7 (Hansen-Schwartz et al. 2003b). ET is perhaps the most studied of the
spasmogens that contribute to cerebral vasospasm. The involvement of ET has been
demonstrated by several pieces of experimental evidence: changes in ET receptors
(Hansen-Schwartz et al. 2003b; Hansen-Schwartz 2004; Hino et al. 1996), increased
levels of ET in CSF and plasma (Juvela 2000; Kessler et al. 2005; Masaoka et al. 1989;
Seifert et al. 1995; Suzuki et al. 2000; Yamaura et al. 1992), experimental induction of
delayed vasospasm by administration of ET-1 (Asano et al. 1989; Ide et al. 1989;
Kobayashi et al. 1991; Kobayashi et al. 1990), and attenuation of cerebral vasospasm by
administration of ET receptor antagonists (Roux et al. 1997).
Physiologically, the vasoconstrictor actions of ET mediated by ETA receptors in
smooth muscle cells are antagonized by nitric oxide that is released by stimulation of ETB
receptors expressed in the endothelium. In cerebral vasospasm, the ET-dependent
vasocontractility seems to be due to the decreased ETB receptor function and increased
sensitivity to ETA receptor (Vatter et al. 2007; Vatter et al. 2011). Hence, ETA selective
antagonists were tested and found to attenuate vasospasm in pre-clinical studies (Roux et
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al. 1997; Wanebo et al. 1998). One of the ETA antagonists, clazosentan, was found to
reduce the frequency and severity of cerebral vasospasm in phase II clinical trials
(Vajkoczy et al. 2005). However, a larger phase 3 placebo-controlled clinical trial failed
to demonstrate a significant effect on mortality and vasospasm-related morbidity and
functional outcome (Beck and Raabe 2011; Macdonald et al. 2011), indicating that ET is
not the only spasmogen that contributes to vasospasm. Experimental evidence from a
mouse model of SAH showed that clazosentan preserved cerebral blood flow, alleviated
vasospasm, but did not reduce the neuronal injury. These data indicate that factors other
than ET-induced vasospasm could still cause the neuronal injury (Sabri et al. 2010). The
questionable reduction in the neurological deficits associated with administration of ET
antagonists in patients were offset by adverse effects including hypotension and
pulmonary complications limiting the use of these drugs to treat vasospasm (Kramer and
Fletcher 2009; Vergouwen 2009).
(ii) Serotonin: Serotonin, also known as 5-hydroxytryptamine (5HT), is a wellrecognized neurotransmitter and potent vasoconstrictor. 5HT exerts its physiological
actions through diverse receptors comprising 7 classes with 15 subclasses (Nichols and
Nichols 2008). The receptor classes are identified as 5HT1-7. All 5HT receptors except
the 5HT3 are G-protein coupled receptors; 5HT3 are receptor-operated ion channels. 5HT
induces a concentration-dependent constriction of rat basilar artery with an Emax of 82%
(compared to K+) and pEC50 of 7.2 (Hansen-Schwartz 2004). The 5HT receptors
expressed in the rat basilar artery are 5HT1B, 5HT1D, and 5HT2A (Hansen-Schwartz 2004).
5HT1B and 5HT2A receptors mediate the constrictor responses and modulate the blood
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flow through the arteries (Cambj-Sapunar et al. 2003; Nishimura 1996). The mRNA level
of 5HT1B was found to be increased fivefold in basilar and cerebral arteries from a rat
model of SAH compared to controls (Hansen-Schwartz 2004; Hansen-Schwartz et al.
2003a). The basilar artery or cerebral artery derived from SAH rats were more sensitive
to the constrictor responses of 5HT and the responses were primarily mediated through
5HT1B receptors (Debdi et al. 1992; Mendelow et al. 1981; Nakagomi et al. 1987;
Svendgaard et al. 1977). Cerebrospinal fluid 5HT levels are significantly elevated in
SAH patients from a normal level of 60 ng/ml to 200 ng/ml (Chehrazi et al. 1989). Apart
from the neuronal source, the majority of the 5HT increase is likely derived from
aggregated thrombocytes after SAH, which contributes to the long-lasting constriction of
the arteries in the brain (Allen et al. 1974; Satoh et al. 1991; Voldby et al. 1982). In
summary, vasoconstriction induced by 5HT is a pivotal component in the pathogenesis of
cerebral vasospasm.
(iii) Vasopressin: Vasopressin ([Arg8]vasopressin; AVP) is a nine amino acid
neuropeptide that exerts its physiological actions predominantly through 2 receptors- V1
(V1a, V1b) and V2 receptors. Vasoconstrictor responses of AVP are mediated through the
V1a receptors that are widely expressed in VSMCs. The V2 receptors, expressed in the
renal collecting tubule, mediate the anti-diuretic effects of AVP. Plasma osmolarity is the
principle stimulus for release of AVP in the circulation and CSF, but can be influenced
by several other physiological and pathological conditions (Schrier et al. 1979). The
normal concentration of AVP in CSF is 0.5-2.0 pg/ml in humans and 3.8-11.5 pg/ml in
rats (Sorensen 1986). The concentration of AVP increases almost 3 times in the CSF of
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patients during the incidence of vasospasm after SAH (Barreca et al. 2001; Jenkins et al.
1984; Mather et al. 1981). Intra cisternal injection of AVP into Brattleboro rats, that lack
the capacity to produce AVP, resulted in an acute basilar artery vasospasm similar to that
observed after injection of blood (Delgado et al. 1988). Rat basilar arteries showed a V1areceptor-mediated enhancement of reactivity to AVP during the vasospasm phase after
SAH (Nishihashi et al. 2005). Intravenous administration of SR49059, a V1a antagonist
attenuated basilar artery vasospasm in a rat model of SAH, suggesting the participation of
AVP in the development of cerebral vasospasm (Trandafir et al. 2004).
(iv) Other spasmogens: Other spasmogens including oxyhemoglobin (Asano
1999; Kolias et al. 2009; Macdonald and Weir 1991), bilirubin oxidation products (BOX)
(Clark and Sharp 2006) from the hemolysate and eicosanoids (Kolias et al. 2009) also
induce spasm or potentiate the constriction induced by other spasmogens. The increased
activity of the spasmogens combined with the reduction in activity of physiological
endothelium-derived relaxing factors like nitric oxide (Hanggi and Steiger 2006; McGirt
et al. 2002; Pluta et al. 1996; Pluta 2006; Sobey and Quan 1999) likely causes the
persistent spasm.

Membrane depolarization and elevation of cytosolic calcium
A continuous elevation of [Ca2+]c (Kim et al. 1996; Tani and Matsumoto 2004)
and myosin light chain (MLC20) phosphorylation (Tani and Matsumoto 2004; Bulter et
al. 1996) has been observed in myocytes derived from spastic arteries, although one
study failed to observe an increase in Ca2+ levels (Yamada et al. 1994). Stimulation of
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Gq-coupled receptors by spasmogens generates phospholipase C that hydrolyses PIP2 to
IP3 and diacylglycerol, with IP3 stimulating release of Ca2+ from the intracellular stores
(Tani 2002). However, prolonged elevation of [Ca2+]c is sustained only by Ca2+ influx
through VSCC (Wellman 2006). Myocytes derived from basilar and cerebral arteries of
rabbits or dogs with experimentally induced SAH were significantly depolarized
(Jahromi et al. 2008a; Harder et al. 1987; Nystoriak et al. 2010; Waters and Harder 1985;
Zuccarello et al. 1996b). Given the predominant role of Ca2+ influx through VSCC in
increasing [Ca2+]c, an increase in open-probability of VSCC in the depolarized vascular
myocytes is proposed as the primary pathology in cerebral vasospasm (Wellman 2006;
Marin 1988). The involvement of VSCC is supported by the beneficial effects of blockers
of these channels in the treatment of cerebral vasospasm (Dorhout Mees et al. 2007;
Allen et al. 1983). Nimodipine, a dihydropyridine Ca2+ channel blocker with a
preferential cerebrovascular action (Kazda and Towart 1982), remains the only
recommended pharmacological treatment available to patients with cerebral vasospasm
(Bederson et al. 2009). The beneficial effects of nimodipine in cerebral vasospasm
however remain controversial, because unlike in animal studies, patients on nimodipine
therapy have no demonstrable reduction in angiographic vasospasm in some studies
(Allen et al. 1983; Jan et al. 1988), but had remarkable effects in other studies (Cho et al.
2011; Biondi et al. 2004). There are suggestions that the beneficial effect of nimodipine
may be predominantly due to its direct neuroprotective effects (Allen et al. 1983;
Mayberg et al. 1994).
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Role of potassium channels in cerebral vasospasm
Since the membrane voltage is primarily regulated by K+ conductance (Faraci and
Sobey 1998), K+ channels are postulated as mediators in the pathogenesis of cerebral
vasospasm and have therefore been identified as possible therapeutic targets to treat the
condition (Wellman 2006). K+ conductance was found to be reduced in basilar arteries
after SAH (Jahromi et al. 2008a; Harder et al. 1987; Jahromi et al. 2005). The roles of
the major classes of K+ channels expressed in basilar and cerebral arteries, KATP, KIR,
BKCa, and 4AP-sensitive-KV channels as contributors to membrane depolarization and
hence cerebral vasospasm have been investigated.
KATP channels expressed in basilar artery remain functional after SAH with their
activity enhanced rather than inhibited. Pharmacological KATP channel activators induced
enhanced dilation of cerebral arteries from SAH animals (Zuccarello et al. 1996b; Sobey
et al. 1996; Sugai et al. 1999). Reduced activity of the functional channels after SAH
may develop due to reduced levels of endogenous KATP channel activators like CGRP
(Edvinsson et al. 1994; Edvinsson et al. 1990). Activation of KATP channels with
cromakalim relaxed pre-constricted basilar artery and attenuated basilar artery vasospasm
in animal models of vasospasm (Zuccarello et al. 1996b; Sugai et al. 1999; Kwan et al.
2000; Kwan et al. 1998). However, administration of KATP channel activators are
associated with hypotension and tachycardia limiting its clinical utility (Spinelli et al.
1990). Alternatively, to avoid systemic hypotension, targeted delivery of CGRP to
activate cerebrovascular KATP channels by implantation of a time-released capsule in the
CSF space (Ahmad et al. 1996; Inoue et al. 1996), adenoviral over expression of CGRP
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in cerebral vasculature (Satoh et al. 2002; Toyoda et al. 2000a; Toyoda et al. 2000b) or
intranasal delivery of CGRP (Sun et al. 2010) have been tested and found to be effective
in animal models. Intravenous infusion of CGRP after SAH in patients failed to show any
beneficial outcome in preventing neuronal deterioration, and produced consistent
systemic hypotension (Bell 1995; Bell 1992). The efficacy of local delivery rather than
systemic administration of KATP channel activators remains to be verified in SAH
patients.
Dysfunction of 4-AP-sensitive-Kv channels after SAH has been proposed as a
mechanism contributing to cerebral vasospasm (Jahromi et al. 2008a; Ishiguro et al.
2006). A significant reduction in the mRNA of Kv channels- Kv2.2, Kv3.4 was observed
in basilar artery myocytes derived from SAH dogs, and the changes in Kv2.2 mRNA
correlated with the degree of vasospasm (Aihara et al. 2004). Protein levels of Kv2.1 and
Kv2.2 channels were also significantly reduced in basilar artery myocytes of SAH dogs
(Jahromi et al. 2008a). Kv currents measured from the basilar artery myocytes of SAH
rats had diminished current amplitude, indicating dysfunction of Kv channels (Jahromi et
al. 2008a; Jahromi et al. 2008c). Both half-activation and inactivation of Kv currents
were also decreased in the myocytes (Jahromi et al. 2008c). The mechanisms that lead to
the downregulation of expression of the Kv channels are not known. Oxyhemoglobin
induces a tyrosine kinase-mediated endocytosis of Kv channels resulting in dysfunction
of the channels (Ishiguro et al. 2006; Ishiguro et al. 2008). Tyrosine kinase activation by
oxyhemoglobin involves matrix metalloprotease activation causing heparin binding of
epidermal growth factor (EGF)-like growth factor shedding and increased epidermal
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growth factor receptor tyrosine kinase activity (Koide et al. 2007). Kv channels have a
high voltage threshold for activation (V0.5 = -1.3 mV in dog basilar arteries) (Jahromi et
al. 2008a). Hence, dysfunction of Kv channels could lead to loss of a compensatory
vasodilatory mechanism, potentiating the vasospasm.
The mRNA of the BK channel α-subunit was not found to be altered in the basilar
artery myocytes from SAH dogs (Aihara et al. 2004). Though mRNA of the β1 subunit of
the BK channels was found to be reduced, the protein levels were unaltered (Aihara et al.
2004). Function of the BK channels was preserved in vasospastic basilar artery myocytes
from a dog model of SAH. There was no difference in the BK current density, kinetics,
Ca2+ and voltage sensitivity, single channel conductance or apparent Ca2+ affinity after
SAH (Jahromi et al. 2008c; Jahromi et al. 2008b). Heme breakdown products known as
bilirubin oxidation end products (BOXs) present in the CSF after hemorrhage have been
shown to reduce the open probability of BK channels in a heterologous expression
system (Hou et al. 2011). The in vivo relevance of the modulation of BK currents by
BOXs remains to be clarified. Pharmacological blockade of BK channels did not
influence the membrane voltage in basilar artery myocytes from SAH dogs when
compared to myocytes from control dogs (Jahromi et al. 2008b). Hence, the role of BK
channel function in the pathogenesis of cerebral vasospasm, at least from the current
understanding, is likely to be minimal.
KIR 2.1 mRNA was increased by more than 2-fold in basilar artery myocytes of
dogs after SAH (Aihara et al. 2004; Weyer et al. 2006a). The mean conductance through
KIR channels increased several fold, from 1.6 pS/pF to 9.2 pS/pF indicating an
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upregulation of these channels (Weyer et al. 2006a). The increase in the channel
expression and function indicate that KIR channels likely act as a compensatory
mechanism to limit the depolarization induced by dysfunction of other ion channels
(Aihara et al. 2004; Weyer et al. 2006a).
In summary, dysfunction of 4AP-sensitive Kv channels might be a contributing
factor for the persistent membrane depolarization observed in artery myocytes after SAH
though there are no available activators to use in clinical therapy. KATP channel openers
have been tested to relieve vasospasm, but were found to have questionable efficacy and
increased the risk of hypotension. Hence, none of the K+ channel subtypes known to be
expressed in the cerebral vasculature has emerged as a successful target to treat cerebral
vasospasm (Wellman 2006).

Involvement of protein kinase C
Stimulation of phospholipase C either by cell surface receptor activation or
mechanical force leads to cleavage of PIP2 to IP3 and DAG. DAG can activate some
members of the family of serine-threonine kinases, called protein kinase C (PKC).
Twelve isoforms of PKC are known. They have been classified into 3 groups based on
their regulation; conventional PKCs (comprised of PKC α, β and γ) requires both DAG
and Ca2+ for activation, novel PKCs (comprised of PKC δ, ε, η and θ) requires DAG for
activation, independently of Ca2+, and atypical PKCs (comprised of λ, μ and ζ) are
insensitive to DAG, but activated by phosphatidyl serine and phorbol esters. The role of
PKCs in mediating the VSMC contraction induced by cell surface receptor activation and
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myogenic response is not entirely understood. PKC increases the Ca sensitivity of the
2+

contractile apparatus, and therefore acts as a modulator to amplify the vasoconstrictor
response to elevated [Ca2+]c in VSMCs (Laher et al. 1989; Laher et al. 1990). The kinase
phosphorylates contractile proteins calponin and/or caldesmon leading to disinhibition of
myosin ATPase thereby sensitizing the contractile apparatus.
The phosphorylation targets mediating the response of PKC also include ion
channels, pumps and exchangers as well as other kinases (Laher and Zhang 2001).
Activation of PKC induces membrane depolarization by suppression of K+ channels
resulting in Ca2+ entry through VSCC. Several potassium channels including KATP, Kv
and BK channels are sensitive to activation of PKC (Standen and Quayle 1998; Aiello et
al. 1996; Minami et al. 1993; Shearman et al. 1989). The sustained Ca2+ entry and
sensitization of contractile apparatus by activated PKC plays a pivotal role in initiation
and maintenance of chronic vasospasm.
Activation of PKC and/or increase in DAG has been observed in vasospastic
arteries undergoing experimental chronic vasospasm (Fujikawa et al. 1999; Sato et al.
1997; Matsui et al. 1991a; Nishizawa et al. 1992; Nishizawa et al. 1995; Sako et al.
1993). Application of phorbol ester (12-0-tetradecanoylphorbol-13-acetate), an activator
of PKC induced sustained constriction of dog basilar artery that lasted 3 days mimicking
cerebral vasospasm; preemptive injection of staurosporine, a PKC inhibitor abolished the
constriction induced by phorbol ester (Sako et al. 1993).
Of the known PKC isoforms, α, δ, η and ζ were the common isoforms present in
the canine basilar artery (Nishizawa et al. 2000; Nishizawa et al. 2001). A chronological
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analysis in dog basilar artery myocytes revealed that PKCδ translocated first followed by
PKCα during the development of experimental cerebral vasospasm. Hence, these
isoforms are considered important for the development and maintenance of vasospasm
(Nishizawa et al. 2000). Treatment with topically applied PKC inhibitors, staurosporine,
and H7, attenuated cerebral vasospasm in a canine model of SAH (Matsui et al. 1991b).
However, PKC inhibitors failed to show similar beneficial effects in a rabbit model of
SAH (Zuccarello et al. 1996b).

Current treatments for cerebral vasospasm
Since Ca2+ entry through VSCC is the principle cause for vasospasm, it is not
surprising that most of the therapeutic options available today attempt to minimize the
Ca2+ entry through these channels. Nimodipine, a selective L-type Ca2+ channel
antagonist, which preferentially dilates cerebral arteries, was shown to improve clinical
outcomes in multiple clinical trials (Weyer et al. 2006b). The utility of nimodipine
remains controversial because the improved outcome and reduction in cerebral infarction
was not always associated with a significant decrease in angiographic vasospasm (Allen
et al. 1983; Mayberg et al. 1994). However, nicardipine, another L-type Ca2+ channel that
was expected to work similarly to nimodipine, did not improve the outcome in patients
with cerebral vasospasm in a randomized clinical trial (Haley et al. 1994). Magnesium,
which acts as a Ca2+ channel blocker and as an intracellular Ca2+ antagonist, was found to
reduce the delayed cerebral ischemia in some clinical studies (Wong et al. 2011), but
most studies failed to show any beneficial effect (Suarez 2011).
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A commonly practiced medical intervention to overcome cerebral vasospasm is
triple-H therapy (hypervolemia, hypertension, and hemodilution) (Lee et al. 2006; Sen et
al. 2003). This is achieved by increasing the volume status in patients accompanied by
administration of vasoactive drugs like dopamine or phenylephrine (Sen et al. 2003).
Increased blood volume, high perfusion pressure and reduced viscosity increases the
cerebral perfusion reducing the risk of ischemia. Triple-H therapy however carries a
substantial risk of pulmonary edema, myocardial ischemia, and hyponatremia, not to
mention the risk of re-bleeding in patients after subarachnoid hemorrhage (Sen et al.
2003; Kassell et al. 1982; Solenski et al. 1995). The efficacy and safety of the triple H
therapy remains a question, but it continues to be practiced due to the paucity of effective
alternatives (Dankbaar et al. 2010; Treggiari and Deem 2009).
Clazosentan, a selective ETA endothelin receptor antagonist, which showed
promise in several animal models of SAH, did not show a significant decrease in
vasospasm in a large clinical trial (Macdonald et al. 2011). Nitric oxide donors met with
a similar fate, limited by significant side effects, which included hypotension and
increased intracranial pressure (Fathi et al. 2011). Intra-arterial papaverine (Liu and
Couldwell 2005), administration of antioxidants (Trilizad mesylate), free radical
scavengers (Nicaravin), anti-inflammatory serine protease inhibitors (nafamostat
mesilate), immunosuppressive agents (cyclosporine, prednisolone) have demonstrated
little to no beneficial effect on outcomes (Bederson et al. 2009).
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Need for new treatment options
To date nimodipine is the only drug available with proven, but limited efficacy to
treat cerebral vasospasm (Keyrouz and Diringer 2007; Weyer et al. 2006b; Velat et al.
2011). The limited efficacy may be due to the presence of heterogeneous Ca2+ channel
subunits with varying sensitivities to nimodipine (Navarro-Gonzalez et al. 2009; Nikitina
et al. 2007) and increased expression of nimodipine-insensitive T-type and R-type Ca2+
channels in vascular myocytes following SAH (Nikitina et al. 2010; Link et al. 2008).
Hence, a drug that inhibits the activation of all VSCC subtypes either directly or
indirectly (e.g. by activation of K+ channels and prevention of the membrane
depolarization that activates VSCC) would be expected to be more efficacious than
nimodipine. Therefore understanding the pathophysiological mechanisms that cause
membrane depolarization and vasospasm could lead to discovery of alternative
therapeutic strategies (Keyrouz and Diringer 2007; Deshaies et al. 2009).

Kv7 potassium channels
The following section reviews literature on Kv7 potassium channels with the
emphasis on why Kv7 channels were chosen to test as candidate channels to control
VSMC excitability and contractile status of the basilar artery.

Discovery of Kv7 channels
The KCNQ voltage-sensitive K+ channels (Kv7 channel family) are relatively
newly found members of the diverse class of K+ channels. KCNQ genes that express Kv7
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channel subunits were cloned in the 1990s along with several other genes cloned during
the molecular biology revolution. The name for the family of channels was adopted as
Kv7 based on the deducted phylogenetic relationships (Gutman et al. 2005), but still
widely used interchangeably with KCNQ based on the KCN nomenclature developed by
Human Genome Organization (HUGO) (White et al. 1997).
The first member of this family– KvLQT1 (later renamed KCNQ1) was
discovered in the heart (Sanguinetti et al. 1996), where four of the Kv7.1 subunits
combine to form channels that conduct the slowly activating delayed rectifier K+ current
(IKs). The interest in Kv7 channels then exploded with the identification of Kv7.2/7.3
heterotetrameric channels as molecular correlates of the “M-currents” (Wang et al. 1998),
which were recognized as regulators of membrane excitability in neurons. Wang and his
collegues demonstrated currents similar to neuronal M-currents by injecting cDNA
encoding KCNQ2 and KCNQ3 in Xenopus oocytes.
M-currents (IM), named by virtue of their sensitivity to muscarinic receptor
stimulation, were first identified in frog and rat sympathetic neurons as non-inactivating
K+ currents, slowly activated by membrane depolarization (Adams and Brown 1980;
Constanti and Brown 1981). Identification of M-currents provided the first clear
demonstration of control of neuronal excitability by voltage-sensitive K+ currents
described by several investigators since the 1960s (Kobayashi and Libet 1968; Krnjevic
et al. 1971; Kuba and Koketsu 1976; Weight and Votava 1970). At present, 5 KCNQ
genes (KCNQ1-5), encoding Kv7.1-7.5 channel subunits, have been cloned and channels
formed by these subunits have been found to have important functions in various
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excitable tissues (Jentsch 2000). A great deal of research has focused on demonstrating
the role of Kv7 channels in membrane excitability of neurons, and QT-interval regulation
in cardiac myocytes (Delmas and Brown 2005; Robbins 2001).

Structure and composition of functional Kv7 channels
The molecular composition of Kv7 channels resembles other Kv channels, with
each functional channel composed of homo- or hetero-tetramers of six transmembrane
spanning (S1-S6) channel subunits (Jentsch 2000). The single pore loop (P-loop) formed
between the S5 and S6 domain of each subunit forms the selectivity filter of the pore and
S4 acts as voltage sensor. Both the amino (N)- and carboxyl (C)-terminus of the channel
subunits lie within the cytoplasm. Kv7 channels are however distinct from other Kv
channels in having a long intracellular C-terminus (Delmas and Brown 2005). The Cterminus has a distinctive conserved A-domain that determines the subunit specificity of
the channels (Schwake et al. 2003). Apart from conferring subunit specificity, the Cterminal domain also plays a crucial role in channel gating, assembly, trafficking and
scaffolding with signaling proteins (Haitin and Attali 2008).
While all the subunits can combine among themselves to form homo-tetramers,
the formation of hetero-tetramers, as elucidated by co-expression studies, are restricted to
certain combinations: Kv7.3 with Kv7.2 (Wang et al. 1998); Kv7.4 with Kv7.3, but not
Kv7.2 or Kv7.1 (Bal et al. 2008; Kubisch et al. 1999); Kv7.5 with Kv7.3 and Kv7.4, but
not Kv7.2 (Bal et al. 2010; Schroeder et al. 2000a). Kv7.1 subunits do not
heterotetramerize with other known Kv7 channel subunits. At present, there is no
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evidence to suggest existence of channels comprising Kv7 channel subunits and other Kv
channel subunits (e.g. 4-AP-sensitive Kv channels of the Kv1, Kv2, and Kv4 subtypes).

Expression of Kv7 channels
Although expression was initially thought to be restricted to neurons and cardiac
myocytes, recent evidence suggests that the expression of KCNQ channels is rather
ubiquitous (Brown 2008; Mackie and Byron 2008). In the heart, homotetramers of Kv7.1
subunits co-assemble with two single-transmembrane ancillary protein called minK or
IsK, that alters the gating characteristics of the K+ current (IKs) (Sanguinetti et al. 1996;
Barhanin et al. 1996). MinK is encoded by the KCNE1 gene which belongs to a family of
5 genes, KCNE1 through 5 (McCrossan and Abbott 2004). Interaction of KCNQ1 with
KCNE1 in the heart enhances the amplitude and slows the activation of currents
(Sanguinetti et al. 1996). Dominant mutations in cardiac Kv7.1 channels lead to long QT
syndrome (LQTS1) also called Romano-Ward syndrome, leading to potentially fatal
cardiac arrhythmia (Chiang and Roden 2000; Herbert et al. 2002; Jespersen et al. 2005).
A recessive mutation identified in Kv7.1 or KCNE1 subunits however leads to a severe
form of the disease called Jervell and Lange-Nielsen syndrome (JLNS), where cardiac
arrhythmia is associated with congenital deafness (Neyroud et al. 1997). The deafness is
due to defects in the trans-epithelial transport of K+ through Kv7.1/KCNE1 channels in
the inner ear (Neyroud et al. 1997).
Kv7.2/7.3 heterotetramers that underlie M-currents are the predominant subtype
expressed in neurons (Wang et al. 1998). Channels comprising Kv7.5 and Kv7.4 subunits
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also add diversification to the M-currents with many regions of brain showing
overlapping expression of Kv7.2, Kv7.3, and Kv7.5 subunits (Schroeder et al. 2000a;
Kharkovets et al. 2000). Unlike cardiac Kv7.1 channels, neuronal Kv7 channels do not
appear to interact with ancillary subunits (Jentsch 2000). Mutations in Kv7.2 subunit or
rarely in Kv7.3 subunit lead to an epileptic condition in infants called benign familial
neonatal convulsions (BFNC) (Biervert et al. 1998; Singh et al. 1998). Kv7.4 channels
are expressed in the inner ear cochlear sensory hair cells and vestibular cells. Mutation of
Kv7.4 channels leads to slow degeneration of sensory hair cells resulting in progressive
deafness (Kubisch et al. 1999; Kharkovets et al. 2000).
Recently, transcripts for all known Kv7 channel subunits and KCNE ancillary
subunits were found to be expressed in murine gastrointestinal smooth muscle cells, with
KCNQ4, KCNQ5 and KCNE4 being the predominant transcripts (Jepps et al. 2009). The
authors proposed that the channels function similarly to neuronal Kv7 channels, in
stabilizing the membrane voltage and limiting the gastrointestinal contractility. Apart
from smooth muscle cells, Kv7 channels are expressed in epithelial cells of the colon
where Kv7.1/KCNE3 channels function in the cyclic-adenosine monophosphate (cAMP)stimulated secretion of Cl- ions (Schroeder et al. 2000b).
K+ currents through Kv7 channels were also shown to induce a hyperpolarizing
influence in urinary bladder interstitial cells of Cajal (Anderson et al. 2009), modulating
the contractile status of urinary bladder (Rode et al. 2010). Expression of Kv7 channels
varied with the stage of gestation in mouse and human myometrial smooth muscle cells
and was proposed as a mechanism to modulate uterine contractions during pregnancy

37
(McCallum et al. 2011). Expression of Kv7 channels in vascular smooth muscle cells are
described in detail in a later section of the review of literature.

Biophysical characteristics of Kv7 currents
Outward K+ currents conducted through Kv7 channels in neurons have unique
biophysical characteristics - (1) threshold of activation around the resting membrane
voltage, usually around -60 mV, (2) slow voltage-dependent enhancement of currents
with membrane depolarization from resting voltages, (3) lack of inactivation. These
characteristics of Kv7 currents tend to oppose membrane depolarization and hence act as
a brake for neuronal excitation. Suppression of the currents increases input resistance that
predisposes to increase in probability of action potential firing, responsiveness to synaptic
input and spike frequency in neurons (Hernandez et al. 2008; Marrion 1997).

Regulation of Kv7 channels
(i) Receptors involved in regulation of Kv7/M-current suppression: The
distinctive biophysical characteristics of the Kv7 channels dispose these channels to be
targets of various physiological regulators in excitable cells. Since the discovery of the
sensitivity of M-currents to muscarinic receptor ligands (Brown and Adams 1980), the
channels were found to be regulated by a plethora of G-protein coupled receptors (Adams
and Brown 1980; Marrion 1997). Stimulation of substance P (Jones 1985), luteinizing
hormone releasing hormone (LHRH) (Adams and Brown 1980), purinergic P2Y (Adams
et al. 1982), β-adrenergic receptors

in bullfrog sympathetic ganglia (Akasu 1988);

38
muscarinic and AT1 angiotensin receptors in rat sympathetic ganglia (Constanti and
Brown 1981; Shapiro et al. 1994); M1/M3 muscarinic (Halliwell and Adams 1982), 5HT2 serotonin (Colino and Halliwell 1987), κ and δ opioid (Moore et al. 1994), and
metabotropic glutamate (Charpak et al. 1990) receptors in hippocampal pyramidal
neurons were found to suppress M-currents.
(ii) PIP2 mediated regulation: A perceptible feature of all the aforementioned
receptors is that they are all Gq-coupled receptors. Using a wide-range of approaches
from molecular to knockout mouse models, it is now established that the M-current
suppression is mediated by the Gαq subunit (Caulfield et al. 1994; Haley et al. 1998;
Haley et al. 2000). Second messengers downstream of Gαq subunit activation,
phospholipase(PLC)-β-mediated PIP2 hydrolysis products (IP3, and diacylglycerol),
protein kinase C (PKC), elevation of cytosolic Ca2+ were each proposed as possible
mediators of M-current suppression (Marrion 1997). The identity of the mediator
however remained elusive even after knowledge about the molecular identity of Mcurrents. In 2002, Hille and his colleague showed the first evidence that the suppression
of currents in response to muscarinic receptor stimulation was not mediated by the
hydrolysis products of PIP2, but by the depletion of membrane-bound precursor PIP2
itself (Suh and Hille 2002). Since then, several studies have established that PIP2 is
required to keep the Kv7 channels open and that a reduction in the membrane PIP2
concentration is the primary mechanism of receptor-induced M-current suppression (Suh
and Hille 2007; Li et al. 2005; Winks et al. 2005; Zhang et al. 2003). A strong correlation
was found to exist between the apparent affinity of the Kv7 channel subunits to PIP2 and
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the divergent maximal open probability (Po) of the channels. Homotetrameric Kv7.3
channels with a Po of almost unity (Li et al. 2004b) had the maximum apparent affinity;
Po was in the order of Kv7.3> Kv7.2/7.3> Kv7.2> Kv7.4 channels (Li et al. 2005).
Taking advantage of the differential affinities of the Kv7 subunits, a recent study
constructed chimeras of Kv7.3 and 7.4 subunits to identify C-terminal inter-helix linker
as the site of PIP2 action (Hernandez et al. 2008).
(iii) Signalosomes orchestrating Kv7 channel regulation: The specificity and
efficiency of signal transduction pathways to dynamically regulate the function of several
cell surface proteins are mediated by signalosomes (Negro et al. 2008). Signalosomes are
discrete multifunction protein complexes that compartmentalize signaling events by
bringing together the regulatory intermediates and their substrates. Several lines of
evidence suggest that Kv7 channels are part of a signalasome tethered together by a
scaffolding protein, A-kinase anchoring protein (AKAP)79/150 in neurons. Named after
its ability to bind to protein kinase A (PKA) holoenzyme (Rubin 1994), AKAP79/150 is a
family of 3 known orthologs- human AKAP79, murine AKAP150 and bovine AKAP75
(Colledge and Scott 1999). Apart from PKA, AKAP binds to protein kinase C (Klauck et
al. 1996), protein phosphatase 2B or calcineurin (Coghlan et al. 1995), calmodulin (Faux
and Scott 1997), phosphodiesterases (Dodge et al. 2001) in a multiprotein complex along
with Kv7 channels (Delmas and Brown 2005). AKAP79/150 constitutively binds to Kv7
channels; and suppression of M-currents by muscarinic receptors were dampened by
perturbation of AKAP binding to Kv7 channels (Hoshi et al. 2003; Zhang et al. 2011).
The requirement of AKAP was further supported by reduced M-current suppression in
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response to muscarinic receptor stimulation in the sympathetic cervical ganglion neurons
of AKAP150 knockout mice (Tunquist et al. 2008). The mice were resistant to seizures
induced by pilocarpine, a non-selective muscarinic agonist (Tunquist et al. 2008). The
interaction of Kv7 channels to AKAP was further clarified with the evidence that
AKAP79 associated with KCNQ2-5, but not KCNQ1 using fluorescence resonance
energy transfer (FRET) under total internal reflection fluorescence (TIRF) microscopy in
a heterologous expression system (Bal et al. 2010).
Suppression of M-currents by activation of muscarinic receptors was thought to
be mediated by PIP2 hydrolysis (Hernandez et al. 2008; Suh and Hille 2002; Suh and
Hille 2007; Li et al. 2005; Zhang et al. 2003; Robbins et al. 2006) independent of
diacylglycerol produced during activation of PLC, or the PKC that it might stimulate
(Hille 1994; Suh and Hille 2006). Later studies however showed that at least part of the
muscarinic suppression of currents is mediated by an AKAP-dependent pathway that
involves PKC (Hoshi et al. 2003; Higashida et al. 2005). Knockdown of AKAP79/150 or
expression of dominant negative AKAP150 that cannot bind PKC showed reduced
suppression of M-currents with muscarinic receptor stimulation (Hoshi et al. 2003; Zhang
et al. 2011; Hoshi et al. 2005). Though the PKC bound to AKAP is in the inactive form
(Klauck et al. 1996; Faux et al. 1999), the anchored pool of PKC seems to be essential
for muscarinic suppression of M-currents (Hoshi et al. 2005). The mechanisms by which
muscarinic receptor stimulation activates PKC in the pool anchored to AKAP79/150
remain unclear. Calmodulin, apart from constitutively binding to the channel, binds to
AKAP in a Ca2+-dependent manner (Faux and Scott 1997). Calcium-calmodulin was
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shown to regulate Kv7 currents by competing with and displacing the inactive PKC
bound to AKAP, facilitating its activation by diacylglycerol (Faux and Scott 1997).
Activation of PKC induces a large positive shift (~17 mV) in the conductance-voltage
curve of Kv7 currents (Nakajo and Kubo 2005). PKC likely produces this effect by direct
phosphorylation of serine or threonine residues in the intracellular loop or the C-terminal
domain of the Kv7 channels subunits. Serine534 and 541 in KCNQ2 and T553 in
KCNQ4 have been identified as critical amino acid residues for regulation of the channel
activity by PKC (Bal et al. 2010; Hoshi et al. 2003).
Depletion of PIP2 or phosphorylation by PKC however does not account for Kv7
current suppression by all Gq-coupled receptor-PLC activation. Stimulation of bradykinin
B2 receptors suppresses Kv7 currents by a distinct Ca2+-dependent mechanism. B2
receptor stimulation elevates [Ca2+]C by IP3-mediated Ca2+ release. The elevated cytosolic
Ca2+ interacts with calmodulin bound to the long C-terminal domain of Kv7 channels
resulting in suppression of the currents (Gamper and Shapiro 2003). Kv7 currents are
exquisitely sensitive to elevations of [Ca2+]C with a IC50 of 70-100 nM, slightly above the
resting Ca2+ levels in neurons (Gamper and Shapiro 2003; Selyanko and Brown 1996).
Ca2+-calmodulin inhibited currents through channels formed by Kv7.2, Kv7.4 and Kv7.5,
but not Kv7.1 and Kv7.3 demonstrating subtle subunit specificity (Gamper et al. 2005).
There are 2 non-continuous binding sites for calmodulin in the Kv7 channel
subunits, with only the apo-calmodulin but not Ca2+ bound calmodulin capable of binding
to it (Wen and Levitan 2002; Yus-Najera et al. 2002). Apo-calmodulin acts as an
accessory subunit for the channel and is essential for the normal opening of the channel.
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Regulation of the channel is likely to be complex with perturbation of calmodulin binding
reported to either reduce or increase channel activity (Gamper and Shapiro 2003; Wen
and Levitan 2002). The sensitivity of the channel to Ca2+ requires calmodulin, but the
mechanism by which calmodulin modulates the channel remains to be understood,
though modulation of phosphorylation has been ruled out (Selyanko and Brown 1996).
Muscarinic receptor-induced suppression of Kv7 currents is independent of Ca2+calmodulin-mediated action, as [Ca2+]C is not elevated after muscarinic receptor
stimulation presumably because the muscarinic receptors and IP3 receptors exist in
distinct “microdomains”. Hence, IP3 produced by PIP2 hydrolysis does not reach
threshold levels near the endoplasmic reticulum to release Ca2+ through IP3 receptors
(Delmas et al. 2004). Apart from its role in regulation of Kv7 channels in the membrane,
calmodulin appears to be a critical regulator for trafficking of the channel to the
membrane (Etxeberria et al. 2008; Alaimo et al. 2009).
Tyrosine phosphorylation of Kv7 channels by a non-receptor tyrosine kinase Src
also suppresses the currents by reducing the open probability of the channels. Src
phosphorylation is subunit selective for Kv7.2, 7.3, Kv7.2/7.3 and 7.5 subunits (Gamper
et al. 2003). The tyrosine residues in Kv7.3 subunits were mapped as Y67 in the N
terminus and Y349 in the C terminus, with simultaneous phosphorylation of both the
residues a requirement for regulation by Src (Li et al. 2004a). Src phosphorylation was
however not a mechanism of M current suppression by muscarinic receptor activation in
sympathetic neurons (Gamper et al. 2003), and the physiological significance of Kv7
channel phosphorylation by Src is uncertain. Activation of receptor tyrosine kinases like
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epidermal growth factor receptor (EGFR) and nerve growth factor (NGF) have also been
reported to suppress Kv7 currents, likely through a tyrosine phosphorylation mechanism
(Jia et al. 2007; Jia et al. 2008).
(iv) Transcriptional regulation: Most studies until recently focused on the
regulation of channels present in the plasma membrane. Recently KCNQ2 and KCNQ3
genes were found to be regulated in dorsal root ganglia (DRG) neurons by two well
known transcription factors- sp1 (specificity factor 1), a transcriptional activator and
REST (Repressor element 1-silencing transcription factor), a transcriptional repressor
(Mucha et al. 2010). Overexpression of REST reduced M-current density and increased
excitability of DRG neurons, highlighting the significance of transcriptional regulation of
Kv7 channels. Neuronal expression of REST increased in response to inflammatory
mediators and correlates with a reduction in Kv7.2 subunit expression (Mucha et al.
2010). REST mediated transcriptional downregulation of Kv7.2 channel expression has
been proposed as a mechanism for neuropathic pain (Rose et al. 2011). Peripheral
application of flupirtine, a Kv7 channel opener, was able to alleviate neuropathic
hyperalgesia in a partial sciatic nerve ligation rat model (Rose et al. 2011), possibly by
activating the reduced population of Kv7 channels and opposing the membrane
depolarization in neurons (Passmore and Delmas 2011).

Pharmacology of Kv7 channels
A number of pharmacological agents are available that modulate either all Kv7
channel subtypes or channels formed by select combinations of Kv7 subunits.
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Linopirdine [DuP 996, 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2Hindol-2-one],
a phenylindolinone derivative originally developed as a cognitive enhancer and
neurotransmitter release enhancer (Nickolson et al. 1990) was subsequently found to be
an M-channel blocker (Aiken et al. 1995). The drug is selective for Kv7 channels and
was without appreciable effects on other Kv channels (Wang et al. 1998). The IC50 for
linopirdine block of pan-Kv7 channel varies between 1.2 - 36 µM depending on the
heterogeneity in the molecular composition of the channels (Brown et al. 2002;
Wickenden et al. 2001). Linopirdine and its potent analog XE991 [10,10-bis(4pyridinylmethyl)-9(10H)-anthracenone] are not used clinically because of their
epileptogenic effects produced due to the blockade of Kv7 channels (Zaczek et al. 1998).
Linopirdine and XE991 are however used extensively in the laboratory for experimental
purposes usually at concentrations ≤10 µM as selective irreversible blockers of Kv7
channels (Schnee and Brown 1998; Wladyka and Kunze 2006). XE991 also moderately
blocks other Kv channels reversibly albeit only at voltages positive to +20 mV (Zhong et
al. 2010).
Flupirtine [D-9998, Katadolon®, Ethyl 2-amino-6-((p-fluorobenzyl)amino)-3pyridinecarbamate] is a triaminopyridine, clinically used as a non-opioid analgesic in
Europe since 1984 even before the discovery of Kv7 channels. Though the analgesic
effect was earlier thought to be due to its N-methyl-D-aspartate (NMDA) receptorblocking and γ-amino butyric acid (GABAA) receptor-potentiating effects, it was later
found that the analgesic activity was due to its ability to enhance IM currents within the
therapeutic range (2-6 µM) (Kornhuber et al. 1999; Martire et al. 2004). Structural
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modification of flupirtine yielded retigabine [known as ezogabine in United States; D23129, ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate], which was
10-30 times more potent as a Kv7 channel activator compared to its N-methyl-Daspartate (NMDA) receptor-blocking and γ-amino butyric acid (GABAA) receptorpotentiating effects. Retigabine and flupirtine activate all channels formed by Kv7.2-7.5
subunits through interaction with residues in the S5 and S6 domains of which a
tryptophan residue in S5 is a key element. Retigabine and flupirtine do not activate
channels formed by Kv7.1 subunits, which lack the tryptophan residue in the S5 domain
(Bentzen et al. 2006; Schenzer et al. 2005). Apart from increasing the open probability of
the channel, retigabine also induces a hyperpolarizing shift in activation of Kv7 currents
(Tatulian et al. 2001; Tatulian and Brown 2003).
Recently, compounds were developed to target specific subtypes of Kv7 channels;
ICA-27243 [ N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] selectively activates
heteroterameric channels formed by Kv7.2/7.3 subunits (Wickenden et al. 2008); S(1)
[(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide [(S)-1]]

preferentially

activates channels formed by Kv7.4 and Kv7.5 subunits, but blocks homomeric channels
formed by Kv7.1 subunits (Bentzen et al. 2006; Wu et al. 2003) and BMS-204352
selectively activates channels formed by Kv7.4 and Kv7.5 subunits (Dupuis et al. 2002;
Schrøder et al. 2001). The binding site of ICA-27283 is in the S1-S4 voltage sensor
domain rather than the pore domain in S5-S6 segment as observed with other nonselective Kv7 channel openers (Padilla et al. 2009). The experiments described in this
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dissertation utilize the prototypic commonly used Kv7 channel activators- flupirtine,
retigabine and the inhibitor- XE991 at concentrations selective for Kv7 channels.

Kv7 channels as therapeutic targets
With increasing recognition that a number of human diseases involve alterations
in Kv7 channel function, a variety of pharmacological modulators were developed to
target Kv7 channels in the nervous system (Dalby-Brown et al. 2006). Flupirtine has
been used for almost 3 decades in Europe as an analgesic with muscle relaxing properties
to treat cancer, postoperative or traumatic pain without developing tolerance (Miceli et al.
2008). The more potent analog of flupirtine, retigabine is likely to become available to
treat partial onset seizures in adults (Gunthorpe et al. 2012; Harris and Murphy 2011).
ICA-27283 is under development to treat cortical spreading depression associated with
migrane (Wu et al. 2003). Kv7 channel openers also hold promise to treat other diseases
with disorders of excessive excitability such as anxiety (Korsgaard et al. 2005),
neuropathic pain, cognitive disorders, urinary incontinence (Wickenden et al. 2004),
Alzheimer’s disease and stroke (Czuczwar et al. 2010).

Kv7 channels in vascular smooth muscle cells
The first evidence of existence of Kv7 channels in VSMCs was provided by Ohya
et al., who showed the expression of KCNQ1 transcripts in murine portal vein myocytes.
They demonstrated a linopirdine-sensitive outwardly rectifying K+ current in the presence
of 5 mM 4-aminopyridine (Ohya et al. 2003). The contribution of Kv7 channels to

47
membrane voltage in the myocytes was demonstrated in a follow up study from the same
laboratory. Kv7 channel blockers, linopirdine and XE991 depolarized the membrane and
augmented the spontaneous contractile responses in the portal vein (Yeung and
Greenwood 2005). Using an analytical subtraction method the authors distinguished the
voltage-step evoked currents through Kv7 channels from 4AP-sensitive Kv currents
(Yeung and Greenwood 2005). Another major advancement was made by Brueggemann
et al., who isolated Kv7 currents in cultured rat embryonic aortic smooth muscle (A7r5)
cells and demonstrated the expression of KCNQ5 mRNA transcripts in both rat aortic
smooth muscle cells and A7r5 cells, but KCNQ1 transcripts only in rat aortic smooth
muscle cells and not in A7r5 cells (Brueggemann et al. 2007). Since then several studies
have demonstrated the expression of KCNQ channels in different vascular beds,
mesenteric, carotid, pulmonary, cerebral, femoral artery and aorta showing a consensus in
the expression of KCNQ1, KCNQ4 and KCNQ5 mRNA transcripts with little or no
expression of KCNQ2 and 3 (Zhong et al. 2010; Joshi et al. 2009; Mackie et al. 2008;
Yeung et al. 2007).
A pivotal role of vascular Kv7 channels in the pulmonary arterial system was
demonstrated by a concentration-dependent constriction of rat intrapulmonary artery by
the Kv7 channel blockers, independent of endothelium or neuronal intervention (Joshi et
al. 2006). The constriction produced was dependent on activation of voltage-sensitive
Ca2+ channels (Joshi et al. 2006) as a corollary to the membrane depolarization of
pulmonary artery myocytes induced by Kv7 channel blockers (Joshi et al. 2009).
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The expression and function of the Kv7 channels in human arteries were found to be
similar to the rodent models validating the role of Kv7 channels in regulating vascular
contractility in humans (Ng et al. 2011). Kv7.1 channels, whose expression was earlier
thought to be restricted to heart was found to be expressed in all rodent and human
vascular myocytes studied so far. However, K+ channels formed by Kv7.1 subunits are
not likely important contributors to regulation of vascular reactivity. The conclusions are
based on the ability of retigabine and acrylamide S1 to dilate the pre-constricted rodent or
human arteries and the inability of selective Kv7.1 channel blockers, chromanol 293B, L768673 to constrict rodent or human arteries (Joshi et al. 2009; Mackie et al. 2008;
Yeung et al. 2007; Yeung et al. 2007; Ng et al. 2011; Ng et al. 2011). Although channels
formed by Kv7.1 subunits do not appear to contribute to the resting vascular tone,
selective activation of these channels dilated pre-constricted arteries indicating that these
channels may function in VSMCs under some conditions (Chadha et al. 2012).
The outwardly rectifying currents conducted through Kv7 channels isolated from
A7r5 cells and mesenteric artery myocytes showed a threshold for voltage-dependent
activation negative to -60 mV (Brueggemann et al. 2007; Mackie et al. 2008). Thus, Kv7
channels activate at resting membrane voltages, negative to the threshold for activation of
the voltage-sensitive Ca2+ channels (~-40 mV), providing a hyperpolarizing influence that
will tend to oppose the activation of VSCC. Kv7.5 channels are the only subtype of
channels present in A7r5 cells (Brueggemann et al. 2007). Knockdown of the channels
using an adenoviral vector expressing KCNQ5 short hairpin(sh)-RNA induced persistent
membrane depolarization, triggering repetitive spontaneous Ca2+ spiking in A7r5 cells

(Mani et al. 2009); Figure 1). The Ca

2+
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spiking responses observed in A7r5 cells were

dependent on membrane depolarization and activation of VSCC (Byron and Taylor
1993). Hence K+ current through Kv7 channels acts as a physiological “sub-threshold
brake” in regulating Ca2+ entry through VSCC and thereby determining the contractile
status of VSMCs (Figure 2). The very negative threshold for voltage-dependent
activation distinguishes Kv7 channels from other voltage-sensitive K+ channels
previously proposed to regulate vascular tone. These distinct properties of Kv7 channels
may also enable them to serve as regulators of excitation of VSMCs.
Suppression of Kv7 channel activity has been proposed as a mechanism by which
the vasoconstrictor hormone vasopressin induces its physiological constrictor effects
(Brueggemann et al. 2007; Mackie et al. 2008). The suppression of Kv7 currents by
vasopressin was dependent on protein kinase C activation (Brueggemann et al. 2007;
Mackie et al. 2008), a common signal transduction intermediate of Gq/11-coupled-receptor
activation. Activation of protein kinase A has been shown to enhance the activity of
certain Kv7 channel subtypes in expression system (Schroeder et al. 1998; Chambard and
Ashmore 2005). If this is true in VSMCs, it is likely to induce vasodilation, for example
in response to activation of Gs-coupled β-adrenergic receptors. Kv7 channels are
therefore well placed to function as common signal transduction effectors to regulate
vascular tone in response to vasoconstrictors/dilators. The roles of signal transduction
intermediaries including PIP2 or Ca2+-calmodulin in regulating Kv7 channels in VSMCs
remain to be tested.
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Figure 1: Knockdown of Kv7.5 channel depolarizes the membrane and induces Ca2+
spiking response in A7r5 cells. A. Effect of Kv7.5 channel knock down on membrane
voltage measured in single cells using patch-clamp technique. Knockdown of Kv7.5
channels by expression of KCNQ5 shRNA was confirmed by immunofluorescence and
abolishment of Kv7 currents (not shown). *Significant difference in membrane voltage
between control cells (n=6) and cells expressing KCNQ5shRNA (n=9) using Student’s
“t” test, p<0.005. B. Representative charts show Ca2+ spiking in control A7r5 cells, cells
expressing KCNQ5 shRNA or scrambled shRNA, measured using Ca2+ binding Fura-2
florescent dye. [Reproduced from Mani BK et al., Cell Calcium, 2009; 45(4): 400-11].
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Figure 2: Kv7 channels act as a sub-threshold brake to prevent activation of
voltage-sensitive Ca2+ channels. Outward K+ conductance through Kv7 channels
(yellow color) maintains the membrane voltage (Vm) negative to the threshold for
activation of VSCC (red color) in vascular smooth muscle cells (VSMCs; top left).
Current-voltage (I-V) relationship (right) shows the activation of Kv7 currents (yellow
line) at voltages around the resting Vm (rectangular column). Kv7 currents maintain Vm
negative to the threshold (~-40 mV) for activation of voltage-sensitive Ca2+ currents
(broken red line). Inhibition of the Kv7 currents depolarizes the membrane to voltages
more positive to -40 mV, activating the steeply voltage-dependent VSCC to allow Ca2+
influx and the ensuing contraction of VSMCs (bottom left). [Reproduced from Mani BK
and Byron KL., British Journal of Pharmacology, 2011; 162: 38-41].
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Cardiovascular effects of cyclooxygenase inhibitors
Cyclooxygenase (COX)-2 inhibitors
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed drugs
to treat inflammation and pain. NSAIDs exert their anti-inflammatory effect by blocking
cyclooxygenase enzymes. These enzymes catalyze the biotransformation of arachidonic
acid to prostaglandin endoperoxide intermediates PGG2 and PGH2. These intermediates
are then converted to a variety of prostanoids including prostaglandins, thromboxanes,
and prostacyclins by action of isomerases and synthases. After purification of
cyclooxygenase-1 (COX-1) several years ago (Hemler and Lands 1976), a second
isoform of the enzyme (COX 2) was discovered (Fletcher et al. 1992; Xie et al. 1991)
with a distinct expression and distribution pattern (Willoughby et al. 2000). COX-1 was
recognized as a constitutive form of the enzyme, and COX-2 as an inducible isoform that
catalyzes the production of prostaglandins involved in inflammation and cancer (Grosser
et al. 2006). It is appreciated that labeling COX-1 as “constitutive” and COX-2 as
“inducible” form is an oversimplification. However, it is more certain that COX-2 is the
predominant form elaborated during inflammatory responses (FitzGerald and Patrono
2001).
An approach called the “COX-2 hypothesis” lead to selective targeting of the
COX-2 isoform to treat inflammation and pain. The concept gained traction in an effort
to avoid the adverse gastrointestinal intolerance associated with COX-1 inhibition. The
gastrointestinal complication associated with COX-1 inhibition was thought to be due to
the reduced COX-1 derived PGE2 and PGI2 in gastrointestinal epithelium that protects
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the mucosa from acid irritation. Though there is some evidence that constitutive actions
of COX-2 are also involved in the mucosal inflammation and ulcer healing, the
incidences of GI complications were fewer with COX-2 selective inhibitors compared to
the non-selective COX inhibitors. Three selective COX-2 inhibitors, celecoxib
(CelebrexTM, Pfizer, New York, NY), rofecoxib (VioxxTM, Merck, Whitehouse station,
NJ) and valdecoxib (BextraTM, Pfizer, New York, NY) were approved within a short span
between 1998 and 2001, based on data from small short-term clinical studies (Psaty and
Furberg 2005).

Cardiovascular risk with COX-2 inhibitors
After only a few years into the market, rofecoxib and valdecoxib were withdrawn
(in 2004 and 2005 respectively) due to observations of an increased incidence of
myocardial infarction and stroke with prolonged use. However, celecoxib along with
other “traditional” non-selective COX inhibitors continue to be available to treat
inflammatory pain, but they are marketed with a “black box” warning to highlight the
small risk of myocardial infarction and stroke associated with these classes of drug
(Grosser et al. 2006). The increased cardiovascular risk with use of selective COX-2
inhibitors has been proposed to be due to increase in synthesis of thromboxane A2, a
potent platelet activator and vasoconstrictor and reduction in the synthesis of vasodilatory
and antiaggregatory prostacyclins (Mukherjee et al. 2001).
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Divergence in cardiovascular risk profile among COX-2 inhibitors
A systematic review and meta-analysis of controlled observational studies
revealed a dose-related cardiovascular risk with rofecoxib and diclofenac (another
NSAID, that was found to have COX-2/COX-1 selectivity similar to celecoxib), but not
with celecoxib at commonly used doses (Juni et al. 2004; McGettigan and Henry 2006;
Zhang et al. 2006). The heterogeneity in the risk profile despite belonging to the same
class of drugs remains poorly understood. The divergence was attributed to differences in
pharmacokinetic and pharmacodynamic properties, altered metabolism, inhibition of
carbonic anhydrase and ensuing diuresis (FitzGerald and Patrono 2001; Aw et al. 2005;
Knudsen et al. 2004; Weber et al. 2004). A meta-analysis of nineteen randomized
controlled trials involving 45,451 participants revealed an increase in blood pressure with
COX-2 inhibitors (Aw et al. 2005). A consistently greater increase in systolic and
diastolic blood pressure was observed with rofecoxib in head-to-head trials vs celecoxib,
consistent with the increased cardiovascular risk observed with rofecoxib (Aw et al.
2005; Whelton et al. 2001; Whelton et al. 2002). A disproportionate rise was observed in
systolic blood pressure, widening the pulse pressure with rofecoxib. A steep relationship
observed between systolic BP and incidence of cardiovascular complications in the
Framingham study (Kannel 2000a; Kannel 2000b) indicates that the change in blood
pressure could be a single large risk factor responsible for the increased incidence of
cardiovascular events associated with rofecoxib.
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Vasodilatory effects of celecoxib
Several recent studies demonstrated vasodilatory effects of celecoxib, but not
rofecoxib (Hermann et al. 2003; Klein et al. 2007; Widlansky et al. 2003) indicative of a
vasodilatory compensatory mechanism associated only with celecoxib opposing the
COX-2 mediated increase in blood pressure. The vasodilatory effect of celecoxib in
humans was dependent on the endothelial function (Widlansky et al. 2003; Chenevard et
al. 2003). Using guinea pig coronary artery and aortic rings, Klein et al., suggested that
phosphodiesterase (PDE) 5 enzyme inhibition and amplification of endotheliumdependent nitric oxide/ cyclic-guanosine monophosphate (cGMP) signaling as a
mechanism for the vasodilatory effects of celecoxib (Klein et al. 2007). The study also
revealed that celecoxib, but not rofecoxib inhibited PDE isoforms 4 and 5 in VSMCs at
low micromolar concentrations. A recent study from our laboratory provided evidence
that celecoxib dilated rat mesenteric artery independently of endothelial actions by
activation of Kv7 channels and inhibition of VSCC in arterial myocytes (Brueggemann et
al. 2009). It remains to be seen if the ion channel modulatory effects of celecoxib is due
to inhibition of the PDE enzymes.

Vascular effects of phosphodiesterase enzyme inhibition
Phosphodiesterase enzymes
Phosphodiesterases are isoenzymes that cleave the phosphodiester bond in the
second messenger molecules cAMP and cGMP. Based on the amino acid sequence, the
overall domain structure, catalytic and regulatory characteristics, 11 distinct PDE enzyme
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families (PDE1-11) are known to exist (Omori and Kotera 2007). The PDE enzymes
differ considerably in their substrate specificity. The cAMP-specific enzymes include
PDE4, 7 and 8; the cGMP-specific enzymes include PDE 5, 6 and 9, while PDE1, 2, 3,
10 and 11 cleave both cAMP and cGMP (Omori and Kotera 2007; Maurice et al. 2003).
cAMP and cGMP are key components of intracellular signaling regulating numerous
cellular functions including metabolism, contractility, motility and transcription in almost
all cells including VSMCs (Maurice et al. 2003; Antoni 2000; Klein 2002). Modulation
of PDE enzyme activity is therefore expected to influence a myriad of cell signaling
pathways in diverse cell systems. The relative expression of the isoenzymes across cell
types confer some selectivity to target specific systems.

Vasodilatory effects of phosphodiesterase enzyme inhibition
Of the known PDE isoforms, PDE1, PDE3, PDE4 and PDE 5 are the predominant
enzyme families expressed in VSMCs (Polson and Strada 1996; Rybalkin et al. 2003).
PDE4 and PDE5 are targeted pharmacologically to treat several clinical conditions. PDE4
inhibitors (eg. rolipram, rofulimilast) are used to treat asthma and chronic obstructive
pulmonary disease (O'Byrne and Gauvreau 2009). PDE5 inhibitors (eg. Sildenafil,
tadafil) are used to treat erectile dysfunction and pulmonary hypertension (Arif and Poon
2011; Sandner et al. 2007). A common observation with the inhibition of PDE4 and 5
isoenzymes is a slight reduction in blood pressure owing to its ability to dilate arteries
(Jackson et al. 1999; Kloner 2004; Reffelmann and Kloner 2005; Webb et al. 1999). The
signal transduction mechanisms that lead to relaxation of VSMCs in the arteries (Atalay
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et al. 2006; Gokce et al. 2010; Han et al. 2012; Inoha et al. 2002; Khajavi et al. 1997;
Nishiguchi et al. 2010) are not clearly understood. Activation of K+ channels and
blocking of Ca2+ currents have been proposed as a mechanism of relaxation induced by
PDE inhibitors, with activation BK currents shown to contribute at least in part to the
enhanced K+ conductance (Bardou et al. 2002; Fellner and Arendshorst 2010; Prieto et al.
2006; Salom et al. 2008).

Cerebral vasospasm and phosphodiesterase enzymes
Several studies have proposed inhibition of PDE5 or PDE3 by using milrinone or
sildenafil respectively as an effective therapeutic strategy to treat cerebral vasospasm
(Atalay et al. 2006; Gokce et al. 2010; Han et al. 2012; Inoha et al. 2002; Khajavi et al.
1997; Nishiguchi et al. 2010). Vasospastic basilar artery isolated from SAH dogs showed
robust increased expression of PDE5 isoenzyme compared to control non-spastic arteries
(Inoha et al. 2002). Milrinone, a selective inhibitor of PDE3 that hydrolyses both cAMP
and cGMP has been shown to attenuate cerebral vasospasm in human subjects (Arakawa
et al. 2001; Arakawa et al. 2004; Fraticelli et al. 2008; Shankar et al. 2011). Knowledge
of downstream targets, ion channels in particular that regulate the contractile response
mechanisms can facilitate identification of pharmacological targets to attenuate cerebral
vasospasm.

CHAPTER 3
RESEARCH OBJECTIVES AND RATIONALE
Significance of the project: The project aims to identify the functional existence of Kv7
channels in basilar artery myocytes. Identification of the function of these channels is
expected to reveal the mechanism(s) involved in the pathogenesis of vasospasm and
potentially identify therapeutic targets to treat cerebral vasospasm.

Main hypothesis: Suppression of Kv7 currents by spasmogens is a central phenomenon
in basilar artery vasospasm after SAH; direct Kv7 channel openers will reverse basilar
artery spasm (Figure 3).
The hypothesis was tested by pursuing the following specific aims.

Specific aim 1: To record Kv7 currents from freshly isolated rat basilar artery myocytes
and to determine whether spasmogens – ET-1, 5-HT, and AVP suppress Kv7 currents
using whole cell electrophysiology.
Rationale: Previous studies identified membrane depolarization and Ca2+ influx
through VSCC in myocytes as the primary mechanism for elevation of [Ca2+]c in
vasospastic arteries. Outward currents through Kv7 channels, as shown in neurons and
mesenteric artery myocytes, stabilize membrane voltage of excitable cells. The existence
and possible involvement of the Kv7 channels in membrane voltage regulation in basilar
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Figure 3: Hypothetical role of Kv7 channels in the pathogenesis of basilar artery
vasospasm. We hypothesize that Kv7 (KCNQ) channels are expressed in basilar artery
myocytes and function to maintain the resting membrane potential. Spasmogens elevated
in response to SAH bind to cell-surface receptors to suppress Kv7 currents through a
signal transduction mediated mechanism. Suppression of Kv7 currents induces membrane
depolarization (ΔVm), which activates voltage-sensitive Ca2+ channels (VSCC) leading to
continuous influx of Ca2+ resulting in vasospasm. Direct Kv7 channel activators may be
able to oppose the actions of spasmogens to relieve the vasospasm.
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artery myocytes will help to elucidate the mechanisms involved in development of
vasospasm. Knowledge of the ability of Kv7 channel openers to reverse the spasmogeninduced suppression of currents will provide evidence at the cellular level about the
feasibility of Kv7 channel openers to reverse vasospasm. Apart from utilizing selective
Kv7 channel openers, the study also utilized celecoxib, a recently reported dual Kv7
channel opener and VSCC blocker. The drug was tested as a possible therapeutic agent to
relieve vasospasm, as it is expected to be more effective because of its dual ion channel
modulatory action.
PKC is a common signal transduction intermediate in the constriction induced by
spasmogens. Activation of PKC in myocytes derived from vasospastic myocytes is
reported in several studies. Hence, experiments were undertaken to test if activated PKC
suppresses Kv7 currents.
Experiments: Sprague-Dawley rats were used as a model to test our hypothesis.
Myocytes derived from basilar artery, one of the major conduit arteries in the base of
brain, which undergoes vasospasm after SAH were used in the studies. Single-cell patchclamp electrophysiology techniques were utilized to isolate and identify Kv7 currents and
to test their role in regulating membrane voltage in rat basilar artery myocytes. The
following experiments tested our hypothesis at a cellular level:
(1)

Isolation and identification of Kv7 currents based on biophysical characteristics and
their modulation by selective Kv7 channel modulators.

(2)

Sensitivities of Kv7 currents to spasmogens involved in vasospasm were examined.

(3)

Effects of Kv7 channel blockers and spasmogens on membrane voltage were tested.

(4)
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Abilities of direct Kv7 channel openers to reverse the spasmogen-induced
suppression of Kv7 currents and membrane depolarization in basilar artery
myocytes was tested.

(5)

Effect of celecoxib on Kv7 currents and voltage-sensitive Ca2+ currents in basilar
artery myocytes was examined.

(6)

The effect of PKC activation on Kv7 currents was tested.

Specific aim 2: To evaluate the ability of Kv7 channel opener(s) to reverse/prevent the
vasoconstriction induced by spasmogens in pressurized rat basilar arteries.
Rationale: We hypothesize that the potent constrictor actions of spasmogens on
basilar artery are mediated by suppression of Kv7 currents, membrane depolarization and
activation of VSCC. Selective small molecule activators of Kv7 channels should hence
be able to reverse the constriction induced by spasmogens. The electrophysiology
experiments described in aim 1 tested our hypothesis at the level of individual myocytes,
whereas the experiments proposed in this aim examined if these cellular mechanisms are
integrated to induce functional basilar artery constriction/dilation.
Experiments: Pressure myography was used to examine the role of Kv7 channels on
the contractile status of basilar artery. The following experiments tested our hypothesis at
the organ level:
(1)

The effect of a Kv7 channel blocker on the contractile status of basilar artery was
examined.

(2)

We hypothesized that vasoconstriction induced by spasmogens involve Kv7 current
suppression and Ca2+ influx through VSCC. Therefore, additivity experiments were
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performed to reveal whether spasmogen-induced constriction involves suppression
of Kv7 currents.
(3)

The ability of selective Kv7 channel openers− flupirtine and/or retigabine, VSCC
blocker− nimodipine and dual Kv7 channel opener and VSCC blocker− celecoxib
to reverse/prevent spasmogen-induced constriction were tested.

(4)

The ability of PKC activators to constrict basilar artery segments was investigated.

Specific aim 3: Evaluate the ability of Kv7 channel openers to attenuate basilar artery
vasospasm in a rat model of SAH.
Rationale: We hypothesize that consequent to SAH, suppression of Kv7 currents in
basilar artery myocytes by elevated concentrations of spasmogens in cerebrospinal fluid
is a basic pathology in vasospasm. Hence, administration of Kv7 channel openers is
expected to overcome Kv7 current suppression and attenuate vasospasm after SAH.
Sustained hypotension may limit the utility of K+ channel openers or CCBs in the
effective treatment of cerebral vasospasm. Therefore, the effect of Kv7 channel openers
on mean arterial pressure (MAP) was measured in normal rats.
Experiments:
(1)

SAH was experimentally induced in rats by injection of autologous blood into the
rat's cisterna magna to simulate the presence of blood after SAH. SAH rats were
administered either the Kv7 channel opener− retigabine or dual Kv7 channel opener
and VSCC blocker− celecoxib after hemorrhage. The ability of Kv7 channel
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openers to attenuate vasospasm was assessed by measurement of basilar artery
diameter 48 hours after hemorrhage.
(2)

The effect of Kv7 channel openers on MAP was measured in normal rats using
radiotelemetry. The dosage schedule for MAP measurements mimicked the drug
administration in the diseased animal model.

Specific aim 4: To identify the mechanism by which celecoxib induces ion channel
modulatory activity.
Rationale: Celecoxib is clinically utilized as a COX-2 inhibitor to treat
inflammation and pain. Celecoxib is a unique COX-2 inhibitor that induces vasodilation
and a modest reduction in blood pressure whereas other drugs that belong to the same
class have a tendency to increase blood pressure. We presented evidence that celexocibinduced Kv7 current enhancement and voltage-sensitive Ca2+ current inhibition could
account for the anti-hypertensive effects of celecoxib. Celecoxib was reported to inhibit
phosphodiesterase (PDE) enzyme isoforms 4 and 5 in VSMCs, physiologically critical
targets among the several other known non-specific molecular targets of celecoxib.
Therefore, we tested if celecoxib induces its ion channel modulatory effect by virtue of
phosphodiesterase enzyme inhibition. These experiments therefore are also expected to
reveal if activation of Kv7 channels is the mechanism by which several clinically
employed PDE inhibitors induce vasodilation and modest reductions in blood pressure.
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Experiments:
(1)

Determine the effect of clinically utilized PDE inhibitors− rolipram (prototype
PDE4 inhibitor), sildenafil (prototype PDE5 inhibitor), papaverine (non-selective
PDE inhibitor) on Kv7 currents in rat aortic smooth muscle (A7r5) cells.

(2)

Determine if PDE inhibitors also mimic the effect of celecoxib as a voltagesensitive Ca2+ channel blocker were also tested using A7r5 cells.

(3)

Determine the effect of the PDE inhibitors on AVP-induced Ca2+ entry, measured in
fura-2 loaded A7r5 cells.

(4)

Determine the effect of PDE inhibition on mesenteric artery segments preconstricted with AVP to validate the dilation induced by PDE inhibitors.

CHAPTER 4
MATERIALS AND METHODS

Animal Welfare and Housing
All animals used in the study were purchased from Harlan laboratories,
Indianapolis, Indiana. Animals were housed in pairs in standard plexiglass cages, fed
with standard rat chow under 12 hours dark-light cycle. All procedures described in this
study were approved by the Institutional Animal Care and Use Committee, Loyola
University Medical Center, Maywood, IL and were carried out according to the
guidelines for animal welfare (Guide for the Care and Use of laboratory Animals,
National Research Council, National Academy press, Washington D.C, Rev. 1996).

Basilar artery dissection
Male Sprague-Dawley rats, 275-325g, were euthanized by cardiac extirpation
(surgical removal of heart) under 4% isoflurane anesthesia. The brain was removed
immediately and placed in ice-cold dissection solution (in mM - 145 NaCl, 4.7 KCl, 1.2
NaH2PO4, 1.2 MgSO4, 2 CaCl2·2H2O, 2 pyruvic acid, 0.02 EDTA dihydrate, 3 MOPS,
and 5 D-glucose with 1% bovine serum albumin (BSA), pH 7.4 at 0° C, osmolarity
adjusted to 300 mOsm/L using D-glucose). The basilar artery was dissected free from the
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brain and used for isolation of myocytes for patch-clamp procedures, polymerase chain
reaction (PCR) or pressure myography.

Isolation of basilar artery myocytes
Myocytes were isolated from the basilar artery by modifying the procedure
described by Berra-Romani et al. for mesenteric artery myocytes (Berra-Romani et al.
2005). The dissected basilar artery was cut into 2 or 3 segments and placed in low-Ca2+
physiological saline solution (low-Ca2+ PSS, in mM): 140 NaCl, 5.36 KCl, 0.34
Na2HPO4, 0.44 K2HPO4, 10 HEPES, 1.2 MgCl2, 0.05 CaCl2, and 10 D-glucose, pH
adjusted to 7.2 at 37°C using NaOH, osmolarity adjusted to 298 mOsm/L using Dglucose) for 30 min. The arterial segments were then subjected to enzymatic digestion in
low-Ca2+ PSS containing (in mg/ml) 2 collagenase type XI; 0.16 elastase type IV , and 2
BSA (fraction V, protease-free) at 37°C for 30 min. The digested segments were
repeatedly washed with ice-cold low-Ca2+ PSS to remove the enzymes and then the
individual myocytes or clusters of myocytes were released from the segments by
trituration using fire-polished Pasteur pipettes.

Polymerase chain reaction
Reverse transcription polymerase chain reaction (PCR) was used to detect the
KCNQ gene products (Kv7 channel mRNA transcripts). Myocytes were freshly isolated
from basilar artery segments by enzymatic digestion and total RNA was isolated using
RNeasy Kit (Qiagen, Valencia, CA). PCR was performed essentially as described
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previously (Brueggemann et al. 2007). cDNA was synthesized with iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA), and then one-tenth of the cDNA product was used
for PCR. PCR was carried out using Platinum PCR Supermix (Invitrogen) and 10 pmols
of forward and reverse primers at the appropriate annealing temperature (dependent on
primer pair). Primers were adapted from previous publications: KCNQ1–3 and KCNQ5
(Ohya et al. 2002) and KCNQ4 (Yeung et al. 2007) to correspond to rat sequences (Table
1).

Electrophysiology
Freshly isolated myocytes or A7r5 cells were allowed to attach to glass coverslips
for 10-15 minutes at room temperature or at 37°C respectively. Whole-cell currents or
membrane voltage were measured by using perforated patch configuration (120 μg/ml
Amphotericin B was included in the internal solution) under voltage-clamp or currentclamp conditions. All measurements were made with continuous perfusion of bath
solution at room temperature.
(A) Kv7 currents in basilar artery myocytes: Whole cell Kv7 currents were
recorded from basilar artery myocytes as described previously (Mackie et al. 2008;
Brueggemann et al. 2009). Bath solution contained (in mM): 140 NaCl, 5.36 KCl, 1.2
MgCl2, 2 CaCl2, 10 HEPES, 10 D-glucose. Bath solution pH and osmolarity was adjusted
to 7.3 and 298 mOsm/L using NaOH and D-glucose respectively. Internal (pipette)
solution contained (in mM): 135 KCl, 5 NaCl, 10 HEPES, 0.05 K2EGTA, 1 MgCl2, 20
D-glucose. Internal solution pH and osmolarity was adjusted to 7.2 and 298 mOsm/L
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using KOH and D-glucose respectively. Currents were recorded by application of 5 s
voltage steps from a -4 mV holding voltage to test voltages ranging from -84 mV to +16
mV. Gadolinium chloride (GdCl3; 100 μM) and spermine (100 µM; to inhibit the
inwardly-rectifying K+ currents) were included to the bath solution. Apart from blocking
L- and T-type Ca2+ channels (Beedle et al. 2002; Biagi and Enyeart 1990) and nonselective cation channels (Miyoshi et al. 2004; Setoguchi et al. 1997; Zhang et al. 2000),
Gd3+ shifts activation of 4-AP-sensitive KV currents to voltages positive to -20 mV
(Figure 4) enabling isolation of Kv7 currents at voltages negative or equal to -20 mV.
Whole-cell K+ currents were digitized at 2 kHz and filtered at 200 Hz. Whole-cell
capacitance was compensated. The steady-state K+ currents recorded during the last 1000
ms (2000 points) of each voltage step were averaged and normalized to cell capacitance
to obtain the current-voltage (I-V) relationship. In experiments with variations in current
density, I-V relationships were derived by normalizing the sustained currents measured at
each voltage to the mean current measured at -20 mV before treatment. Time-course of
enhancement or inhibition of isolated Kv7 currents was recorded by continuous
measurement of outward currents at -20 mV holding potential.
(B) Membrane voltage measurements in basilar artery myocytes: Membrane
voltages were recorded from individual myocytes or clusters of myocytes in current
clamp (I = 0) mode. The bath solution and the internal solution were the same as used to
record Kv7 currents, but performed in the absence of GdCl3 and spermine. Membrane
voltage was recorded for at least 5 min before treatment. The effect of treatment on
membrane
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Figure 4: Addition of gadolinium enables isolation of Kv7 currents. A. Currentvoltage curves show response of 4-AP-sensitive Kv currents to the addition of 100 µM
Gd3+. B. Normalized conductance plots of 4-AP-sensitive-Kv currents fitted by a single
Boltzmann function shows positive shift in activation of the currents with the addition of
Gd3+ (half maximal activation of currents is shifted by approximately 15 mV, n=3). This
enabled isolation of Kv7 currents at voltages ≤ -20 mV, without contribution from 4-APsensitive Kv currents. [Reproduced from Mani BK et al., British Journal of
Pharmacology, 2011; 164: 237-249].
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membrane voltage was determined by taking the mean of the values recorded over at
least a 1 min period, prior to treatment, and at the end of treatment.
(C) Voltage-sensitive calcium currents in basilar artery myocytes: To record
currents through voltage-sensitive Ca2+ channels in basilar artery myocytes, 10 mM Ba2+
was used as a charge carrier. Inclusion of Ba2+ as a charge carrier is routinely used in
patch-clamp experiments to measure voltage-sensitive Ca2+ currents for two reasons: (i)
switching from Ca2+ to Ba2+ as the charge carrier changes the rapidly inactivating
currents to a more slowly inactivating and larger currents, (ii) use of Ba2+ as charge
carrier avoids entry of Ca2+, which would activate the contractile apparatus and constrict
the myocytes. The bath solution contained (in mM): 140 NaCl, 2.7 KCl, 10 BaCl2, 10
HEPES. Bath solution pH and osmolarity was adjusted to 7.3 and 298 mOsm/L using
NaOH and D-glucose or water respectively. Internal solution contained (in mM): 135
CsCl, 10 HEPES, 10 Cs2EGTA, 2.5 MgCl2, 10 D-glucose. Internal solution pH and
osmolarity was adjusted to 7.2 and 298 mOsm/L using CsOH and D-glucose respectively.
Whole-cell capacitance was compensated. Ba2+ currents were recorded in isolation by
application of a 300 ms voltage step protocol from -90 mV holding voltage to test
voltages ranging from -85.2 to +44.8 mV. Whole-cell voltage-sensitive Ba2+ currents
were digitized at 10 kHz and filtered at 5 kHz and the peak inward current was measured
and normalized to cell capacitance.
(D) Kv7 currents in A7r5 cells: Whole-cell Kv7 K+ currents were recorded in
A7r5 cells, essentially as described previously (Brueggemann et al 2009). The standard
bath solution contained (in mM): 5 KCl, 130 NaCl, 10 HEPES, 2 CaCl2, 1.2 MgCl2, 5 D-
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glucose. Bath solution pH and osmolarity was adjusted to 7.3 and 268-270 mOsm/L
using NaOH and D-glucose respectively. Standard internal (pipette) solution contained
(in mM): 110 K gluconate, 30 KCl, 5 HEPES, 1 K2EGTA. Internal solution pH and
osmolarity was adjusted to 7.2 and 268-270 mOsm/L using KOH and D-glucose
respectively. GdCl3 (100 μM) was added to external solution to isolate Kv7 currents. The
currents were recorded using a 5 s voltage steps from a -74 mV holding potential to test
potentials ranging from -94 mV to +36 mV. Whole-cell capacitance was compensated.
Whole-cell K+ currents were digitized at 2 kHz and filtered at 200 Hz. The last 2000
points recorded during each voltage step (corresponding to 1000 ms recording time) were
averaged and normalized by cell capacitance to obtain end pulse steady-state K+ current
for each voltage step. In experiments with variations in current density, I-V relationships
were derived by normalizing the sustained currents measured at each voltage to the mean
current measured at -20 mV before treatment. Time course of changes in isolated Kv7
currents with treatment were recorded by continuous measurement of outward current at 20 mV holding potential.
(E) Voltage-sensitive calcium currents in A7r5 cells: To record voltage-sensitive
Ca2+ currents in isolation in A7r5 cells, a Cs+-containing internal solution was used (in
mM): 110 Cs aspartate, 30 CsCl, 5 HEPES, 1 Cs2EGTA, pH 7.2. Internal solution pH and
osmolarity was adjusted to 7.2 and 268 mOsm/L using CsOH and D-glucose respectively.
Voltage sensitive Ca2+ currents were recorded using 10 mM Ba2+ as a charge carrier (in
mM): 120 Tris-MES, 10 BaCl2, 5 HEPES, 1 MgCl2, pH 7.3, 268 mOsm/L. Isolated Ca2+
currents were recorded with a 300 ms voltage step protocol from -90 mV holding

2+

potential. Whole-cell Ca
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currents were digitized at 10 kHz and filtered at 5 kHz; peak

inward current was measured and normalized by cell capacitance. In experiments with
variations in current density, I-V relationships were derived by normalizing the peak
currents measured at each voltage to the maximal peak inward current measured before
treatment.
For all electrophysiology measurements, liquid junction potentials were
calculated using Junction Potential Calculator provided by PCLAMP8 software and
subtracted off-line. At least two control recordings were made to ensure that the currents
were stable before treatment. Current-voltage (I-V) curves for the K+ currents and
voltage-sensitive Ca2+ currents were derived after leak subtraction using a procedure
described by Passmore et al. (Passmore et al. 2003). To analyze the voltage-dependence
of channel activation of Kv7 currents, the conductance was calculated from steady-state
K+ currents according to the equation G=I/(V-Erev) and normalized by maximum
conductance for each experiment. In the equation, I is the steady-state current, V is the
step potential and Erev is the reversal potential (Wickenden et al. 2001). Erev for K+ was
calculated to be -86 mV using the Nernst equation. Normalized conductance was fitted by
a Boltzmann distribution: G/Gmax=1/[1+exp(V0.5-V)/s], where G/Gmax is fractional
maximal conductance, V0.5 is the voltage of half-maximal activation and s is the slope
factor.
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2+

[Ca ]c measurements in A7r5 cells using Fura-2
Changes in the [Ca2+]c were measured using fura-2/acetoxymethyl ester at room
temperature as described previously (Mani et al. 2009). A7r5 cells cultured to confluent
monolayers in six-well plates were washed twice with modified Kreb’s medium (135 mM
NaCl, 5.9 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 11.5 mM D-glucose, and 11.6 mM
HEPES, pH adjusted to 7.3 using NaOH) and then incubated in the same medium with 1
μM fura-2 acetoxymethyl ester (Invitrogen), 0.1% bovine serum albumin, and 0.02%
Pluronic F127 detergent for 60 min at room temperature (22–25°C) in the dark. Changes
in [Ca2+]c with treatment were measured using a Biotek Synergy HT plate reader (340and 380-nm excitation, 510-nm emission) (BioTek Instruments, Winooski, VT).
Frequency of spiking was calculated as the number of spikes per minute from the time of
onset of repetitive Ca2+ spiking. Each “n” represents the mean of triplicate wells.

Pressure Myography
The effects of various treatment conditions on basilar artery diameter were
studied using a pressure myograph system (DMT-USA, Atlanta, GA) as described
previously (Henderson and Byron 2007). The pipette contained physiological saline
solution (in mM - 145 NaCl, 4.7 KCl, 1.2 NaH2PO4, 1.2 MgSO4, 2 CaCl2·2H2O, 2
pyruvic acid, 0.02 EDTA dihydrate, 3 MOPS, and 5 D-glucose with 1% BSA, pH 7.4
adjusted at 37°C with NaOH, osmolarity adjusted to 300 mOsm/L with D-glucose) and
the bath contained the same solution without BSA. The artery segment was transferred to
the pressure myograph system and secured to the glass pipettes using nylon sutures. By
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gradually increasing the pressure using a pressure column, the arteries were pressurized
to 80 mmHg (the pressure that would be expected in the basilar artery in vivo) (Weyer et
al. 2006a). The bath solution was gradually warmed to 37°C. The viability of the vessel
was confirmed by observation of a quick constrictor response to the depolarization
induced by transient application of 60 mM KCl saline solution. The artery segment was
then allowed to equilibrate and arteries with diameters that were stable for at least 30 min
were used in the study. Arteries that developed myogenic tone (a decrease in diameter
coinciding with pressurization to 80 mmHg) or that failed to respond to KCl were
discarded. The concentration of spasmogens was chosen based on the EC50
concentrations to constrict basilar artery (Nishimura 1996; Katori et al. 2001; Mayhan
1998). The vasoconstrictor/vasodilator responses to various treatments were measured
and the results are presented as changes in outer vessel diameter, in micrometers.
Pressure myography experiments utilizing mesenteric artery segments were also
performed similar to the basilar artery pressure myography experiments described above.
Third or fourth order mesenteric artery segments were utilized for the study.

SAH-induced cerebral vasospasm model
SAH in humans is produced primarily by the spontaneous rupture of aneurysms
commonly found in cerebral arteries. The syndrome is not reported in animals, but animal
models of SAH are developed by introduction of blood into the subarachnoid space. Two
common methods of introduction of autologous blood are stereotactic injection of blood
into the cisterna magna or endovascular puncture of cerebral blood vessels (Megyesi et
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al. 2000; Titova et al. 2009). While dogs and rabbit were commonly used previously,
many investigators have recently moved to rat model of SAH for ease of use (Nystoriak
et al. 2010; Titova et al. 2009; Marbacher et al. 2011).
In the present study, SAH-induced cerebral vasospasm was induced in rats by
introduction of blood using a posterior cranio-cervical approach under aseptic conditions.
Male Sprague-Dawley rats (300- 350g) were used for a single-injection SAH model using
procedures similar to those described previously (Gules et al. 2002). The left or right
femoral artery was first cannulated under 3% isoflurane anesthesia. The rat was then
anesthetized by intramuscular administration of ketamine (80 mg/kg) and xylazine (8
mg/kg) and secured in a stereotaxic apparatus. A small sub-occipital incision was made to
expose the arch of the atlas, the occipital bone, and the atlanto-occipital membrane. The
cisterna magna was tapped to remove 0.1 ml of CSF followed by 2 min slow injection of
0.3 ml of artificial cerebrospinal fluid (aCSF; solution contained, in mMol/L - 125 NaCl,
2.5 KCl, 1 MgCl.6H2oO, 1.25 NaH2PO4, 2 CaCl2·2H2O, 25 NaHCO3 and 25 D-glucose,
pH 7.3 at 37° C, 300 mOsm/L) or autologous blood drawn from the femoral artery.
Immediately after injection, the hole was sealed with glue to prevent fistula. The animal
was tilted at a 30º angle for 30 min in a head lowered position to permit distribution of
blood (or aCSF) in the subarachnoid space. Pain was relieved by subcutaneous injection
of buprenorphine (0.03 mg/kg). The rats were returned to the cage after suturing the skin
to allow recovery from anesthesia. Of the 51 rats that underwent the surgery, 13 rats, all
of which were injected with arterial blood into the cisterna magna, died during the
surgery. The surviving rats were grouped randomly and treated with intra-peritoneal
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administration of retigabine (7.5 mg/kg), celecoxib (20 mg/kg) or the solubilizing vehicle
(DMSO; (1 ml/kg) starting an hr after SAH and repeated twice a day until 48 hr (4 doses
in total). Doses of retigabine and celecoxib were adopted from the previous studies in
which the drugs were utilized for their anti-seizure and anti-inflammatory properties,
respectively (Cuzzocrea et al. 2002; Blackburn-Munro et al. 2005). Two SAH rats, one
treated with vehicle and the other treated with retigabine, died during the course of
treatment. Body temperature was measured rectally using a digital thermometer (Warner
Instruments, CT).
Body temperature measurements were made every 24 hr after the surgical
induction of SAH before the impending drug treatment. The neurological endpoints were
assessed using behavioural tests used in ischemic stroke models (Garcia et al. 1995). The
functions assessed were spontaneous activity, symmetry in movement of limbs when
suspended by tail, forepaw out reaching, climbing on a wire cage, body proprioception,
and response to vibrissae touch. All assessments were conducted by personnel who were
blinded to the treatments given to the rats. The rats were humanely euthanized with 100%
CO2 inhalation 48 hr after surgery (or 12 hr after last drug treatment). The brain was
removed immediately and the basilar artery was photographed using a dinocapture digital
system (AnMo Electronics Corporation, Taipei, Taiwan). Measurements of the outer
diameter of the basilar artery were made at 10 places along the length of the basilar
artery. The measurements were averaged to obtain the basilar artery diameter of each rat
and expressed in micrometers.
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Blood pressure measurements
The catheter tips of previously used Physiotel® PA-C40 or C50-PXT transmitters
(data Science International, St. Paul, MN) were re-gelled, and the pressure and
temperature offsets were checked as per the instructions provided by the manufacturer.
The transmitters were then sterilized using Cidex® OPA solution (0.55% Orthophthalaldehyde), rinsed and stored in saline prior to implantation. Thirteen male SpragueDawley rats (275- 325g) were aseptically implanted with PhysioTel® PA-C40 or C50PXT radio-telemetry transmitters (Data Sciences International (DSI), St. Paul, MN) to
allow continuous recording of blood pressure in freely moving rats. Under 3% isoflurane
anesthesia, a ventral midline laporatomy was performed and the abdominal contents were
gently exteriorized into a moist and warm sterile gauze. Blood flow through the
abdominal aorta was briefly interrupted using a bulldog clamp. The catheter of the radiotransmitter was inserted through a puncture made posterior to the blockade of blood flow.
The puncture hole was immediately sealed with medical glue and the blood flow was
restored. The abdominal contents were placed back into the peritoneal cavity. The
transmitter body was placed in the cavity and secured with abdominal sutures. Rats were
administered buprenorphine 0.03 mg/kg s/c and ampicillin 50 mg/kg i/m every 8-12
hours for 2 days or as needed after surgery. The rats were allowed to recover from
surgery for 10 days and then distributed into 2 groups such that MAP measured before
treatment was approximately equal in each group. Blood pressure (mm Hg) was
measured in each rat for 10 seconds every 10 minutes for 72 hours (Dataquest A.R.T 3.1
Gold Telemetry System, DSI, with RPC1 receivers). Each group underwent 2 treatments
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separated by a 72-hour recovery period. The first treatment was control (no treatment) or
vehicle treatment (DMSO, 1ml/kg i.p, every 12 hours) and the second treatment was
retigabine (7.5 mg/kg i.p, every 12 hours) or celecoxib (50 mg/kg i.p, every 12 hours).
Prior to each treatment, baseline blood pressure was recorded for 24 hours. This was
followed by a 48-hour recording during treatment. Data were exported offline using
Dataquest ART analysis software (DSI) to a spreadsheet for further analysis.

Data presentation and Statistics
Data are presented as group mean ± standard error of the mean. Data were
analyzed using Clampfit (Axon Instruments) and SigmaStat (Systat Software, Inc.)
software programs. Student's ‘t’ test was used for comparison between 2 groups,
Student's paired‘t’ tests were used for comparisons of parameters measured before and
after treatments. Data derived by multiple treatments on the same system were
statistically compared by using repeated measures analysis of variance (RM-ANOVA)
followed by Holm-Sidak post hoc test. Comparisons among multiple independent
treatment groups were evaluated by analysis of variance (ANOVA) followed by HolmSidak post hoc test. Differences with P-value ≤ 0.05 were considered statistically
significant.

Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) with the
exception of the following. Amphotericin B and nimodipine were from Calbiochem (San
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Diego, CA), BSA fraction V was from Boehringer Mannheim (Germany), celecoxib were
from LKT Laboratories, Inc. (St. Paul, MN), retigabine was from LGM Pharma, Inc.
(Boca Raton, FL), XE991 was from Ascent Scientific (Princeton, NJ). Drugs were
prepared as stock solutions in vehicle for patch-clamp and pressure myography
experiments and used at dilutions between 1:1000 and 1:10,000.
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Gene

Primer (+) sense, (-) antisense

Accession #

Amplicon

KCNQ1

(+) CACATCCAGGGCCGCGTCTA
(-) GACTACAGAGCCCAGGAGCC

AJ133685

453 bp

KCNQ2

(+) GATTGCCTCCATTGCTGTGCT
(-) ATGAGGGTAACGTCGCTGCTA

AF087453

372 bp

KCNQ3

(+) AACAGCACCGTCAGAAGCACT
(-) TAGCCCCTGTCTCTGTCATG

AF091247

424 bp

KCNQ4

(+) GCTCACGGTGGATGATGTCA
(-) TGTGGTAGTCCGAGGTGATG

XM233477

359 bp

KCNQ5

(+)CCACCACTCAAAACCGTCATCCGAGCCATCAG
(-)TCTCGTGTTCTGCCGTTATTTTCTCTCGGCTCTT

XM001071249

240 bp

Table 1: Primers used for reverse-transcriptase polymerase chain reaction. Presence
of KCNQ mRNA was assessed in isolated rat basilar myocytes using the primers listed.
Positive (+) sequences represent the 5’ to 3’ sense strand and the negative (-) sequences
represent the 5’ to 3’ antisense strand.

CHAPTER 5
RESULTS
Expression of KCNQ genes in rat basilar arteries
Reverse transcriptase-PCR was used to evaluate the gene expression pattern of
Kv7 channels in basilar artery myocytes. The mRNAs of all five mammalian KCNQ
genes (KCNQ1-5, encoding Kv7.1-Kv7.5 channels) were detected (Figure 5).

Kv7 currents in basilar artery myocytes
To assess the presence of functional channels, Kv7 currents were recorded in
basilar artery myocytes using patch-clamp electrophysiology under voltage-clamp
conditions (Figure 6A). Kv7 currents were isolated by using a pharmacological approach
and by utilizing the distinct biophysical properties of Kv7 currents (activation at very
negative membrane voltages of around -60 mV, non-inactivation). GdCl3 (100 μM) was
included to the bath solution to block L- and T-type Ca2+ channels, non-selective cation
channels, and to shift activation of 4-AP-sensitive KV currents to voltages positive to -20
mV (Figure 4; (Brueggemann et al. 2012). Outwardly rectifying currents were recorded
with a threshold for voltage-dependent activation < -60 mV and half-maximal activation
(V0.5) at ~ -34 mV (Figure 6C and D). Addition of 10 µM flupirtine, a selective Kv7
channel activator, significantly enhanced the Kv7 currents at all voltages tested from 49.2 to +5.8 mV; at -20 mV, the voltage at which we observed near-maximal activation,
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Figure 5: Kv7 channels are expressed in basilar artery myocytes. Reverse
transcriptase (RT)-PCR detection of KCNQ1 through KCNQ5 from mRNA extracted
from basilar artery myocytes. Expected sizes of each reaction product are KCNQ1, 453
bp; KCNQ2, 372 bp; KCNQ3, 424 bp; KCNQ4, 359 bp; and KCNQ5, 240 bp. Molecular
weight marker (100 base-pair ladder, New England Biolabs, Ipswich, MA., is shown in
the left lane). The reaction products were confirmed by sequencing. [Reproduced from
Mani BK et al., British Journal of Pharmacology, 2011; 164: 237-249].
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Figure 6: Kv7 currents in basilar artery myocytes. A. Representative current traces
recorded form a basilar artery myocyte (capacitance = 38.72 pF) under control conditions
(left, untreated), treatment with 10 µM flupirtine (middle) and 10 µM XE991 (right;
dotted lines indicate zero current). Inset shows the schematic of the voltage protocol used
to record the Kv7 currents. B. Representative time course of Kv7 currents recorded by
continuous holding at -20 mV in a single basilar artery myocyte before and during the
application of 10 µM flupirtine. The voltage-activated currents were enhanced with the
application of flupirtine and restored to control levels after wash out of flupirtine (Bars
above the trace indicate the duration of treatment or wash out. C. Summarized I-V
curves show the outwardly rectifying Kv7 currents (control; ) and the response to
application of 10 µM flupirtine ( ) and 10 µM XE991 ( ). *Significant enhancement of
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Kv7 currents at all tested voltages from -49.2 to +5.8 mV compared to control (Paired
Student's ‘t’ test, p < 0.05; n = 4). D. Normalized conductance plots fitted by a single
Boltzmann function shows no significant shift in the steady-state voltage dependence of
activation of currents with addition of flupirtine; G/Gmax, fraction of maximal
conductance. [Reproduced from Mani BK et al., British Journal of Pharmacology, 2011;
164: 237-249].
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currents more than doubled with the addition of flupirtine (0.04 ± 0.01 pA/pF before
(control) compared to 0.09 ± 0.02 pA/pF after addition of flupirtine (n=4; Figure 6C).
The effect of flupirtine was reversible on wash out (Figure 6B). There was no significant
shift in the steady-state voltage-dependence of activation of the currents with addition of
flupirtine (V0.5 for flupirtine was -36.8 ± 0.8 mV compared to control -33.9 ± 1.5 mV;
Figure 6D). XE991 (10 µM), a selective Kv7 channel blocker (Wang et al 1998)
effectively abrogated the currents after wash out of flupirtine between voltages of -60 to 20 mV (Figure 6A, C). Outward currents recorded positive to -20 mV are contributed by
currents through other K+ channels including the 4-AP-sensitive-Kv channels and hence
were not sensitive to XE991 (Figure 6C).
Retigabine, an analog of flupirtine also robustly enhanced Kv7 currents in freshly
isolated rat basilar artery myocytes and the effect was completely reversible on wash out
(Figure 7A). Enhancement of currents with retigabine (10 µM) was significant at all
voltages tested from -59.2 mV to +0.8 mV (Figure 7B). At -20 mV, the voltage where
near maximal activation of currents were observed (Figure 7C), currents increased from
0.2 ± 0.09 pA/pF before treatment to 0.46 ± 0.17 pA/pF during treatment with retigabine,
n=5. Retigabine, unlike flupirtine, induced a significant leftward shift in the steady-state
voltage dependence of activation; V0.5 (control) was -30.2 ± 1.4 mV, V0.5 (retigabine) was
-41.4 ± 0.5 mV (Figure 7C).
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Figure 7: Retigabine enhances Kv7 currents in freshly isolated rat basilar artery
myocytes. A. Time-course of XE991-sensitive Kv7 currents with the addition of 10 µM
retigabine, recorded from a single basilar artery myocyte by continuous holding at -20
mV. B. Current-voltage curves (I-V) of mean steady-state Kv7 currents before (control;
) and during treatment with 10 µM retigabine ( ) and 10 µM XE991 ( ), normalized to
control current measured at -20 mV before treatment. *Significantly different from
control at indicated voltages using paired Student’s “t” test, p<0.05, n=5. C. Normalized
conductance plotted against membrane voltage was fitted by a single Boltzmann function
to show the effect of retigabine on steady-state voltage dependence of activation,
*Significantly different from control using paired Student’s “t” test, p<0.05, n=5.
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Contribution of Kv7 channels to membrane voltage and contractile status of basilar
artery
The Kv7 currents have a very negative threshold for voltage-dependent activation
(Figure 6D, 7C), suggesting that K+ conductance through Kv7 channels should contribute
to maintenance of resting membrane voltages. To evaluate this possibility, we measured
the effect of the Kv7 channel blocker XE991 on whole cell membrane voltage under
physiological ionic conditions. Addition of 10 µM XE991 significantly depolarized the
basilar artery myocytes (by ~22 mV; from -57.5 ± 6.3 mV mean resting voltage to -35.3
± 1.8 mV, n=4; Figures 8A, B). Vehicle for XE991 (deionized water) did not induce
significant depolarization, n=4 (Figure 8B). To confirm that the depolarization of
myocytes’ membrane translates functionally into a constrictor response, we assessed if
blockade of Kv7 channels would constrict the intact basilar artery using pressure
myography. Application of 10 µM XE991 to pressurized basilar arteries induced a
significant constrictor response (15.1 ± 1.6 % compared to 0.25 ± 0.06 % constriction
with vehicle treatment, n=5; Figure 9A, B), which was almost completely reversed by
addition of the L-type Ca2+ channel blocker nimodipine (2 µM, Fig. 9A).

Spasmogens suppress Kv7 currents and induce membrane depolarization in basilar
artery myocytes
Myocytes derived from basilar artery of SAH-induced animal models are
persistently depolarized (Jahromi et al. 2008a; Harder et al. 1987), an effect generally
attributed to increased local concentrations of spasmogens. The cellular mechanism(s) by
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which the spasmogens induce membrane depolarization is not clear. Since K+
conductance through Kv7 channels is a critical determinant of resting membrane voltage
in rat basilar artery myocytes and artery tone (Figure 8, 9) we tested if Kv7 currents are
regulated by spasmogens. We tested three spasmogens (ET-1, 5HT and AVP) that have
been implicated in cerebral vasospasm. All three spasmogens significantly suppressed
Kv7 currents measured in the physiological voltage range (Figure 10, 11). Currents
measured at -20 mV were suppressed by 56%, 49% and 37% with the addition of
serotonin (100 nM), ET-1 (250 pM) and AVP (250 pM) respectively. The current
amplitudes at -20 mV were 0.18 ± 0.04 pA/pF before and 0.07 ± 0.02 pA/pF during
application of 5HT (n=6), 0.12 ± 0.02 pA/pF before and 0.06 ± 0.01 pA/pF during
application of ET-1 (n=4), 0.37 ± 0.13 pA/pF before and 0.27 ± 0.12 pA/pF during
application of AVP (n=6). Kv7 current amplitude was more than fully restored with
addition of 10 µM retigabine in the presence of spasmogens. In the presence of 5HT, ET1 and AVP at the concentrations indicated above, 10 µM retigabine increased current
amplitude (measured at -20 mV) to 72%, 65% and 78% above the control levels,
respectively.
Since Kv7 currents are active at resting membrane voltages (Figure 6, 7) and Kv7
current suppression induces membrane depolarization (Figure 8), we tested if the
spasmogens also induce membrane depolarization of myocytes. As expected, all three
spasmogens induced significant depolarization: 5HT, from -57.1 ± 6.3 mV to -35.4 ± 2.4
mV, n=4; ET-1, from -62.1 ± 2.3 mV to -42.8 ± 1.3 mV, n= 4; AVP from -53.2 ± 4.2 mV
to -37.9 ± 1.4 mV, n=4 (Figure 12 A, C). More importantly, simultaneous addition of 10
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Holm-Sidak test, p<0.05, n=6. C. Current-voltage curves (I-V) of steady-state Kv7
currents before (Control; ), during treatment with 250 pM ET-1 ( ) and following
addition of 10 µM retigabine in the continued presence of ET-1 ( ) (currents at each
voltage step are normalized to control currents measured at -20 mV before treatment).
ET-1 significantly suppressed currents at voltages from -39.2 mV to -4.2 mV (using
repeated-measures (RM) one-way ANOVA followed by post hoc Holm-Sidak test,
p<0.05, n=4). D. Summary of ET-1-induced suppression of Kv7 currents measured at -20
mV. Addition of retigabine enhanced Kv7 current amplitude in the presence of ET-1. *,
#
Significantly different from control using RM one-way ANOVA followed by post hoc
Holm-Sidak test, p<0.05, n=4.
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µM retigabine to enhance activation of Kv7 currents prevented membrane depolarization
by 5HT (Figure 12 A, B). The voltage measured was -65.2 ± 4.6 mV before and -64.7 ±
4.3 mV after combined treatment with 10 µM retigabine and 100 nM 5HT, n=3. These
results indicate that activation of Kv7 currents can oppose the membrane depolarization
induced by spasmogens involved in cerebral vasospasm.

Basilar artery constriction induced by spasmogens involve Kv7 current suppression
Pharmacological inhibition of Kv7 channels with XE991 was sufficient to
constrict rat basilar arteries and this effect was almost completely reversed by application
of the L-type CCB, nimodipine (Figure 9A). Nimodipine (1 µM) also dilated basilar
artery segments pre-constricted by spasmogens (Figure 13). This finding implicates
membrane depolarization and Ca2+ influx through VSCC as the predominant mechanism
for constriction induced by spasmogens at the concentrations measured following SAH.
Since spasmogens involved in cerebral vasospasm suppressed Kv7 currents and induced
membrane depolarization (Figure 10, 11 and 12), we sought to determine whether
spasmogen-induced basilar artery constriction involves suppression of Kv7 currents. To
address this question, we tested whether addition of spasmogens in the presence of
XE991 (10 µM, a concentration that fully suppresses Kv7 currents; Figure 6C, 7B)
induces additive basilar artery constrictor responses. Of the three spasmogens tested, 100
pM AVP and 100 pM ET-1 induced a slight but non-significant additional constriction in
the presence of XE991; addition of 75 nM 5HT to XE991 induced a constrictor response
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that was significantly more than the constriction induced by either XE991 alone or the
spasmogen alone.
The percentage constriction induced by XE991 before addition of AVP was 15.1
± 1.6%, AVP in the presence of XE991 was 20.2 ± 2.1% and AVP alone was 15.0 ±
2.7%; XE991 before addition of 5HT was 17.5 ± 2.3%, 5HT in the presence of XE991
was 28.3 ± 1.7% and 5HT alone was 19.4 ± 2.5%; XE991 before addition of ET-1 was
19.0 ± 2.6%, ET in the presence of XE991 was 22.0 ± 1.8% and ET-1 alone was 16.7 ±
1.0%, n = 4-8 (Figure 14). As the values indicate, none of the spasmogens tested induce
an additive constrictor response when combined with Kv7 channel blocker XE991 (10
µM). i.e., percentage constriction induced by the combined presence of spasmogen and
XE991 is less than the sum of constrictor response induced by spasmogens alone and
XE991 alone. This indicates involvement of Kv7 current suppression in the constriction
induced by spasmogens.

Activation of protein kinase C (PKC) suppresses Kv7 currents in basilar artery
myocytes
Myocytes isolated from spastic arteries derived from SAH animal models showed
activation and translocation of PKC to the plasma membrane (Laher and Zhang 2001).
Inhibition of PKC was previously found to attenuate rat basilar artery constriction
induced by each of the three spasmogens used in the present study (Murray et al. 1992a;
Murray et al. 1992b), indicating that activation of PKC is a common signal transduction
intermediate in spasmogen-induced basilar artery constriction. PKC was previously
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implicated as a mediator of the AVP-induced suppression of Kv7 currents in A7r5 rat
aortic smooth muscle cells (Brueggemann et al. 2007). Therefore, we tested whether
activation of PKC is sufficient for suppression of Kv7 currents in basilar artery myocytes
and constriction of the basilar artery, using a direct activator of PKC: phorbol-12myristate-13-acetate (PMA; 10 nM). PMA significantly suppressed Kv7 currents at
voltages from -44.2 mV to +15.2 mV (Figure 15) and PMA (100 nM) also constricted rat
basilar artery segments (Figure 16). An inactive phorbol ester did not constrict basilar
artery segments (Figure 16).

Kv7 channel activators dilate basilar artery segments pre-constricted with
spasmogens involved in cerebral vasospasm
To assess the functional consequences of Kv7 current enhancement, we studied
the efficacy of flupirtine or retigabine in reversing the constriction induced by
spasmogens involved in the pathogenesis of cerebral vasospasm: 5HT, ET-1 and AVP.
Flupirtine induced a concentration-dependent relaxation of basilar arteries pre-constricted
with 100 pM ET-1, 100 pM AVP or 75 nM serotonin (Figure 17A, B). The EC50 of
relaxation induced by flupirtine was ~40-60 µM (Figure 17B). Flupirtine (100 µM) did
not reverse 5HT-induced constriction in the presence of 10 µM XE991 (flupirtine
induced 2.8 ± 2.5 % dilation in the presence of XE991 compared to 97.4 ± 1.7 % dilation
in the absence of XE991; data not presented) indicating that the dilation induced by
flupirtine was specifically through activation of Kv7 channels. We then assessed whether
flupirtine is more efficacious than nimodipine in dilating the basilar artery. Application of
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100 µM flupirtine either alone or combined with nimodipine induced a significant
additional dilation of basilar artery compared with nimodipine alone (Figure 17C, D).
Retigabine, an analog of flupirtine and a Kv7 channel activator (Figure 7) also induced
92.8% reversal of the constriction induced by 5HT with the maximally used
concentration of 100 µM. The EC50 retigabine was 23.7 µM, n=5 (Figure 18).

Celecoxib enhances Kv7 currents and inhibits voltage-sensitive Ba2+currents in
basilar artery myocytes
Celecoxib was recently reported to be a dual Kv7 channel activator and VSCC
blocker in cultured rat aortic smooth muscle cells and rat mesenteric artery myocytes
(Brueggemann et al 2009). The ion channel modulatory effects of celecoxib were tested
in basilar artery myocytes. Celecoxib (10 µM) significantly enhanced the Kv7 currents in
basilar artery myocytes at all voltages tested from -34.2 to +0.8 mV; at -20 mV the
currents more than doubled in amplitude, from 0.08 ± 0.02 pA/pF to 0.19 ± 0.04 pA/pF
(Figure 19). Celecoxib did not induce a significant shift in the voltage-dependence of
activation (V0.5 for celecoxib was -35.6 ± 1.6 mV compared to control -29.8 ± 2.1 mV;
Figure 19D).
Voltage–sensitive Ca2+ channels were recorded using Ba2+ as a charge carrier.
Celecoxib (10 µM) inhibited IBa at all voltages from -20.2 to +39.8 mV (Figure 20A, B).
The peak inward currents were reduced from 1.78 ± 0.1 pA/pF to 0.08 ± 0.05 pA/pF with
the addition of 10 µM celecoxib. The effects of celecoxib on the IBa were slightly
reversible after wash out of celecoxib (Figure 20B).
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Celecoxib is a more efficacious voltage-sensitive calcium channel blocker than
nimodipine
Since nimodipine is the standard therapeutic agent used to treat patients with
cerebral vasospasm, we compared the ability of nimodipine to inhibit IBa with that of
celecoxib. The concentration of nimodipine used (2 µM) was found to be maximally
effective in dilation of basilar artery segments pre-constricted with vasoconstrictor
agonists (Figure 17C, 22C). Celecoxib was significantly more effective in inhibiting IBa
in basilar artery myocytes than was 2 µM nimodipine (Figure 21). The inhibition of peak
inward Ba2+ currents with application of 2 µM nimodipine alone was 85.5 ± 2.9%; with 2
µM nimodipine + 10 µM celecoxib it was 97.0 ± 0.3%; and with 10 µM celecoxib alone,
it was 96.0 ± 2.2%.

Celecoxib reverses/prevents basilar artery constriction induced by spasmogens
involved in cerebral vasospasm
Celecoxib, the dual Kv7 channel activator and VSCC blocker, was a more potent
dilator of the basilar artery compared to flupirtine. Basilar artery segments pre-constricted
with ET-1, AVP or 5HT were dilated by celecoxib in a concentration-dependent manner,
with an EC50 of relaxation between 14 and 17 µM (Figure 22A, B). Celecoxib (30 µM)
either alone or when combined with nimodipine (2 µM) induced significant additional
dilation of basilar arteries compared to dilation induced by nimodipine alone (Figure
22D, E).
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nimodipine + 10 µM celecoxib and 10 µM celecoxib alone. *Celecoxib either alone or
when added along with nimodipine produced significantly more inhibition of IBa
compared to nimodipine alone (One-way ANOVA followed by post hoc Holm-Sidak test,
p < 0.05; n = 5-6).
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Figure 22: Celecoxib reverses the spasmogen-induced constriction in basilar artery
more effectively than nimodipine. A. Representative trace shows the concentrationdependent effect of celecoxib on a basilar artery segment pre-constricted with a 75 nM
5HT. B. Mean concentration-response curves of the percentage relaxation induced by
celecoxib in arteries pre-constricted with the spasmogens: 5HT, AVP and ET-1. C.
Representative time course trace shows the dilation induced by nimodipine and celecoxib
when pre-constructed with 5HT. Increasing the concentration of nimodipine above 1 µM
did not induce additional dilation. However addition of celecoxib induced additional
dilation in the same artery. D. Summary of the percentage dilation of basilar artery with
the application of 2 µM nimodipine alone, 2 µM nimodipine + 10 µM celecoxib and 10
µM celecoxib alone. *Celecoxib either alone or when added along with nimodipine
induced significantly more dilation compared to nimodipine alone (One-way ANOVA
followed by post hoc Holm-Sidak test, p < 0.05, n = 3-6). [Reproduced from Mani BK et
al., British Journal of Pharmacology, 2011; 164: 237-249].
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Development of cerebral vasospasm is delayed and is appreciable usually 3 days
after SAH. Therefore, we also sought to address whether celecoxib could prevent the
development of vasospasm when administered preemptively. In order to simulate that in
an acute experimental system, the ability of a spasmogen to constrict basilar artery in the
presence of celecoxib was tested. Serotonin was not able to constrict basilar artery
segments pre-treated with 30 µM celecoxib, but after wash out of both 5HT and
celecoxib, re-addition of 5HT in the presence of the vehicle of celecoxib induced a robust
constriction in the same artery (Figure 23A). The mean constriction induced by 5HT in
the presence of celecoxib was 0.11 ± 0.34% compared to 17.3 ± 1.7% induced in the
presence of vehicle for celecoxib in the same arteries (Figure 23B). The constriction
induced by 5HT in the presence of vehicle was subsequently overcome by application of
30 µM celecoxib (Figure 23A).

Kv7 channel openers attenuate basilar artery vasospasm in a rat model of SAH
Single-cell electrophysiology and pressure myography studies strongly indicated
the ability of Kv7 channel openers to attenuate spasmogen-induced membrane
depolarization and basilar artery constriction (Figure 12, 17, 18, 22 and 23). We therefore
tested the efficacy of Kv7 channel openers to relieve basilar artery vasospasm in vivo
using a rat model of SAH. We used an established single hemorrhage model that induces
biphasic vasospasm of basilar artery, reaching its peak at day 2 after initiation of SAH
(Delgado et al. 1985; Nikaido et al. 2004). Rats were treated with either retigabine (7.5
mg/kg, i.p) or celecoxib (20 mg/kg, i.p) twice daily starting an hour after hemorrhage and
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Figure 23: Celecoxib prevents spasmogen-induced constriction in basilar artery A.
Time-course shows that 75 nM 5HT was not able to constrict the basilar artery segment
in the presence of 30 µM celecoxib. However after wash out, serotonin was able to
constrict the same artery in the absence of celecoxib. Re-application of celecoxib
completely reversed the 5HT-induced constriction (representative of n=3). B. Summary
of the percentage constriction induced by 5HT in the presence of 30 µM celecoxib and
vehicle of celecoxib. *Significant constriction by serotonin in the presence of vehicle
compared to constriction induced in the presence of 30 µM celecoxib (Student’s ‘t’ test
n=3, p < 0.05). [Reproduced from Mani BK et al., British Journal of Pharmacology,
2011; 164: 237-249].
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continuing for 48 hours (4 doses in total). Basilar artery outer diameter measured at 48
hours (12 hours after the last injection) was used as the endpoint criterion to assess the
severity of vasospasm and efficacy of treatments. SAH induced by an intracisternal
injection of autologous blood induced significant basilar artery vasospasm compared to
control rats that had no surgery or that were injected with artificial cerebrospinal fluid
(aCSF) instead of blood (Figure 24). Both retigabine and celecoxib significantly
attenuated the basilar artery spasm when compared with vehicle control in the rat model
of SAH (Figure 24). The mean diameter of basilar artery in the treatment groups were—
no surgery control: 147.0 ± 9.2 µm, sham surgery (aCSF) group: 143.5 ± 6.7 µm, SAH
group: 114.9 ± 9.9 µm, SAH + retigabine treatment group: 158.4 ± 9.0 µm and SAH
group + celecoxib treatment group: 176.8 ± 10.7 µm, n=9 in each group.
A striking observation was a pronounced hypothermia with administration of
retigabine in SAH rats. Rats administered retigabine had significant hypothermia even 12
hours after drug administration. The rectal temperature of rats in the retigabine group
(33.1 ± 1.4 °C) was approximately 5°C lower than the mean temperature in all untreated
control groups (Figure 25). Celecoxib also tended to induce mild hypothermia, though
this effect was not statistically significant. Rats treated with retigabine and celecoxib
demonstrated a significant reduction in locomotor activity. Both the ambulatory
movements (scored by consecutive breaks of adjacent photobeams) and fine movements
(scored by consecutive break in a single photobeam) were reduced with treatment (Figure
26). Neurological endpoints assessed using behavioural tests used in ischemic stroke
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Figure 24: Kv7 channel openers attenuate basilar artery spasm in a rat model of
SAH. A. Illustrative photographs show basilar artery in the base of brain from rats in
different treatment groups. Brains were photographed 48 hours after injection of blood or
aCSF and compared with brains of control rats (no surgery). B. Bar graph shows the
mean basilar artery outer diameter measured in each of the treatment groups— Control
(no surgery), aCSF control (sham surgery), SAH rats treated with vehicle (DMSO,
1ml/kg, ip, bid), SAH rats treated with retigabine (7.5 mg/kg, ip, bid) and SAH rats
treated with celecoxib (20 mg/kg, ip, bid). *Significant difference between the treatment
groups as indicated using one-way ANOVA followed by post hoc Holm-Sidak test,
p<0.001, n=9 in each group.
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Figure 25: Retigabine induces hypothermia in the rat model of SAH. A. Rectal
temperature of rats in different groups (as indicated), measured 48 hours after induction
of SAH or sham surgery to inject aCSF, along with control rats (no surgery).
*Significantly different from controls (open bars) and SAH rats treated with vehicle,
using one-way ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=9 in each
group. In treatment groups, body temperature was measured 12h after last treatment time.
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Figure 26: Kv7 openers dampen locomotor activity performance of SAH rats. Line
plot of fine (A) and ambulatory (B) movements of rats belonging to various treatment or
control groups, measured on days before and after surgery (day 0 is the day of surgery).
*significant reduction in activity compared to vehicle treated SAH rats (One-way
ANOVA test followed by post hoc Holm-Sidak test, p<0.05, n=9) in each group.
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models (Garcia et al. 1995) showed no significant change in neurological function
compared to rats injected with aCSF into the cisterna magna.

Kv7 channel openers induce transient hypotension, but do not alter long-term mean
arterial pressure
One of the limitations in the use of direct CCBs like nimodipine to treat cerebral
vasospasm is its propensity to induce sustained hypotension (Porchet et al. 1995).
Systemic hypotension reduces the perfusion pressure to the brain further exacerbating
ischemia (Ahmed et al. 2000). We tested the effect of the Kv7 channel opener retigabine
(7.5 mg/kg i.p) and the dual Kv7 channel opener and CCB celecoxib (50 mg/kg i.p) on
systemic mean arterial pressure (MAP) in conscious rats (MAP was monitored by
radiotelemetry). The drugs were administered intraperitoneally every 12 hours for 48
hours (4 doses in total) to mimic the schedule of test drug administration in SAH rats.
Both the drugs induced a transient drop in MAP lasting for 30-60 min after each
administration (Figure 27). By comparison vehicle administration tended to increase
MAP transiently (Figure 27A). Despite the differences in MAP immediately after drug
administration, the 24 h MAP (Figure 27B) and heart rate (Figure 28) were not
significantly different between vehicle- and drug-treated groups.
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Figure 27: Kv7 channel openers induce a transient drop in blood pressure. A.
Change in mean arterial pressure (MAP) during treatment, compared to the 24h baseline
MAP measured before treatment. Areas in grey shade are dark hours and areas in white
are light hours during the 12h dark/light cycle. Arrows indicate treatment times. Each
data point represents the average change in BP during a 30 min interval. Standard error is
not represented for clarity. *Significantly different from vehicle group, using one-way
ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=6-7. B. Line graph shows the
24h mean BP recorded in untreated rats (control) or rats treated with vehicle (DMSO,
1ml/kg, ip, bid), retigabine (7.5 mg/kg, ip, bid) or celecoxib (50 mg/kg, ip, bid), N.S— no
significant difference from control, n=6-7.
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Figure 28: Kv7 channel openers do not alter 24h heart rate in rats. A. Change in
mean heart rate (HR) during treatment, compared to the 24h baseline HR measured
before treatment. Areas in grey shade are dark hours and areas in white are light hours
during the 12h dark/light cycle. Arrows indicate treatment times. Each data point
represents the average change in HR during a 30 min interval. Standard error is not
represented for clarity. *Significantly different from vehicle group, using one-way
ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=6-7. B. Line graph shows the
24h mean HR recorded in untreated rats (control) or rats treated with vehicle (DMSO,
1ml/kg, ip, bid), retigabine (7.5 mg/kg, ip, bid) or celecoxib (50 mg/kg, ip, bid), N.S— no
significant difference from control, n=6-7.
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Phosphodiesterase inhibitors activate Kv7 channels and inhibit voltage-sensitive
calcium currents in A7r5 cells
Celecoxib is prescribed in clinical practice to treat prostaglandin-mediated
inflammation and pain (Frampton and Keating 2007). Celecoxib induces its antiinflammatory effect by inhibiting a specific class of prostaglandin producing enzyme
called cyclooxygenase (COX)-2. We tested if the ion channel-mediated vasodilatory
effect of celecoxib is due to its ability to inhibit COX-2. Rofecoxib, a more potent and
selective COX-2 inhibitor than celecoxib (FitzGerald and Patrono 2001), did not dilate
basilar artery segments pre-constricted with 5HT (75 nM). Application of celecoxib at
equimolar concentrations (30 µM) in the same arteries almost completely reversed the
5HT-induced constriction (Figure 29A, C). Dimethyl celecoxib, an analog of celecoxib,
which is devoid of COX-2 inhibitory activity (Kardosh et al. 2005), but retains the Kv7
channel and VSCC modulatory activity (Brueggemann et al. 2009), mimicked the
vasodilatory effects of celecoxib (Figure 29B, C). These results indicate that celecoxibinduced ion channel-mediated vasodilatory effects are independent of its COX-2
inhibitory effects, therefore not a “class-effect” (Figure 29).
Celecoxib, but not rofecoxib, was reported to be an inhibitor of phosphodiesterase
enzyme isoform 4 and 5 (Klein et al. 2007). Hence, we hypothesized that celecoxib
induces the ion channel modulatory effects (Kv7 channel activation and VSCC block)
through inhibition of the PDE enzyme(s). To that end, we tested the effect of selective
PDE enzyme inhibitors on Kv7 currents in A7r5 cells. Rolipram, a selective PDE4
inhibitor, induced a concentration dependent enhancement of Kv7 currents in A7r5 cells
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Figure 29: Vasodilatory effect of celecoxib is not dependent on COX-2 inhibition.
Representative time course trace shows that 30 µM rofecoxib failed to dilate basilar
artery segments pre-constricted with a 75 nM serotonin. Application of 30 µM celecoxib
(CXB) completely reversed the serotonin-induced constriction of the same artery. B.
Representative time course trace shows that 30 µM dimethyl celecoxib (DMC)
completely reversed the serotonin-induced constriction of basilar artery. C. Summary of
the percentage dilation induced by rofecoxib and dimethyl celecoxib. *Significant
dilation compared to 30 µM rofecoxib (One-way ANOVA followed by post hoc HolmSidak test, p < 0.05, n = 3 each). [Reproduced from Mani BK et al., British Journal of
Pharmacology, 2011; 164: 237-249].
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(Figure 30). Rolipram at concentrations as low as 1 nM induced about 50% enhancement
of Kv7 currents in A7r5 cells. The concentration response curve for enhancement of Kv7
currents was bell shaped, with a maximal 3.4-fold enhancement of currents with addition
of 100 nM rolipram and suppression of currents at a concentration above 100 nM (Figure
30B, C). Rolipram also mimicked the voltage-sensitive Ca2+ current inhibitory action of
celecoxib (Figure 31). Rolipram inhibited IBa with a maximal suppression of peak inward
currents at a concentration of 100 nM. The concentration response curves for
enhancement of Kv7 currents and inhibition of voltage-sensitive Ca2+ currents with
rolipram showed similar concentration-dependence (Figure 30C, 31C). Sildenafil, a
PDE5 inhibitor and papaverine, a non-selective PDE inhibitor also enhanced Kv7
currents in A7r5 cells (Figure 32, 34). Sildenafil induced a maximal 2.7-fold
enhancement of Kv7 currents at a concentration of 10 μM and papaverine induced a 3.1
fold enhancement of the currents at a maximally tested concentration of 100 μM.
Sildenafil also inhibited voltage-sensitive Ca2+ currents similar to the effects of celecoxib
and rolipram (Figure 33). These results indicate that inhibition of either PDE4 or PDE5
enzyme is sufficient to simulate the ion channel modulatory action of celecoxib.

Phosphodiesterase inhibitors attenuate AVP-induced calcium spiking response in
A7r5 cells; dilate mesenteric artery segments
We then tested if the ion channel modulatory effects of PDE inhibitors translated
functionally to inhibition of Ca2+ entry in A7r5 cells. Physiological concentrations of
AVP (10-100 pM) induces Ca2+ spiking responses attributed to Kv7 current suppression,
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Figure 30: Rolipram enhances Kv7 currents in A7r5 cells. A. Current traces show
enhancement of non-inactivating outward Kv7 K+ currents with the addition of rolipram,
a selective PDE4 inhibitor. B. Current-voltage curves of steady-state Kv7 currents
recorded before (control) and during treatment with increasing concentrations of rolipram
as indicated (currents recorded at each voltage step were normalized to control currents
measured at -20 mV before treatment). C. Concentration-response relationship
demonstrates a more than 3-fold maximal enhancement of Kv7 currents with the addition
of rolipram. Currents measured at -20 mV in the presence of rolipram were normalized to
currents measured at -20 mV before the addition of rolipram. *significantly different
from pre-treatment levels, using repeated measures one-way ANOVA followed by HolmSidak post hoc test, p < 0.001, n= 4-5).
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Figure 31: Rolipram inhibits voltage-sensitive Ba2+ currents in A7r5 cells. A. Inward
Ba2+ current traces recorded before (control) and during treatment with 100 nM rolipram.
B. Current-voltage curves show the mean IBa recorded across the voltages tested with the
addition of different concentrations of rolipram. (Currents at each voltage step were
normalized to the peak inward IBa measured before treatment). C. Summarized
concentration-response relationship shows significant suppression of peak inward IBa with
increasing concentrations of rolipram. Peak inward IBa measured in the presence of
rolipram were normalized to the peak inward IBa measured before treatment.
(*significantly different from pre-treatment levels, repeated measures one-way ANOVA
followed by Holm-Sidak post hoc test, p < 0.001, n=3-5).
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Figure 32: Sildenafil enhances Kv7 currents in A7r5 cells. A. Current-voltage curves
of the steady-state Kv7 currents recorded before (control), during treatment with
increasing concentrations of sildenafil as indicated (currents recorded at each voltage step
were normalized to control currents measured at -20 mV before treatment). B.
Concentration-response relationship demonstrates enhancement of Kv7 currents with the
addition of sildenafil. Currents measured at -20 mV in the presence of sildenafil were
normalized to currents measured at -20 mV before the addition of sildenafil.
*significantly different from pre-treatment levels, using repeated measures one-way
ANOVA followed by Holm-Sidak post hoc test, p < 0.05, n= 4 each).
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Figure 33: Sildenafil inhibits voltage-sensitive Ba2+ currents in A7r5 cells. A.
Current-voltage curves show the mean IBa recorded across the voltages tested with
addition of different concentrations of sildenafil. (Currents at each voltage step were
normalized to the peak inward IBa measured before treatment). B. Summarized
concentration-response relationship shows significant suppression of peak inward IBa with
increasing concentrations of sildenafil. Peak inward IBa measured in the presence of
sildenafil were normalized to the peak inward IBa measured before treatment.
(*significantly different from pre-treatment levels, RM one-way ANOVA followed by
Holm-Sidak post hoc test, p < 0.05, n=3-5).
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Figure 34: Papaverine enhances Kv7 currents in A7r5 cells. A. Current-voltage
curves of steady-state Kv7 currents recorded before (control) and during treatment with 2
different concentrations of papaverine (10 and 100 µM) (currents recorded at each
voltage step were normalized to control currents measured at -20 mV before treatment).
B. Concentration-response relationship demonstrates enhancement of Kv7 currents with
the addition of papaverine. Currents measured at -20 mV in the presence of papaverine
were normalized to currents measured at -20 mV before the addition of papaverine.
*significantly different from pre-treatment levels, using repeated measures one-way
ANOVA followed by Holm-Sidak post hoc test, p < 0.001, n= 4 each).
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membrane depolarization and Ca entry through VSCC in A7r5 cells (Brueggemann et
2+

al. 2007; Mani et al. 2009; Byron 1996). Pre-treatment with 100 nM rolipram (Figure
35), 10 μM sildenafil or 100 μM papaverine (not shown) significantly attenuated AVP
(25 pM)- induced Ca2+ spiking responses in A7r5 cells. Rolipram and sildenafil also
induced concentration-dependent relaxation of mesenteric artery segments preconstricted with 30 pM AVP, indicating that the ion channel modulatory effects of PDE
inhibitors translate functionally into vasodilatory response (Figure 36).
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Figure 35: Rolipram inhibits calcium spiking responses in A7r5 cells. A.
Representative traces show Ca2+ spiking in response to addition of 25 pM AVP (indicated
by arrow) in fura-2 loaded A7r5 cells pretreated with vehicle or 100 nM rolipram for 30
min. B. Bar graph summarizes the effect of rolipram on AVP-induced Ca2+ spiking
response. **significant reduction in the Ca2+ spiking frequency in cells pre-treated with
100 nM rolipram, Student’s ‘t’ test, p < 0.001, n=4 (Data generated by Kakad).
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Figure 36: Phosphodiesterase4/5 inhibitors reverse AVP-induced constriction in rat
mesenteric artery. A. Representative time course shows rolipram-induced
concentration-dependent dilation of mesenteric artery pre-constricted with 30 pM AVP.
Summarized dose-response relationship of the dilation induced by rolipram (B) and
sildenafil (C) in arteries pre-constricted with AVP. **Significant dilation with addition of
rolipram or sildenafil compared to absence of the drugs, using RM one-way ANOVA
followed by Holm-Sidak post hoc test, p < 0.001, n=4-5.

CHAPTER 6
DISCUSSION
This study presents several novel findings:
(1) Kv7 channels are expressed and functional in rat basilar artery myocytes.
(2) K+ conductance through the Kv7 channels maintains hyperpolarized resting
membrane voltages, limiting the activation of VSCC in myocytes, thereby regulating
the contractile status of basilar artery.
(3) Suppression of Kv7 currents is a central mechanism by which multiple spasmogens
implicated in SAH-induced cerebral vasospasm induce membrane depolarization and
constrict basilar artery.
(4) Direct Kv7 channel openers (retigabine or flupirtine) are able to restore the Kv7
current amplitude in the presence of spasmogens. This action attenuates the
spasmogen-induced membrane depolarization and artery constriction.
(5) Celecoxib is a dual Kv7 channel activator and VSCC blocker in basilar artery
myocytes. Celecoxib was able to reverse/prevent spasmogen-induced basilar artery
constrictor responses.
(6) Flupirtine and celecoxib are more effective in dilating basilar artery than the L-typecalcium channel blocker, nimodipine, which is currently used as the standard care for
patients with cerebral vasospasm.
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(7) Retigabine and celecoxib are effective in preventing the sustained basilar artery
vasospasm in a rat model of SAH. These drugs do not alter long-term mean arterial
pressure.
These findings suggest that Kv7 channels are critical mediators of cerebral
vasospasm and that clinically used drugs that enhance Kv7 channel activity may be
effective in reducing vasospasm and preventing or attenuating stroke following SAH.

Expression of Kv7 channels in rat basilar artery myocytes
Message transcripts of all the known KCNQ genes (KCNQ1-5, encoding Kv7.17.5 channels) were detected in rat basilar artery myocytes (Figure 5). A quantitative
assessment of the expression of KCNQ genes in rat basilar artery and middle cerebral
artery myocytes by Zhong et al. also revealed the presence of all five KCNQ mRNAs,
though the mRNAs of KCNQ2 and KCNQ3 were much less abundant than those of
KCNQ1, KCNQ4 and KCNQ5 (Zhong et al. 2010). Kv7.1 channels are insensitive to
drugs (e.g., flupirtine, retigabine, and N-ethyl maleimide) that activate the other Kv7
channel subtypes (Gamper et al. 2005; Munro and Dalby-Brown 2007) and Kv7.1
subunits do not heteromerize with other Kv7 channel subunits (Schwake et al. 2003).
Considering that the whole cell Kv7 currents measured in basilar artery myocytes were
robustly enhanced by flupirtine and retigabine (Figure 6, 7), the contribution of outward
K+ conductance through homomeric Kv7.1 channel is likely to be minimal. Using
selective pharmacological modulators for Kv7.1 channels, a recent study indicated that
Kv7.1 channels may be functional, but do not contribute to the resting tone of mesenteric
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arteries (Chadha et al. 2012). Hence, the functional Kv7 channels that contribute to the
resting tone in basilar artery myocytes are likely to be predominantly constituted by
homo- or hetero-tetramers of Kv7.4 and Kv7.5 channel subunits.
Expression profiles of KCNQ channel transcripts in VSMCs from various
vascular beds reveal expression of KCNQ1, KCNQ4 and KCNQ5 subunits, and either
absence or very little expression of KCNQ2 and KCNQ3 subunits (Zhong et al. 2010;
Joshi et al. 2009; Mackie et al. 2008; Yeung et al. 2007). This indicates that the
expression profile of KCNQ genes in basilar artery and VSMCs in general is different
from neurons where the predominant expression is KCNQ2 and KCNQ3 (Jentsch 2000;
Delmas and Brown 2005).

Kv7 currents in rat basilar artery myocytes
This study presents the first successful isolation of Kv7 currents in the cerebral
vasculature (Figure 6, 7). Whole cell KV currents were recorded using voltage-clamp
conditions. Currents recorded at test voltages between -60 mV and -20 mV can
reasonably be attributed to Kv7 channel activity based on several observations: 1) the
currents measured under our recording conditions were robustly enhanced by 10 µM
flupirtine or retigabine, selective Kv7 channel activators, 2) the currents were completely
inhibited by 10 µM XE991, a selective Kv7 channel blocker, 3) the currents had
electrophysiological characteristics of Kv7 currents (non-inactivating, voltage-dependent
with a very negative threshold for activation and half-maximal activation (V0.5) of ~ -34
mV (Wickenden et al. 2001; Brueggemann et al. 2007; Mackie et al. 2008; Adams and
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Brown 1982). Currents recorded at voltages more positive than -20 mV were not
completely blocked by XE991 suggesting that at these more depolarized voltages we
were recording a mix of currents, with likely contributions of other K+ channels, such as
4-AP-sensitive Kv channels and Ca2+-activated K+ channels (KCa) channels.
In the present study, both Kv7 channel activators− retigabine and flupirtine
significantly enhanced Kv7 currents over the physiological voltage range, with more than
100% enhancement of Kv7 currents measured at -20 mV (Figure 6, 7). Retigabine
induced a significant hyperpolarizing shift in voltage-dependence of activation of the
currents (Figure 7C). The voltage of half-maximal activation of the currents (V0.5) shifted
with addition of 10 μM retigabine from -30.2 ± 1.4 mV in control conditions to -41.4 ±
0.5 mV. Retigabine induced a similar hyperpolarizing shift in activation of currents
through Kv7.2/Kv7.3 heteromeric channels expressed in CHO cells; V0.5 shifted from 28.7 mV to -40.1 mV with addition of retigabine (Tatulian and Brown 2003). Flupirtine
only induced a small non-significant shift in the voltage-dependence of activation of
currents (Figure 6D), similar to our previous observation in mesenteric artery myocytes
(not shown). Flupirtine, however, induced a significant hyperpolarizing shift in voltagedependence of activation of Kv7 currents (~ 11 mV) measured in guinea pig airway
smooth muscle cells (Brueggemann et al. 2012). The reason for the difference is not
immediately apparent, but could be due to the difference in cell type and differential
expression of Kv7 channel subtypes. Retigabine increased the maximal Po of single
Kv7.2/Kv7.3 channels expressed in CHO cells from 0.13 to 0.38 (Tatulian and Brown
2003). Hence, the increase in whole cell current amplitude with addition of Kv7 channel
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openers in basilar artery myocytes is likely due to increase in open probability (Po) of the
channels.
The subunits constituting the functional channel is difficult to ascertain because of
the lack of subunit-selective pharmacological activators and the difficulty in using
molecular approaches. The present study utilized well established Kv channel activators
retigabine and flupirtine, both of which activate all Kv7 channel subtypes, except Kv7.1
channel homomers. Recently, several classes of Kv7 channel activators have started to
emerge with the identification of a new target site in these channels (Xiong et al. 2008).
Most of these compounds were tested only against neuronal Kv7.2/7.3 heterotetramers.
While some recent compounds showed relative selectivity to certain channel subtypes,
compounds that can serve as tools to identify channel subunits and/or for selective
cardiovascular or neuronal therapy remain to be identified (Bentzen et al. 2006;
Wickenden et al. 2008; Gribkoff 2008; Brueggemann et al. 2011).

Kv7 channels are critical contributors to resting membrane voltage and basilar
artery contractile status
The resting membrane voltage of basilar artery myocytes measured in the current
study was -57.5 ± 6.3 mV, within the range reported in previous studies for basilar artery
myocytes (Jahromi et al. 2008a; Chrissobolis and Sobey 2002; Allen et al. 2002). The
maximal density of K+ currents through Kv7 channels is small (< 0.3 pA/pF, Figure 6C)
compared to maximal current densities reported for 4-AP-sensitive-KV (36.9 pA/pF) and
KCa channels (~140 pA/pF) (Jahromi et al. 2008a; Jahromi et al. 2008b). However, Kv7
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channels are likely to play an important role in determining the resting membrane
voltage, more so than KV and KCa channels, as they are activated at negative membrane
voltages than 4-AP-sensitive-KV and KCa channels [V0.5 for Kv7 currents is -34 mV
(Figure 6D), compared to V0.5 of -1.3 mV for 4-AP-sensitive-KV currents (Jahromi et al.
2008a) and +86.8 mV for large-conductance KCa currents at 200 nM [Ca2+]c (Jahromi et
al. 2008b)]. This is supported by the evidence that blockade of Kv7 channels with
XE991 significantly depolarized the cell membrane (Figure 8). This brought the
membrane voltage from -58 mV, at which L-type VSCC have very low activity, to -35
mV, which is in the range of membrane voltage where VSCC activity increases in a
steeply voltage-dependent manner (Figure 8B). Our results shown in Figure 9 support
this hypothetical mechanism: XE991 robustly constricted the basilar artery and this effect
was reversed by the L-type VSCC blocker nimodipine. Kv7 channels have a wellestablished role in stabilizing resting membrane voltages and suppression of their activity
is a common depolarizing stimulus in neurons and arterial myocytes (Joshi et al. 2009;
Mackie et al. 2008; Adams and Brown 1982).

Suppression of Kv7 currents as a mechanism of vasoconstriction by spasmogens
Though it is well established that basilar artery spasmogens depolarize the
vascular myocytes and trigger Ca2+ influx through VSCC to induce constriction, the
signal transduction events that lead to membrane depolarization remain poorly
understood. Most previous evidence points to activation of non-selective cation channels
as a mechanism for spasmogen-induced membrane depolarization (Albert and Large
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2006). Our results show that spasmogens suppress Kv7 currents (Figure 10, 11) that are
active at resting membrane voltages, an effect which is associated with significant
membrane depolarization (Figure 8, 12). Direct inhibition of Kv7 currents by XE991 was
sufficient to induce constriction of basilar arteries (Figure 9), suggesting that resting
inward leak currents are sufficient to induce membrane depolarization. Suppression of the
K+ channel activity at resting voltages would be expected to increase membrane
resistance and thereby amplify the voltage change induced by inward currents, further
enhancing membrane depolarization. The additional constriction induced by 5HT when
Kv7 currents were already fully inhibited by XE991 (Figure 14B, C) could be due to
activation of inward currents (non-selective cation currents and/or chloride currents) that
induces further membrane depolarization (Albert and Large 2006) and/or direct activation
of VSCC (Worley et al. 1991). Neither ET-1 nor AVP induced significant additional
constriction in the presence of XE991, suggesting that Kv7 current suppression may be
sufficient to account for their constrictor actions at the concentrations tested (Figure
14C).

Protein kinase C as a mediator of the spasmogen-induced suppression of Kv7
currents
The signal transduction intermediates involved in the spasmogen-induced
suppression of Kv7 currents are not currently known. Activation of PKC, a common
signal transduction intermediate following activation of Gq/11–coupled receptors, is
consistently observed in vasospastic myocytes after SAH (Laher and Zhang 2001).
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Previous studies reported that PKC inhibitors attenuate spasmogen-induced constrictor
responses in rat basilar artery, indicating activation of PKC as an intermediate for the
constrictor response to spasmogens (Murray et al. 1992a; Murray et al. 1992b). In our
experiments, activation of PKC using phorbol-12-myristate-13-acetate (PMA) suppressed
Kv7 currents (Figure 15) and constricted basilar artery (Figure 16), mimicking the effects
of the direct Kv7 channel blocker XE991. Hence, PKC activated during vasospasm is
likely mediating its constrictor responses at least in part via the suppression of Kv7
currents in basilar artery myocytes. Suppression of the Kv7 currents by PKC could be
due to either direct phosphorylation of the channels (Higashida et al. 2005) or through
activation of other kinases like Src (Gamper et al. 2003; Li et al. 2004a) that can
phosphorylate the channels.

Kv7 current enhancement attenuates spasmogen-induced membrane depolarization
and vasoconstriction
Retigabine reversed the spasmogen-induced suppression of Kv7 current amplitude
(Figures 10, 11) and attenuated membrane depolarization in basilar artery myocytes
(Figure 12). These effects translated functionally into dilation of the basilar artery when it
was pre-constricted by spasmogens (Figure 18). Retigabine alone more than doubled the
amplitude of resting Kv7 currents (Figure 7). In the presence of the spasmogens, when
Kv7 currents were suppressed, retigabine still enhanced currents to about 65-80% above
control levels (an approximately 3-fold increase in current compared with current levels
measured in the presence of spasmogen alone (Figure 10, 11)). The increase in Kv7
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current amplitude was accompanied by a hyperpolarizing shift of more than 10 mV in the
voltage dependence of steady-state current activation (Figure 7C). Thus, in the presence
of retigabine at physiological resting membrane voltages, Kv7 channels would have
much greater probability of opening and hence provide a greater stabilization of negative
membrane voltage. This would effectively oppose spasmogen-induced membrane
depolarization (Figure 12) and opening of L-type voltage-sensitive Ca2+ channels. The
latter is the primary stimulus for constriction of the basilar artery at physiological
concentrations of vasoconstrictor agonists (Figure 13). This mechanism can explain why
retigabine and flupirtine oppose the constrictor effects of spasmogens (Figure 17, 18).
The actions of retigabine and flupirtine might be due to enhanced voltage-dependent
activation of the proportion of Kv7 channels that were not suppressed by the spasmogens.
Alternatively, (or perhaps in addition) the Kv7 channel openers may reverse the
suppression of the Kv7 channels by spasmogens by virtue of their direct binding to the
channel. Our findings do not distinguish between these two possibilities.
Addition of flupirtine in the presence of nimodipine induced additional dilation of
basilar artery segments (Figure 17C, D). We speculate that flupirtine induced an
additional vasodilatory effect by opposing the membrane depolarization induced by the
spasmogens, and thereby preventing the activation of both nimodipine-sensitive and
nimodipine-insensitive VSCC. Our results shown in Figure 21 are consistent with this
idea in that we can detect Ba2+ currents in basilar artery myocytes that are activated by
membrane depolarization, but not fully blocked by 2 µM nimodipine.
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The spasmogen and Kv7 channel opener concentrations used in the patch-clamp
experiments and the vascular reactivity studies in pressure myography differ because of
the varying sensitivities of the two systems used (Figures 6, 7, 10-14, 17-23). The
differential sensitivity is likely because in intact arteries depolarization of a small
proportion of smooth muscle cells leads to depolarization of the adjacent smooth muscle
cells connected by gap junctions. Hence, lower concentrations of Kv7 current suppressors
(spasmogens) and higher concentrations of Kv7 channel openers were required in artery
preparations compared to patch clamp experiments.

Celecoxib is a Kv7 channel activator and voltage-sensitive calcium channel blocker
Celecoxib (Celebrex®) is marketed as a selective inhibitor of the cyclooxygenase2 (COX-2) enzyme and is widely prescribed to treat pain and inflammation. However,
our present findings indicate that celecoxib is also a robust Kv7 channel activator (like
flupirtine and retigabine) (Figure 19). Enhancement of the currents (Figure 19C) was not
accompanied by a significant shift in the voltage-dependence of activation (Figure 19D).
Previous work from our laboratory demonstrated similar effects of celecoxib in
mesenteric artery myocytes and provided evidence that these effects are apparent at
concentrations of celecoxib that could be achieved with clinical therapy (Brueggemann et
al. 2009). Potassium currents conducted by human Kv7.5 channels expressed in VSMCs
were also shown to be activated by celecoxib further indicating the translational
relevance for the action of celecoxib (Brueggemann et al. 2009). Using an expression
system, Du et al., expanded the repertoire of Kv7 channels activated by celecoxib.
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Celecoxib activated Kv7.2-7.4, Kv7.2/7.3 and Kv7.3/7.5 channels, but inhibited Kv7.1
and Kv7.1/KCNE1 channels (Du et al. 2011). The actions of celecoxib on Kv7 channels
in that study were concentration-dependent with a half-maximal concentration between 25 μM, within the concentration range used in the present study.
Incidentally, Kv7 channels are not the only K+ channels modulated by celecoxib.
Celecoxib has been shown to block 4AP-sensitive Kv1.5, Kv4.3 and Kv2.1 channels
apart from blocking Kv7.1 channels (Frolov et al. 2010; Macías et al. 2010). Celecoxib
inhibited Kv2.1 currents by modifying the gating kinetics and by inducing open- and
closed-channel block (Frolov et al. 2010). It is also worthy to note that celecoxib is not
the first COX inhibitor known to activate Kv7 channels. Several N-phenylanthranilic acid
derivatives, that are mostly non-selective COX-inhibitors including meclofenamic acid,
flufenamic acid, mefenamic acid, niflumic acid and diclofenac activate Kv7 currents
(Brueggemann et al. 2011; Abitbol et al. 1999; Busch et al. 1994; Peretz et al. 2005).
These compounds activate Kv7 currents by direct binding to the channel, and the activity
is independent of its COX inhibitory effects (Peretz et al. 2007). Celecoxib is a
benzenesulfonamide, structurally unrelated to the N-phenylanthranilic acid derivatives.
The mechanism(s) by which celecoxib activates Kv7 channels are currently not known.
Du et al., suggested possible direct binding of celecoxib to Kv7 channels (Du et al.
2011), but that remains to be validated.
Celecoxib also inhibited voltage-sensitive Ca2+ currents in basilar artery myocytes
independently of its enhancement of Kv7 currents (Figure 20). Celecoxib was more
effective as a VSCC blocker than 2 µM nimodipine in basilar artery myocytes (Figure
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21). The concentration of nimodipine (2 µM), which induced significantly less
suppression of VSCC than did 10 µM celecoxib, is more than 1000-fold higher than
concentrations achieved in cerebrospinal fluid after nimodipine administration in patients
(Allen et al. 1983). A similar Ca2+ channel blocking activity of celecoxib was observed in
rat undifferentiated pheochromocytoma cells derived from adrenal gland (Zhang et al.
2007).
As expected from its dual ion channel effects, celecoxib very effectively reversed
the constriction induced by the spasmogens (Figure 22A, B). And, like flupirtine,
celecoxib was a more effective dilator of basilar artery than nimodipine (Figure 22C, D).
The additional dilation induced by celecoxib can be plausibly due to two mechanisms: 1)
enhancement of Kv7 currents, thereby limiting the voltage change necessary to activate
all of the VSCCs; or 2) Kv7 channel-independent inhibition of nimodipine-insensitive
VSCC. Our results provide evidence for both of these mechanisms. The finding that
flupirtine induces an additional dilation in the presence of nimodipine supports the former
(Figure 17D) and that celecoxib induces additional inhibition of voltage-sensitive Ba2+
currents in the presence of 2µM nimodipine supports the latter (Figure 21). Celecoxib
also prevented the constrictor effect of 5HT, indicating that celecoxib can potentially be
employed as a pre-emptive therapy to prevent vasospasm (Figure 23).
Rofecoxib, a more potent COX-2 inhibitor than celecoxib (FitzGerald and
Patrono 2001), but devoid of the ion channel modulatory activity (Brueggemann et al.
2009; Du et al. 2011), did not induce vasodilatory responses (Figure 29A, C). Dimethyl
celecoxib, a structural analog of celecoxib modified to eliminate COX-2 activity

142
(Kardosh et al. 2005), that retained the ion channel modulatory actions of celecoxib
(Brueggemann et al. 2009), almost completely dilated spasmogen pre-constricted artery
segments (Figure 29B, C). Hence, the vasodilatory effects observed with celecoxib are
independent of its ability to inhibit the COX-2 enzyme. Disruption of endothelium did
not attenuate the vasodilatory effect of celecoxib in pressurized mesenteric arteries
(Brueggemann et al. 2009). Hence, the vasodilatory action of celecoxib are mediated
through action on vascular smooth muscle cells rather than modulation of endothelial
function as implicated previously (Klein et al. 2007). Though Kv7 channel activation and
VSCC blockade in vascular smooth muscle cells are likely the principle mechanisms for
vasodilatory responses observed with celecoxib, it is not possible to rule out modulation
of other ion channels or intracellular Ca2+ mobilization pathways by celecoxib that may
also contribute in part to the responses.

Kv7 channel activators prevent basilar artery vasospasm in a rat model of SAH
Since Kv7 channel openers were able to reverse and/or prevent the constrictor
responses of spasmogens (Figure 17, 18, 22 and 23), we tested the efficacy of two Kv7
channel openers, retigabine and celecoxib, as potential therapies to reduce basilar artery
vasospasm in a rat model of SAH. We used a single hemorrhage model that produces
biphasic vasospasm of basilar artery that peaks at day 2 after injection (Delgado et al.
1985). The basilar artery is the most common artery that undergoes spasm after injection
of arterial blood into cisterna magna (Gules et al. 2002). In our disease model, injection
of autologous arterial blood (but not aCSF) into the cisterna magna induced a sustained
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constriction of the basilar artery that persisted 48 hours after the initial injury (Figure 24).
Both the Kv7 channel openers, retigabine (7.5 mg/kg, i.p) and celecoxib (20 mg/kg, i.p),
when administered twice daily, significantly attenuated the sustained basilar artery
vasospasm in this model (Figure 24). Basilar artery outer diameter measured at 48 hr (12
hr after the last injection) was used as the endpoint criterion to assess the severity of
vasospasm and efficacy of treatments.
Celecoxib offers a dual action (Kv7 current enhancement and voltage-sensitive
Ca2+ current inhibition), which may account for its tendency to induce a greater dilation
of the basilar artery in the SAH model (Figure 24), translating its ex vivo vasodilatory
efficacy (Figure 22, 23). Apart from modulating the activities of vascular ion channels,
celecoxib is likely to provide neuroprotective and anti-inflammatory effects due to its
clinically utilized COX-2 inhibitory activity. Cytokine-mediated upregulation of COX-2
expression has been observed in endothelial cells of basilar artery in several animal
models of SAH contributing to the inflammatory response after SAH (Tran Dinh et al.
2001; Osuka et al. 2006; Osuka et al. 1998). COX-2 inhibition has been demonstrated to
significantly reduce neuronal deterioration in a mouse model of aneurysmal SAH (Ayer
et al. 2011). Thus, celecoxib may have multiple beneficial effects for patients suffering
from SAH-induced cerebral vasospasm.
The limitation of the rat animal model is that the rats did not exhibit the
neurological deficits (Gules et al. 2002; Germano et al. 1994) observed in humans. A
double hemorrhage model, involving a second injection of blood into cisterna magna 48
hours after the first injection, induces a more sustained basilar artery constriction
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simulating the timeline of vasospasm development in humans (Gules et al. 2002). Despite
that improvement, rats in the double hemorrhage model did not exhibit a neurological
profile similar to humans (Gules et al. 2002; Jeon et al. 2009). We attempted to assess the
neurological endpoints using behavioural tests used in ischemic stroke models (Garcia et
al. 1995). The SAH rats did not exhibit any significant change in neurological function
compared to rats injected with aCSF into the cisterna magna (not shown). Assessment of
neurological endpoints were further limited due to the significant reduction in the activity
of rats with treatment of retigabine and celecoxib (Figure 26). A limitation in most of the
neurological tests used in this study and elsewhere in the literature is that these
neurological tests were developed to detect deficits caused by focal ischemia as seen in
traumatic brain injury models (Jeon et al. 2009). Focal ischemic lesions are very
uncommon in patients after SAH. The patients suffer from deficits in neurobehavioural
function such as memory, visuospatial/construction ability and executive function (Jeon
et al. 2009; Al-Khindi et al. 2010; Anderson et al. 2006; Kreiter et al. 2002). Since focal
deficits are rare in animal models of SAH (Jeon et al. 2009), it is not surprising that none
of the neurological tests showed a change with SAH. Impaired memory and behavior
deficits after SAH in rodents can be assessed using paradigms like morris water maze,
matching-to-sample tests, and open field behavior. However, these assessments were not
feasible because of the significant reduction in the locomotor activity of rats treated with
retigabine or celecoxib (Figure 26).
Direct neuroprotective effects of Kv7 channel activators: Emerging evidence
suggests that cortical spreading depression (CSD) is a major contributing factor to
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cerebral ischemia after SAH (Leng et al. 2011). CSD is manifested as slow (2-5 mm/min)
waves of depolarization in cerebral gray matter that propagate across the brain (Leao
1944). The spreading depression is characterized by near-complete depolarization of
neurons (from -70 mV resting voltage to -10 mV) and a maximal shunt in membrane
resistance in neurons (Canals et al. 2005; Dreier 2011). The ensuing depolarizationinduced hypermetabolic rate of neurons results in disrupted neurovascular coupling,
hypoxia, and toxic accumulation of metabolic end products. This cascading events lead to
an inverse hemodynamic effect in response to depolarization of neurons and a reduction
of regional cerebral blood flow (Dreier 2011). A vicious cycle is likely established- the
spreading depolarization maintains vasoconstriction and ischemia, and the ischemia
maintains spreading depolarization (Dreier 2011). Hence, CSD is likely a co-morbid
pathology with chronic vasospasm that contributes to delayed cerebral ischemia in
patients (Bosche et al. 2010; Dreier et al. 2009). Electrocorticography recordings
detected spreading depolarizations in 72% of patients after SAH and recurrent spreading
depolarizations had a time locked correlation to cerebral ischemia (Lauritzen et al. 2011).
The events that instigate CSD (and vasospasm) after SAH remain unclear. The fact that
endothelin can induce CSD (Dreier et al. 2002) and vasospasm (Asano et al. 1990)
indicates there might be some common etiological factors involved.
Neuronal Kv7 channels may be important regulators of CSD, based on previous
findings that inhibition of Kv7 channels with linopirdine induced spreading depression in
hippocamal slices (Okada et al. 2003) and S(1)-acrylamide, a Kv7.2-selective channel
opener, prevented CSD induced by K+ in a rat model (Wu et al. 2003). Thus, a Kv7.2-7.5
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channel opener like retigabine is expected to reduce cerebral ischemic deficits by exerting
direct neuroprotective effects by antagonizing CSD after SAH. Direct neuroprotective
effects of retigabine and flupirtine have been reported in several studies (Boscia et al.
2006; Gamper et al. 2006; Seyfried et al. 2000). Therefore, Kv7 channel openers will
likely reduce neuronal deficits after SAH through direct neuroprotective effects as well as
from their direct vasodilatory actions mediated by Kv7 channels in the basilar artery
myocytes (Figure 24).
Kv7 channel activators induce hypothermia in a the rat model of SAH:
Increased body temperature after SAH is associated with vasospasm, increased functional
disability and cognitive impairment, and high mortality in patients (Badjatia et al. 2010;
Fernandez et al. 2007; Oliveira-Filho et al. 2001). Mild hypothermia (33-34°C) has been
reported to have a neuroprotective effect and increases the functional outcome in patients
with delayed cerebral vasospasm (Gasser et al. 2003; Maekawa et al. 1994; Nagao et al.
2000; Nagao et al. 2003) and in a rat model of SAH (Torok et al. 2009). Induction of
moderate hypothermia also reduced the hypoperfusion-induced metabolic alterations in a
rat model of SAH (Schubert et al. 2008). Therapeutic hypothermia has emerged as a
potent and practicable neuroprotective treatment for ischemic and hemorrhagic stroke and
intracerebral hemorrhage (Feigin et al. 2002; Hemmen and Lyden 2009; Linares and
Mayer 2009). The mechanism for the neuroprotective effects likely includes reduced
metabolic demand of the brain parenchyma (Erecinska et al. 2003; Jiang et al. 1992),
stabilization of the blood-brain barrier (Jiang et al. 1992; Smith and Hall 1996), reduced
post-ischemic cerebral edema (Kurasako et al. 2007), reduction of ischemia-induced
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neurotoxic glutamate release (Busto et al. 1989; Globus et al. 1995) and free radical
production (Globus et al. 1995; Lee et al. 2009).
We found that retigabine induced significant hypothermia in the rat model of
SAH, even 12 hours after administration (Figure 25). Celecoxib (20 mg/kg) also tended
to lower body temperature. A recent study also observed hypothermia with
intraperitoneal administration of Kv7 channel openers: retigabine, ICA-27243, S(1)acrylamide and BMS-204352 in mice (Kristensen et al 2011). The hypothermic response
in mice (about 4°C reduction in temperature) with retigabine administration was rapid in
onset and lasted only up to an hour after administration (Kristensen et al. 2011). The
reason for the long lasting hypothermia observed in the rat model of SAH in not clear,
but could involve modulation of Kv7 channels in the hypothalamus that encompasses the
thermoregulatory center (Cooper et al. 2001; Weber et al. 2006). Nevertheless, the
hypothermic effect observed with Kv7 channel activators is likely to improve the
functional outcome in patients after SAH. Severe hypothermia produces several
complications ranging from electrolyte imbalances to multiple organ failure in patients
with cerebral vasospasm (Seule et al. 2009). Therefore, a careful individualized
examination of the risk: beneficial effects of the Kv7 channel activation-induced
hypothermia need to be undertaken if administered to patients with cerebral vasospasm.

Kv7 channel activators do not induce sustained hypotension
Sustained hypotension may limit the utility of other classes of K+ channel openers
(e.g. KATP channel openers) or CCBs in the effective treatment of cerebral vasospasm
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(Spinelli et al. 1990; Porchet et al. 1995). In contrast, intraperitoneal administration of
either retigabine (7.5 mg/kg) or celecoxib (50 mg/kg) induced only a transient drop in
MAP without any appreciable change in the 24-hour MAP (Figure 27) or heart rate
(Figure 28). The reason for resiliency to effects of Kv7 channel openers on MAP is likely
because (1) these channels are active under physiological conditions in a sub-threshold
voltage range (-60 to -40 mV, Figure 6) in which VSCCs are not appreciably active; (2)
the whole-cell conductance through Kv7 channels is very small compared to 4-APsensitive Kv and BK channels (Jahromi et al. 2008c).
The half-life of retigabine in male rats is 2 h and that of celecoxib is 3.7 h
(Mazarati et al. 2008; Paulson et al. 2000). Both the drugs accumulate significantly in the
brain, exceeding the plasma concentrations when administered to rats (Rostock et al.
1996; Pfizer Canada 2007). This could also account for the short-lived effect on systemic
arterial blood pressure, but long-lasting vasodilatory effect on basilar artery.
The vascular effects (vasodilation) of enhanced Kv7 channel activity would
primarily result from relaxation of myocytes with depolarized membrane voltages (e.g.
basilar artery myocytes following SAH), with little effect on the systemic vasculature
where arterial myocytes have resting voltages between -60 and -40 mV. In this regard,
the function of Kv7 channels in vascular myocytes is analogous to their function in the
excitability of neurons, where dysfunction, either by suppression of M-currents, or
inactivating mutations of Kv7 channels, results in hyperexcitability precipitating seizures
(Jentsch 2000). In arteries, activation of Kv7 currents relaxes the constricted arterial
myocytes (Figure 24) without producing marked systemic hypotension (Figure 27)
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similar to the effects of retigabine used as an anti-epileptic agent, where it dampens
neuronal hyperexcitability with little effect on the normal function of the nervous system
(Gunthorpe et al. 2012).

Kv7 channel activators as candidates to treat cerebral vasospasm
A number of pharmaceutical companies are currently developing novel Kv7
channel openers to treat epilepsy and neuropathic pain (Miceli et al. 2008). Retigabine
was recently approved by the US Food and Drug Administration as an adjunctive
treatment for partial-onset seizures in adult patients (Gunthorpe et al. 2012; Harris and
Murphy 2011; Stafstrom et al. 2011). More than 20 patents for selective openers of
Kv7.2-7.5 channels have been issued and an estimated more than 100 applications are
currently under review (Castle 2010; Wulff et al. 2009). Therefore, it is reasonable to
expect that Kv7 channel openers with better pharmacodynamic and pharmacokinetic
profiles will be available soon. Our findings suggest that, in addition to their direct
neuroprotective effects (Boscia et al. 2006), these drugs with established safety profiles
(Blackburn-Munro et al. 2005; Frampton and Keating 2007; Brodie et al. 2010; French et
al. 2011; Ueberall et al. 2011) can be readily adopted to prevent or limit cerebral
vasospasm after SAH. Based on the pronounced antivasospastic effect of Kv7 channel
openers reported here, we would add cerebral vasospasm to the expanding repertoire of
conditions potentially treatable with Kv7 channel openers.
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Phosphodiesterase inhibitors activate Kv7 channels and block voltage-sensitive
calcium channels in A7r5 cells
We utilized cultured aortic smooth muscle (A7r5) cells derived from rat embryos
to study the mechanism by which celecoxib modulates ion channels. Since a previous
study suggested that celecoxib is a PDE4 and 5 inhibitor (Klein et al. 2007), we tested if
selective PDE inhibitors simulate celecoxib’s action on ion channels. Selective
pharmacological inhibition of PDE4 (with rolipram), PDE5 (with sildenafil) or a nonselective PDE inhibition (with papaverine) significantly enhanced the voltage-activated
Kv7 currents (Figure 30, 32 and 34). Similarly, all these PDE inhibitors also inhibited
voltage-sensitive Ca2+ currents (Figure 31, 33, (Han et al. 2007)) in vascular smooth
muscle cells. Application of either rolipram or sildenafil attenuated AVP-induced Ca2+
spiking responses in A7r5 cells (Figure 35; sildenafil results not shown) and dilated preconstricted mesenteric artery segments (Figure 36), again simulating the effect of
celecoxib (Brueggemann et al. 2009). However, whether inhibition of PDE enzymes
accounts for all (or even any) of the ion channel modulatory effects of celecoxib is not
known. Experiments undertaken to address that question using whole cell patch-clamp
experiments were inconclusive because of the bell-shaped dose-reponse for the ion
channel modulatory actions of both celecoxib and the PDE inhibitors (Figure 30, 31
(Brueggemann et al. 2009)). Another possible mechanism for the ion channel modulatory
effects of celecoxib could be due direct binding of the drug to the channels as proposed
for Kv7 channels (Du et al. 2011). The ability of celecoxib to enhance single channel
currents through overexpressed Kv7 channels would be an approach to test whether
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activation of Kv7 channels by celecoxib is due to direct binding of the drug to the
channels or mediated through a signal transduction pathway as proposed here.
Nevertheless, these present experiments suggest enhancement of Kv7 currents and
inhibition of voltage-sensitive Ca2+ currents as likely contributors to the vasodilatory
responses observed with PDE inhibitors. Further experiments are needed to confirm
whether inhibition of PDE enzymes fully accounts for ion channel modulatory effects of
celecoxib.
All the aforementioned PDE inhibitors are used clinically to treat a variety of
clinical conditions. Rolipram was used to treat depression and chronic obstructive
pulmonary disease (O'Byrne and Gauvreau 2009), sildenafil is used to treat erectile
dysfunction (Sandner et al. 2007) and papaverine is used to treat cerebral vasospasm (Liu
and Couldwell 2005). Despite their extensive clinical utility and the well-characterized
vasodilatory responses and reduction in blood pressure associated with their use (Oliver
et al. 2006; Zusman et al. 1999), understanding of the cellular mechanisms leading to
vascular responses is nascent.
PDE4 selectively hydrolyses cAMP [Km (μM), cAMP/cGMP=2/>300), and
PDE5 selectively hydrolyses cGMP [Km (μM), cAMP/cGMP=150/1) (Keravis and
Lugnier 2012). Inhibition of either PDE4 or PDE5 with selective blockers rolipram or
sildenafil produced the same tendency to activate Kv7 channels and block Ca2+ channels
(Figure 30-33). Downstream kinases activated by the nucleotides have been shown to
exert feedback regulation of the activity of either the same PDE family of enzymes that
hydrolyses the nucleotides or distinct family of PDE enzymes (Keravis and Lugnier
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2012). Furthermore, activation of the downstream kinases by the nucleotides: PKA by
cAMP and PKG by cGMP, while selective, are known to cross-activate the other kinase
(Keef et al. 2001). Therefore, a simplistic model with both or either of the nucleotides
regulating the channel through activation of a vertical downstream signal transduction
cascade may be unlikely.
In neurons, Kv7 channels exist in a signaling complex along with PKC, PKA, and
protein phosphatase 2B (PP2B) held together by a multivalent scaffolding protein, AKAP
(Hoshi et al. 2003; Higashida et al. 2005; Hoshi et al. 2005). AKAP has also been shown
to immunoprecipitate with Kv7.5 channels in A7r5 cells and is proposed to be in a
signaling complex that includes PKC (Hummert et al. 2011), similar to the existence in
neurons. PDE4 enzymes have been also demonstrated to be constitutively associated with
AKAP in VSMCs (Dodge et al. 2001; Raymond et al. 2009; Houslay et al. 2007). Hence,
there is a possibility that AKAP tethers Kv7 channels in a signalosome, along with PDE4
and PKA, thereby facilitating phosphorylation of the channels by the cAMP-activated
PKA to enhance Kv7 currents.
Functional analysis in cardiomyocytes indicated that PDE4 and cAMP-activatedPKA are in close proximity, and are held together by AKAP (Dodge et al. 2001).
Enhanced activity of PDE4 was found to reduce PKA activity; elevated cAMP and kinase
activity had a negative feedback stimulation of PDE4 enzyme in cardiac or vascular
myocytes (Dodge et al. 2001; Rose et al. 1997). Another study also showed that longterm elevation of cAMP by exogenous administration of cAMP-elevating drugs to rats
stimulated transcription of PDE 3 and 4 enzymes in vascular myocytes (Tilley and
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Maurice 2002). This highlights the complex overlapping feedback loops at different
levels, which enables a tight control of the cAMP levels and the downstream PKA
activity. The possible existence of the signalosome and the negative feedback
mechanisms in vascular myocytes could contribute to the bell shaped concentration
response curves observed here (Figure 30, 31).
The mechanism by which sildenafil regulates the Kv7 channels is not known and
requires further investigation. As an inhibitor of PDE5, sildenafil is expected to increase
cGMP levels. Voltage-sensitive Ca2+ channels are known to be modulated by cyclic
nucleotides, cAMP and cGMP. Elevation of cGMP using a membrane-permeable analog,
8Br-cGMP or nitric oxide (NO) donors have been shown in several studies to inhibit
VSCC in a PKG-dependent manner (Keef et al. 2001). PKG-mediated VSCC blockade
may therefore explain the sildenafil effect observed here. PKG has been shown to
phosphorylate both the Cav1.2 α1c subunit and the accessory β2 subunit of VSCC in a
heterologous expression system; phosphorylation of a serine residue in the β2 subunit
accounted for the PKG-induced inhibition of the currents (Yang et al. 2007). Thus, a
direct phosphorylation of VSCC by PKG could account for the inhibition of voltagesensitive Ca2+ currents observed with sildenafil.
In the present study, addition of rolipram, which is expected to increase cAMP,
inhibited voltage-sensitive Ca2+ currents. Regulation of voltage-sensitive Ca2+ currents by
cAMP and the downstream kinase (PKA) in VSMCs is controversial, with several studies
showing either enhancement, inhibition, or no effect on the currents (Keef et al. 2001).
Elevation of intracellular cAMP by stimulation of Gs-coupled seven transmembrane
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receptors results in dilation of intact arteries (Satake and Shibata 1997), consistent with
our electrophysiological and functional results with rolipram. However, further studies
are needed to elucidate the downstream effectors that lead to inhibition of VSCC with
addition of rolipram.
An increase in the expression of PDE5 enzyme and enhanced PDE5 enzyme
activity was observed in vasospastic canine basilar artery myocytes compared to control
basilar artery myocytes (Inoha et al. 2002). Another study using a mouse model of SAH
found increased PDE5 enzyme activity, but no increase in the expression of the enzyme
in vasospastic arteries (Han et al. 2012). Treatment with sildenafil attenuated the basilar
artery vasospasm in the canine, rat and mouse models of SAH (Gokce et al. 2010; Han et
al. 2012; Inoha et al. 2002). The fact that sildenafil is a Kv7 channel activator (Figure 32)
indicates that at least part of its anti-vasospastic effects might be mediated through
activation of Kv7 channels.

CHAPTER 7
CONCLUSIONS
This comprehensive dissertation provides the first evidence for the presence of
Kv7 channels in basilar artery and a central role of the channels in regulating the
contractile status of the artery. The results show that known basilar artery spasmogens,
including the Gq/11-coupled receptor agonists, serotonin, endothelin, and vasopressin,
potently suppress the activity of Kv7 channels in basilar artery myocytes and induce
membrane depolarization. This may account for the depolarization that has been observed
in myocytes following SAH. This study also demonstrates for the first time that celecoxib
is an effective dilator of basilar artery by activating Kv7 channels as well as by blocking
voltage-sensitive Ca2+ channels. Pharmacological Kv7 channel activators oppose the
effect of spasmogens on Kv7 currents and membrane depolarization, and relax
pressurized basilar arteries that are pre-constricted with these spasmogens. We also
demonstrate that clinically used Kv7 channel activators, retigabine, and celecoxib were
effective in relieving basilar artery spasm in vivo in rats with experimentally-induced
SAH. Hence, these results provide evidence supporting the use of Kv7 channel activators
as a novel class of drugs to treat patients who develop or are likely to develop cerebral
vasospasm (Figure 37).
Our laboratory was the first to propose that Kv7 potassium channels are signal
transduction intermediates in the vasoconstrictor actions of physiological concentrations
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of vasopressin. This dissertation provides the first evidence that this mechanism is shared
by multiple vasoconstrictors that activate Gq/11-coupled receptors in basilar artery
myocytes. As such, its significance extends beyond the role of these channels in the
cerebral circulation, providing mechanistic insights into the signal transduction processes
that contribute to physiological and pathological regulation of blood flow and blood
pressure in general. This dissertation also provides the first evidence that activation of
Kv7 channels is a mechanism by which phosphodiesterase inhibitors induce vasodilation
and reduction in blood pressure (Figure 37).
In summary, Kv7 channels in basilar artery myocytes are critical regulators of the
vasoconstrictor/dilator response. Apart from revealing a potential novel therapeutic target
for treatment of cerebral vasospasm, identification of the role of Kv7 channels in the
vasculature is likely to aid in the development of alternative treatment options for other
dreadful cardiovascular disorders like coronary vasospasm, hypertension, and septic
shock, which are conditions characterized by dysregulated vasoconstriction. This
dissertation project, thus, identifies a possible solution to contain several epidemic
cardiovascular diseases that engulf our society and continue to expand.

157

K+

+

∆Vm

Ca2+

Figure 37: Spasmogens suppress Kv7 currents to induce basilar artery vasospasm;
Kv7 channel activators oppose the spasm. Spasmogens, by binding to their specific
receptors, suppress the Kv7 currents through a signal transduction mediated mechanism.
Suppression of the Kv7 currents depolarizes the membrane, activating voltage-sensitive
Ca2+ channels, resulting in influx of Ca2+ and, initiation and maintenance of constriction.
Administration of the Kv7 channel activator, retigabine, or the dual Kv7 channel
activator and voltage-sensitive Ca2+ channel blocker, celecoxib, prevents/overcomes the
spasmogen-induced vasospasm.

CHAPTER 8
FUTURE DIRECTIONS
The dissertation project presents the first evidence for the presence and function
of Kv7 channels in rat basilar artery myocytes. This study adds to the previous findings
that Kv7 channels play a pivotal role in maintaining the resting membrane voltage of
excitable cells. Single-cell patch-clamp and pressure myography studies provided
evidence for the mechanism by which Kv7 channel activators could be a novel class of
drugs to treat patients with cerebral vasospasm. The study also provided “proof-ofconcept” evidence that Kv7 channel activators attenuate basilar artery vasospasm in an
acute model of SAH. However, the study does not address whether the anti-vasospastic
effects of Kv7 channel activators would result in a favorable clinical outcome in terms of
reduction in neurological deficits and perhaps reduction in mortality. This is not an easy
question to address in the current scenario, given that there are no good animal models
that can predict the neurological outcome in patients. Alternatively, since both the Kv7
channel activators employed here are clinically utilized drugs with established safety
profile, a clinical study with a small cohort of patients can be performed.
The findings from the study, if they hold in humans, could have immense
translational value and offer a possible effective alternative therapeutic approach for
cerebral vasospasm. However, additional information is needed to realize the potential of
the current study. For one thing, there is a paucity of information regarding the
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expression of Kv7 channels in the human cerebral vasculature and even vascular
myocytes in general. To date there is only one report, which shows the existence of Kv7
channels in human vasculature (Ng et al. 2011). Evidence for the expression and function
of these channels in human cerebral vasculature is therefore required before initiation of
clinical trials using Kv7 channel activators to treat cerebral vasospasm.
The study provides strong evidence that inhibition of phosphodiesterase
enzymes(s) using clinically utilized drugs activate Kv7 currents in cultured A7r5 cells.
The findings need to be validated in myocytes derived from human vasculature to address
the translational relevance of the presence findings. In a classic case of reverse
pharmacology, the findings opens the door for understanding signal transduction
mediated regulation of ion channels, including Kv7 channels and voltage-sensitive Ca2+
channels. As mentioned in the discussion section, there is a very high likelihood that Kv7
channels are in a signalasome that includes PKA and PDE, held together by AKAP
(Figure 38). Studying the mechanisms by which celecoxib and phosphodiesterase
inhibitors regulate Kv7 channels is therefore expected to shed more light on the
regulation of vascular tone and therefore potentially identify new targets to modulate
vascular tone.
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Figure 38: Hypothetical mechanism by which celecoxib and rolipram regulate Kv7
currents in vascular smooth muscle cells. Activation of the membrane-bound enzyme
adenlyl cyclase synthesizes cyclic adenosine monophosphate (cAMP) from adenosine
triphosphate (ATP). The cytosolic levels of cAMP is dynamically regulated by
degradation to adenosine monophosphate (AMP) by cAMP-selective phosphodiesterase
(PDE) enzymes, like PDE4. PDE4 is likely tethered in a signalasome that also
encompasses protein kinase A (PKA), and Kv7 channels, held together by a scaffolding
protein, A-kinase anchoring protein (AKAP). Inhibition of PDE4 enzyme by celecoxib or
rolipram results in accumulation of cAMP, which activates PKA. PKA likely
phosphorylates the channels in setine/threonine residue(s) to activate the Kv7 channels.
Sildenafil similarly enhances cyclic guanosine monophosphate (cGMP) levels, protein
kinase G (PKG) activity, which could modulate the Kv7 channel activity either by direct
phosphorylation of the channels or by modulating the cAMP-PKA pathway.
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